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1.2 Fundamentals of immunology 
The immune system is the body's defense against infectious organisms and other 
invaders.1 It is made up of a network of cells, tissues, molecules and organs that 
work together, through a series of steps called immune response, to protect the body 
against the invasion of organisms and substances that can cause diseases. Molecules 
which are perceived by the immune system as a foreign invader or simply as 
potentially dangerous for the host are referred to as antigens. The first barrier 
against external agents is physical and includes mechanical defenses, such as 
epithelial tissues (skin and mucous), and their secretions. 
 
1.2.1 Specific and nonspecific immunity 
The immune system can react against pathogens by the integration of two distinct 
arms of the immune response: the innate and the adaptive responses (Figure 1). The 
former is rapid and aspecific, and establishes the first line of immune defense, 
acting during the early stages of infection (within minutes). Inflammation is a sign 
of the activation of this defensive line: it is initiated by antigen-presenting cells 
(APCs) present in all tissues, mainly resident macrophages, dendritic cells (DCs), 
histiocytes, Kupffer cells, and mastocytes. These cells present receptors named 
pattern recognition receptors (PRRs), which can be stimulated by molecules that are 
broadly shared by pathogens but distinguishable from host molecules, collectively 
referred to as pathogen-associated molecular patterns (PAMPs). At the onset of an 
infection, these cells undergo activation and release soluble chemical factors, 
including specialized chemical mediators, called cytokines, which recruit 
specialized white blood cells (monocytes, macrophages, phagocytes, dendritic cells, 
NK cells) to sites of infection. Moreover, they activate the complement system, a 
biochemical cascade that helps, or “complements”, the ability of antibodies to clear 
pathogens or mark them for destruction by other cells. The cascade is composed of 
many plasma proteins, synthesized in the liver, primarily by hepatocytes. 
On the contrary, the adaptive response is slower (typically takes days to weeks to 
develop) but recognizes pathogens with high affinity, providing the fine antigenic 
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specificity required for complete elimination of the infective agent and the 
generation of the immunological memory. Antigen-presenting cells, and in 
particular dendritic cells, provide a crucial bridge between the innate and adaptive 
responses. 
The immunological response causes the production of specific proteins (commonly 
known as antibodies) and the participation of many different types of cells called 
lymphocytes, which belong to the leukocyte class. In detail, the specific immunity 
is different from the nonspecific one by four main characteristics: 
- specificity: is the ability of the immune system to recognize, in an extremely 
selective way, and destroy particular antigens by producing specialized 
lymphocytes and specific antibodies. The antigens which are able to provoke 
such a response are viruses, bacteria, fungi, protozoa and parasitic worms.  
- diversity: it is derived from the ability of the specific system to respond to 
millions of different antigens. Such a variety of reactions is made possible by 
the presence of a great number of lymphocytic cells, each specific to a 
particular immunological agent. 
- recognition of self/non-self: this characteristic refers to the skill of the immune 
system to distinguish own-body molecules from the foreigners (antigens). 
Anomalies which affect this recognition ability can cause severe diseases, 
called autoimmune, in which the immune system attacks tissues of its own 
organism, misidentifying them as external. 
- memory: it is related to the faculty of the specific system to “remember” 
antigens which has already encountered. As a result, the reaction is faster and 
more effective when successive exposures to the same antigen occur. The 
practice of vaccination is founded upon this characteristic. 
Immunity acquired through vaccination is called artificial immunity, as opposed to 
the active one which naturally develops in patients recovered from an infectious 
illness. Vaccines consist of a large variety of microorganisms or parts of them 
(living attenuated bacteria, killed germs, toxoids, microbial products) deprived of 
their power of infection but not of their immunogenicity. Moreover, antibodies can 
be transmitted from a person to another: this is the passive immunity. Such an 
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immunity can be natural, as from mother to son through the placenta, or artificial, 
through the direct administration of antibodies from an animal or from a human 
being already immune against the disease of interest. 
 
Figure 1: the immune system. 
 
1.2.2 B and T Lymphocytes and immunoglobulins 
Lymphocytes play a key role in the immunological response. In vertebrate 
organisms there are two different kinds of lymphocytes: the B ones, responsible for 
the humoral response, and the T ones, which take part in the cell-mediated reaction 
(Figure 2a). As mentioned above, the APCs surface is plenty of pattern-recognition 
receptors (PRRs), including the recently discovered Toll-like receptor family 
(TLRs), that can recognize a huge variety of PAMPs, leading to full maturation of 
DCs, antigen uptake and intracellular processing (Figure 2a). The triggering and 
amplification of the adaptive arm of the immune response initiates when mature 
DCs migrate to the draining lymph nodes, where they prime naïve T cells. The 
crucial event for T cell activation/differentiation is the immunological synapse, 
initiated by the formation of a ternary complex between MHC (major 
histocompatibility complex, class I or II) on DC surface, antigen and T cell receptor 
(TCR) on the T cell surface. Depending on the antigen exposed on the DC surface, 
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the immunological synapse might induce the activation of cytotoxic T lymphocytes 
(CTL, or CD8+ T cells, in cases in which the antigen is presented by class I MHC), 
effector T cells that destroy target cells infected by intracellular viruses or bacteria, 
and/or the proliferation of helper T cells (Th, or CD4+ T cells, in cases in which the 
antigen is presented by a class II MHC). Furthermore, T and B cells can cooperate 
in a so-called T cell-dependent immune response mechanism. Activated Th cells 
interact with resting B cells through a class II MHC and driving their proliferation 
and differentiation into plasma cells (antibody-forming cells, mainly producing 
low-affinity IgM-type antibodies) and memory B cells. Unlike plasma cells, 
memory B cells survive for a long time in the body and respond rapidly to 
subsequent exposures of antigen by secreting high-affinity IgG antibodies. 
Antibodies are a class of proteins named immunoglobulins (Ig) possessing 
particular combinatory sites that can bind structural-complementary particles 
(antigens). Antibodies consist of two different parts: the constant region, which is in 
common to all immunoglobulins belonging to the same class, and a variable region, 
which includes the site of interaction with the antigen. From a structural point of 
view, immunoglobulins consist of four glycopeptide chains (tetramers): two light 
chains identical to each other and two heavy chains also identical to each other. 
Tetramers are tied to each other (in a Y-shape) by 3 to 14 disulphide bond, 
depending on the immunoglobulin class. The heavy chains, next to each other, are 
the trunk of the Y, while the light chains are the arms. There are five classes of 
human immunoglobulins: IgG, IgA, IgM, IgD, IgE. 
Several antigens are protein structures or polysaccharide molecules, often 
components of the external coatings of the immunogenic agent. Usually, antibodies 
are not able to recognize the whole molecule. In fact, they can recognize only a 
small superficial part of it called antigenic determinant or epitope. 
As above mentioned, activation of B cells in order to create memory B cells is a 
process that requires participation of T-helper cells. Antigens which are able to 
stimulate this cooperative response are called T-dependent. Conversely, T-
independent antigen can provoke humoral immunological reaction without 
collaboration with T-helper cells. Carbohydrates, such as the polysaccharide chains 
  
7 
found in capsule of bacteria, are typical T-independent antigenic molecules. They 
stimulate B cells by cross-linking the B-cell receptors (BCRs) and drive the 
production of IgM immunoglobulins. This process results in a lack of production of 
new memory B cells and a depletion of the memory B cell pool, so that subsequent 
immune responses are decreased (Figure 2b). 
 
Figure 2: diagramatic representation of the immune response. 
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1.3 Carbohydrates and immunological response 
The first communication about polysaccharides in immunology dates back to 1917, 
when Dochez and Avery published an article which dealt with a “specific soluble 
substance” secreted by Pneumococcal bacterium during its growth.2 Few years 
later, in 1923, Heidelberger and Avery demonstrated that the soluble substance was 
simply a polysaccharide.3,4 This fundamental discovery had a double result: it was 
the first example of the correlation between chemical structure and immune 
specificity of antigens and, on the other hand, denied the belief that only proteins 
could be antigens. Immunological properties of polysaccharides were found in their 
abilities to induce immunological response and to subsequently create specific 
antibodies (globulins). In the following years, the concept that only a particular 
small part of the polysaccharide (determinant zone or epitope) is essential in the 
antigen-antibody interaction and, as a result, for the antigenic specificity, has been 
developing. There are two categories of epitopes: sequential epitopes, characterized 
by a specific linear sequence, and conformational epitopes with a particular 3D 
structure. Moreover, an antigen molecule may contain several epitopes, each 
recognized by different antibodies. 
 
1.3.1 Anatomy of the bacterial cell 
In order to examine in detail the immunology of polysaccharides, it is useful to 
briefly describe the anatomy of the microorganisms which are the objects of the 
immunological response. From a structural point of view, bacteria (unicellular 
prokaryotic microorganisms) are primarily composed of a plasma membrane which 
encloses the cytoplasm. This membrane, made of phospholipids and proteins, is a 
semipermeable barrier that acts as a support platform for enzymes of the respiratory 
chain, of the biosynthesis of membrane phospholipids, of wall polymers and of 
DNA. Outside the plasma membrane there is the cell wall, which gives structural 
rigidity to the cell. In prokaryotes, this element mainly protects the internal osmotic 
pressure caused by the great discrepancy between protein (or other molecules) 
concentration inside and outside the cell. Bacterial cells are different from all other 
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cells in nature because of the presence of peptidoglycans near the cytoplasmic 
membrane. The layer of complex peptides (peptidoglycans) consists of a skeleton 
composed of alternate units of N-acetylglucosamine and N-acetylmuramic acid, to 
which peptide chains are linked by amide bonds between L-alanine units and COO- 
moiety of the muramic acid. In addition, the peptide sequence creates cross-links 
with polyglycines by –NH2 group in lysine. All these interactions result in the 
formation of a narrow network structure which is able to give rigidity to the wall of 
the cell. Even though all the bacterial cell walls contain peptidoglycans not all of 
them have the same structure: this diversity, which reflects in permeability 
differences, makes it possible to classify bacterial microorganisms in Gram-
negative and Gram-positive. In the latter the peptidoglycan layer is relatively thick 
(200-800 Å) and, in addition, there are teichoic and lipoteichoic acids. On the 
contrary, in Gram-negative bacteria the peptidoglycan layer is thinner (50-100 Å). 
Furthermore, there is an additional outer membrane made by lipopolysaccharides, 
lipoproteins and phospholipids (Figure 3). The chemical structure of the 
lipopolysaccharide membrane (also called endotoxin) is often specific for any 
bacterial strain and is one of the main factors of immunogenicity in these bacteria. 
 
Figure 3: cross section of bacterial cell walls. 
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1.3.2 Bacterial capsule 
Regardless of being Gram-negative or Gram-positive, several bacteria possess one 
more outer membrane called capsule, and so they are referred to as encapsulated 
bacteria. It is composed of polysaccharide chains, homo- or heteropolymers usually 
consisting of small oligosaccharide repeating units (1-6 monosaccharide elements, 
often D-glucose, D-galactose, D-mannose and L-fucose), but with a great variability 
of functionalizations. The capsule is considered a virulence factor because it 
enhances the ability of bacteria to cause disease. The capsule can protect bacterial 
cells from engulfment by eukaryotic cells, such as macrophages and delays the 
protective action of the specific immune system. Currently, encapsulated bacteria 
are one of the main causes of the high mortality rate owed to bacterial infections in 
several geographic areas. 
As previously described, interactions between antigen and antibody do not involve 
the whole polysaccharide chain, but only small portions are responsible for the 
recognition phenomenon. A logic consequence is that both primary and secondary 
structures of the polysaccharide capsule are significant. The former is responsible 
for the serological characteristic of the bacterium, whereas the latter determines the 
physical and biological properties. As well as proteins, polysaccharides can adopt 
particular 3D structures using inter- or intramolecular interactions which are 
sensible to changes in temperature. It is this ordered conformation that makes it 
possible the interaction between bacteria and the host. 
 
1.3.3 Immunogenic polysaccharides and cellular response 
As already highlighted in 1.2.2, the cooperation between T and B cells is essential 
for the establishment of the immunological memory. However, immune responses 
to polysaccharides are typically T cell-independent. Because of their polymeric 
structures, polysaccharides bind several B cell receptors (BCRs) simultaneously, 
leading to direct activation of B cells without cooperation with T cells. As a result, 
the hallmark of the immune response to carbohydrates is an exclusively primary 
immune response with low-affinity IgM production and no class switch to high-
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affinity IgG antibodies. Moreover, pure polysaccharides cause immune responses of 
relatively short duration, and they do not induce immunological memory (i.e., they 
fail to evoke a booster effect). This effect is even more evident in immunologically 
immature individuals, such as infants and children, who do not have sufficiently 
differentiated G and M immunoglobulins able to provide an immunological 
protection. 
  
1.3.4 Glycoconjugate vaccines 
The use of polysaccharide-based vaccines as prophylactic method has started in the 
middle of last century. However, due to the T-independent response raised by 
polysaccharides, vaccines based on CPS have limited clinical usefulness. In 1929 
Avery and Goebel reported for the first time the use of low molecular weight 
carbohydrates (containing the epitope of capsular bacterial polysaccharides) linked 
to carrier proteins.5 These constructs were able to stimulate the response of the 
immune system through the production of specific antibodies. These findings 
demonstrated the possibility to enhance the immunogenicity of T cell-independent 
polysaccharides by conjugation to an immunogenic carrier protein, generating T 
cell-dependent glycoconjugate antigens able to induce immunological memory. The 
protein carrier incorporates T cell epitope peptides, which facilitate uptake and 
processing of the glycoconjugate by APCs, enhancing the presentation of the 
carbohydrate antigen for activation of helper T cells.6 In this way immunological 
memory is established, raising a strong, durable and protective immune response 
from early childhood. Carrier proteins must be non-toxic, non reactogenic and 
should not share T cell epitopes with relevant capsular pathogens. Diphtheria toxoid 
(DT), CRM197, keyhole limpet hemocyanin (KLH), tetanus toxoid (TT), 
recombinant exoprotein from Pseudomonas aeruginosa (rEPA), outer membrane 
protein from N. meningitidis serogroup B (OMP) and more recently protein D 
derived from non-typeable H. influenzae are among the most used proteins. 
Commonly employed conjugation methods make use of chemoselective reactions 
between suitable functional groups available both on the protein and on the 
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carbohydrate moiety. Anchoring sites on the protein can be lateral amines (lysine 
residues), carboxylic acids (aspartic or glutamic acid) or sulfhydrils (cysteine). In 
addition, specific functional groups can be introduced on the protein through site 
selective modification techniques. On the contrary, attachment sites on the 
carbohydrate portion can be the intrinsic carbonyl group at the reducing end or 
aldehyde groups inserted by random periodate oxidation of oligo- or 
polysaccharides, whereas the use of synthetic carbohydrates provided with a 
suitable linker ending with amino, carboxylic, sulfhydrilic or olefinic groups 
ensures to preserve the structural integrity of the saccharide moiety (Figure 4).7 
Even if glycoconjugate vaccines are among the most used worldwide in current 
routine immunization programs, they suffer from some problems. First of all, the 
random strategies do not allow an accurate control of the conjugation reaction. 
Moreover, the precise structure of the carbohydrate portion eliciting the immune 
response cannot be established a priori, leading to an increase in manufacturing 
cost due to low batch-to-batch reproducibility and difficult characterization of the 
products. Additionally, in some cases the immunological response of the protein 
can interfere with that of the saccharide moiety. This is especially true for 
glycoconjugates of short chain oligosaccharides. Lastly, care must be taken in the 
choice of the linker. In fact, it has been shown that these moieties could be highly 
antigenic and therefore suppress antibody responses to weakly immunogenic 
saccharide antigens such as self-antigens.8,9 For all these reasons, the identification 
of alternatives to glycoconjugate constructs is becoming nowadays a relevant task 
in the vaccinology research field. 
Furthermore, in order to achieve optimal host protection, a vaccine setting should 
include a component (adjuvant) capable of amplifying the immune response. In 
particular, because saccharide antigens are often poorly immunogenic, 
carbohydrate-based vaccines need adjuvants to improve their efficiencies and the 
quality and specificity of their immune responses. Typical immunoadjuvants widely 
explored in vaccine settings are complete and incomplete Freund’s adjuvants, 
Detox, QS-21 (a saponin extracted from the bark of the Quillaja saponoria tree), 
and monophosphoryl lipid A (MPLA). 
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Figure 4: commonly employed strategies for the conjugation of carbohydrate antigens 
to carrier proteins. 
 
The administration of these strong immunoactive species can cause undesired side 
effects, however, and milder and safer lipopeptide-based immunoadjuvants have 
been employed in many vaccine candidates. In particular, a number of derivatives 
of the lipopeptide tripalmitoyl-S-glyceryl-cysteine (Pam3Cys) have been covalently 
linked to other components and included as “built-in” immunoadjuvants in vaccine 
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constructs (Figure 5). Adjuvants are perceived as “danger signals” after binding to 
PRRs, and stimulate the activation and maturation process of APCs, thus enhancing 
the speed and duration of both the innate and the adaptive immune responses. In 
particular, adjuvants function as immune potentiators, providing the pro-
inflammatory context necessary for optimal antigen-specific immune activation and 
amplifying the innate immune response. On the other hand, adjuvants can also act 
as delivery systems to localize vaccine components and to target them to APCs. 
 
Figure 5: composition of glycoconjugate vaccines. 
 
1.3.5 Multivalency 
Biological interactions involving carbohydrates have an extremely low glycan-
receptor affinity, often in the mM range. In nature, this issue is circumvented by 
multivalent receptor-ligand interactions, where multiple ligands interact 
simultaneously with multimeric receptors inducing an increase of the binding 
affinities of several order of magnitude. This is called “multivalent effect” or just 
“multivalency”. When this phenomenon is referred to carbohydrate-receptor 
interactions, it is commonly named “cluster glycoside effect”.10 It is a widespread 
opinion that this effect is essential for many fundamental biological interactions. 
Generally speaking, the valency of a system is the number of connections of the 
same type it can generate during the interaction process with a receptor. The main 
difference between mono- and multivalent interactions has thermodynamic causes. 
The association constant of a polyvalent interaction kpoly is higher than that of the 
monovalent interaction kmono. This difference depends on the structure and on the 
geometry of the receptor, as well as on the disposition of the ligands on the surface. 
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As far as the immune system is concerned, it is well known that all the classes of 
antibody have two receptor sites. Polyvalent bond with recognition patterns seems 
to be a peculiar characteristic of the immune system. A major goal pursued by the 
vaccinology research is therefore to reproduce the multivalency effect into fully 
synthetic systems using polyfunctional scaffolds capable of displaying multiple 
copies of carbohydrate antigens. Under this point of view, the traditional 
glycoconjugate vaccines can be considered as an example of replication of the 
cluster glycoside effect, since they contain a large number of carbohydrate antigens 
exposed on the protein surface that are collectively much more immunogenic than 
the corresponding monovalent forms. Fully synthetic vaccines are based on a 
modular architecture and incorporate into the same molecule different functional 
units: a synthetic glycan or a multivalent glycocluster, a synthetic T cell epitope and 
an adjuvant, such as a ligand of TLR or C type-lectin receptor onto dendritic cells 
surface. Each of them is synthesized independently, and then chemically conjugated 
in a convergent way, providing total control on the chemical structure (Figure 6). 
 
Figure 6: composition of a fully synthetic vaccine. 
 
During the last years, a wide range of synthetic clustered glycosides has been 
designed to interfere in an array of immune-related biological processes. Among 
them, glycopeptides,11-14 glycodendrimers,15-20 glycopolymers,21-25 
glyconanoparticles,26,27 glycofullerenes,28-30 glycocalixarenes,31-35 and sugar-
functionalized carbon nanotubes36 and quantum dots37-39 were shown to be efficient 
biomimetics of natural glycoclusters, often reaching low nM activities. 
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1.3.6 Zwitterionic polysaccharides 
Zwitterionic polysaccharides (ZPS) are a class of structurally distinct bacterial 
polysaccharides that possess a zwitterionic charge motif distributed along the chain 
(i.e. they contain both positive and negative charge centers within a repeating unit 
structure). Typical examples are the Sp1 capsular polysaccharide from S. 
pneumoniae type 1 and capsular polysaccharides A1, A2 and B from Bacteroides 
fragilis (Figure 7). 
 
Figure 7: examples of zwitterionic polysaccharides. 
 
ZPSs display a unique behavior among bacterial polysaccharides. A number of 
recent reports described the ability of such compounds to act like traditional T cell-
dependent antigens, activating CD4+ T cells both in vitro and in vivo through the 
traditional MHC-dependent mechanism, without protein conjugation.7,40-44 More 
interestingly, it seems that also the introduction of a zwitterionic motif into a 
naturally non-zwitterionic polysaccharide induces the activation of T cells.45,46 The 
immunogenic activity of ZPS is strictly related to their three dimensional 
conformation and overall spatial charge organization: it has been proposed that they 
assume an helical conformation, where all the charges are exposed on the outer 
surface of the polymer, in a regularly spaced pattern.47,48 Based on these findings, 
ZPS might offer previously unrecognized opportunities for the design of new 
classes of vaccines: 
- the use of ZPSs as scaffolds, acting both as carrier and adjuvant (as shown by 
Andreana and co-workers).49-51 
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- the artificial introduction (by chemical and/or chemo-enzymatic methods) of a 
zwitterionic charge motif onto the surface glycans of selected pathogens. 
The latter methodology could represent a novel and valuable alternative to currently 
employed glycoconjugate vaccines (see 1.3.4), and could afford vaccines useful for 
the prevention of a variety of infectious diseases, especially in pediatric area at high 
risk of infections. 
However, a better understanding of how ZPS antigens stimulate the host immune 
system and a correlation of the ZPS structural properties with their biological 
activity are required. 
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Salmonella typhi and typhoid fever 
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2.1 Salmonella typhi 
Salmonella enterica serovar typhi, briefly Salmonella typhi, is a Gram-negative 
bacterium belonging to the family of Enterobacteriaceae (Figure 8). 
 
Figure 8: Salmonella typhi. 
 
It is a highly invasive bacterium that passes through the intestinal mucosa to reach 
the reticuloendothelial system. After 8-14 days of incubation, it precipitates a 
systemic illness.  
S. typhi has three antigens (Figure 9): 
- the H antigen is a heat sensitive protein of the peritrichous flagellae. 
- the O or somatic antigen is a cell-wall lipopolysaccharide.52 Its repeating unit is 
the following: 
-[--D-Man(14)--L-Rha-(13)--D-Gal-(12)-]n- 
 3 4 
   
 1 1 
         -Tyv            -D-Glc(2OAc) 
- the Vi antigen is the capsular polysaccharide which overlies the O antigen. Its 
presence prevents the O-specific antibodies from binding the O antigen. 
The Vi antigen is present in strains freshly isolated from patients. Felix and Pitt, 
from both epidemiologic observations and clinical studies, found out that this 
antigen enhances the pathogenicity of the bacterium and for this reason they called 
it “Vi”, abbreviation of virulence.53,54 
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Figure 9: H, O and Vi antigens from Salmonella typhi. 
 
Vi antigen is an anionic homopolymer composed of N-acetylgalactosaminuronic 
acid repeating units predominantly O-acetylated at position 3 (Figure 10).55 The 
degree of 3-O-acetylation ranges from 60% to more than 90% in some strains. The 
immunogenicity of Vi antigen is closely related to its degree of O-acetylation. 
Partial O-deacetylation slightly increase immunogenicity, whereas complete O-
deacetylation eliminate the immunogenicity of Vi.56 
ORO
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Figure 10: chemical structure of the Vi antigen. 
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2.2 Typhoid fever 
2.2.1 Symptoms and transmission 
Typhoid fever (caused by Salmonella typhi) is a systemic infection characterized by 
high fever (39-40 °C), abdominal pain, nausea, loss of appetite and headache. In the 
early stage of the illness a bronchitic cough is common and in several patients liver 
dysfunctions can been detected. In more severe form of typhoid fever cerebral 
dysfunction, such as delirium or coma and shock may be present. This disease may 
have complications which involve any organ; an example is intestinal perforation 
followed by hemorrhage.57 Other kinds of complications are: central nervous 
system (3-35%), cardiovascular system (1-5%) and pulmonary system (1-6%).58 
This infection lasts for numerous weeks and sometimes may last for months. 
However, not all cases are hospitalized, only 10-40% of them. Humans are the only 
natural hosts of Salmonella typhi and transmission can occur by consume of 
polluted water or infected food. Indeed, human fecal material can contaminate 
water in areas where sanitation is primitive and water supplies are not treated. 
People can transmit typhoid fever as long as the bacteria remain in their body. Most 
people are infectious during the first week of convalescence but also up to three 
months if not treated. Furthermore, 2-5% of untreated patients can become 
permanent carriers of the bacterium. Anyway, diffusion of the illness from person 
to person by contact is uncommon. Studies showed that the intensity of the 
consequences of the infection depends on the concentration of the bacterium in the 
vehicle.57 Moreover, the incidence of typhoid fever seems to follow seasonal 
patterns. In some endemic areas its peak can be seen in the hot, dry months because 
of the lack of rain which increase the concentration of the organisms in water 
supplies. Instead, in other places, a peak occurs in the rainy seasons because of the 
breakdown in the system that separate sewage from drinking water.58 
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2.2.2 Epidemiology 
Because of the ways of transmission, typhoid fever is mostly spread in developing 
countries where health conditions are inadequate, hygiene is poor, and lack of 
drinking water occurs. This situation was present at the end of the 19th century in 
most large cities in the USA and western Europe, where water supplies were 
available but the water wasn’t treated, so that the transmission was amplified and 
the disease was highly endemic in those areas. With the introduction of water 
treatments in the 20th century, the incidence of typhoid fever decreased enormously. 
Even though the infection almost disappeared from industrialized cities, nowadays 
it remains in most of the less-developed areas, such as Africa, Asia and South-
America (Figure 11). According to the World Health Organization (WHO), in 2000, 
typhoid fever caused an estimated 21.7 million illnesses and 217,000 deaths, which 
makes typhoid fever a serious global public health issue.59   
 
Figure 11: geographical distribution of typhoid fever. 
 
Its incidence is highest in children and young adults between 5 and 19 years old 
(Figure 12). These cases as of 2010 caused about 190,000 deaths up from 137,000 
in 1990. Infants, children, and adolescents in South-central and South-eastern Asia 
experience the greatest burden of illness. Nonetheless, outbreaks of typhoid fever 
are frequently reported from sub-Saharan Africa and countries in South-eastern 
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Asia. Historically, in the pre-antibiotic era, the case fatality rate of typhoid fever 
was 10–20%. Today, with prompt treatment, it is less than 1%. However, about 3-
5% of individual who are infected will develop a chronic infection in the gall 
bladder. Since Salmonella typhi is human-restricted, these chronic carriers become 
the crucial reservoir and can persist for decades, further spreading the disease and 
complicating the identification and treatment of the disease.60-64 
 
Figure 12: distribution of typhoid fever, by age group, at various incidences. 
 
The global population which may be exposed to typhoid fever infection can be 
divided into three main groups which, for their higher probability to be infected, are 
called “risk groups”. They are: 
- people living in the endemic area; 
- travellers; 
- clinical microbiological technicians. 
The first class is the most obvious. Among all the indigenous populations, children 
are at the higher risk. Moreover, travellers and military personnel from 
industrialized countries are probably at special risk in the endemic areas. Indeed, 
they do not have the background immunity which most of the indigenous 
population has acquired as a consequence of the numerous infections. However the 
most unusual class at risk of exposure is that of clinical microbiological technicians. 
A laboratory is supposed to be safe from infections, especially concerning typical 
vehicles of typhoid fever, contaminated water and food. But probably in the special 
conditions of a laboratory the disease may be spread by aerosol or contact which is 
extremely in contrast whit the usual way of transmission.57 
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2.3 Diagnosis, treatment and immunization 
2.3.1 Diagnosis: a challenge 
It is not easy to diagnose typhoid fever. The most commonly employed method is 
the blood culture, but it is positive in only 40-60% of cases, usually early in the 
course of the disease. Moreover, in much of the developing world, widespread 
antibiotic availability and prescribing is another reason for the low sensitivity of 
blood cultures. Stool and urine cultures become positive after the first week of 
infection but their sensitivity is much lower whereas bone marrow cultures are more 
sensitive but difficult to obtain, relatively invasive, and of little use in public health 
settings. The classic Widal test measures antibodies against O and H antigens of S. 
typhi and is more than 100 years old. Although robust and simple to perform, this 
test lacks sensitivity and specificity, and reliance on it alone in areas where typhoid 
fever is endemic may lead to overdiagnosis. Newer diagnostic tests, such as the 
Typhidot or Tubex, which directly detect IgM antibodies against a host of specific 
S. typhi antigens have been developed, but these have not proved to be sufficiently 
robust in large scale evaluations in community settings. Despite all these new 
developments, the diagnosis of typhoid fever in much of the developing countries is 
made on clinical criteria. This poses problems, since typhoid fever may mimic 
many common febrile illnesses without localizing signs and, subsequently, the 
differential diagnosis includes malaria; sepsis with other bacterial pathogens; 
infections caused by intracellular organisms such as tuberculosis; and viral 
infections such as dengue fever, acute hepatitis, and infectious mononucleosis.65 
 
2.3.2 Treatment 
Early diagnosis of typhoid fever and prompt institution of appropriate antibiotic 
treatment are essential for optimal management, especially in children. Typhoid 
fever started to be treated with antibiotics in the mid-20th century. The first 
antibiotic used was chloramphenicol which could decrease the severity of the 
illness and the fatality rate. Subsequently, between 1970 and 1985 sporadic 
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outbreaks of chloramphenicol-resistant typhoid fever occurred. As a result, other 
antibiotics were introduced such as ciprofloxacin which was highly effective and 
amoxicillin which was useful in developing countries, where the cost of therapy is a 
critical factor. The emergence of multidrug resistant typhoid fever in the 1990s led 
to widespread use of fluoroquinolones as the treatment of choice for suspected 
typhoid fever, especially in South Asia and South East Asia where the disease was 
endemic. Standard treatment with chloramphenicol or amoxicillin is associated with 
a relapse rate of 5-15% or 4-8% respectively, whereas the newer quinolones and 
third generation cephalosporins are associated with higher cure rates. In recent 
years, however, the emergence of resistance to quinolones has placed tremendous 
pressure on public health systems in developing countries as treatment options are 
limited. Studies of short course antibiotic treatment for multidrug resistant typhoid 
fever have shown that fluoroquinolones can achieve satisfactory cure rates, but 
parenteral ceftriaxone was associated with higher rates of relapse.65 
 
2.3.3 Immunization 
Until proper sanitary conditions and clean drinking water are guaranteed in 
developing countries, vaccination against typhoid fever remains the most cost-
effective defense for susceptible populations and is recommended by the WHO.66 
Up to now, only three licensed vaccines are available on the market.67 First 
generation inactivated whole-cell vaccine were introduced in 1896 but their efficacy 
was proved only in 1960. The cells were inactivated in different ways: by heat, 
alcohol, formalin or acetone. The latter was the most used method because 
preserved the Vi antigen and improved the stability of the vaccine on long-term 
storage. Trials in different endemic areas showed that two doses of this type of 
vaccine resulted in 73% efficacy over three years (95% confidence interval 65% to 
80%), but also that the inactivated whole-cell vaccines caused fever and systemic 
reaction in 9% to 34% of recipients.67 Therefore, albeit still licensed, this kind of 
vaccine is no longer available for routine vaccinations.67 
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Consequently, only two newer types of vaccine are commercially available: orally 
administrated Ty21a and parenteral Vi polysaccharide. 
Ty21a consists of an attenuated strain of S. typhi in which multiple genes, including 
the genes responsible for the production of Vi antigen, have been mutated 
chemically so as to render it harmless but nevertheless immunogenic. This vaccine 
exists in two different oral formulations which need to be kept refrigerated: liquid 
or enteric-coated capsule. There are no differences in activity between them. Three 
doses are required to make the Ty21a vaccine effective. Protection starts 10-14 days 
after the third dose. Vaccination has to be repeated every year for travelers and 
every 3 years for those living in endemic areas in order to boost the protection 
against infection. This vaccine is licensed in 56 countries in Asia, Africa, Europe, 
South America and USA only for people 6 years and older.68 A theoretical problem 
is the reversion of the mutated strain in the virulent S. typhi. However, this 
possibility has never been detected in all the trials carried out. 
The Vi polysaccharide is a parenteral vaccine made of purified natural Vi antigen. 
The extraction procedure results in a non-denatured polysaccharide that preserves 
all N- and O- acetyl moieties. Only a single parental dose is required. Protection 
begins 7 days after the administration, while the maximum protection is achieved 
28 days later when the highest concentration of antibodies is present. Revaccination 
is suggested every three years. The only adverse effect detected is a local pain in the 
area of injection, but it is mild and of short-time. This vaccines is licensed in 
Australia and in 92 countries in Africa, Asia, the Americas and Europe for adults 
and children 2 years and older.69 
Even though they have fewer adverse effects than the previous one, they are both 
less effective over a three-years period (cumulative efficacy is 51% for Ty21a and 
55% for Vi) and the duration of protection is not well determined, with estimates of 
five to seven years for the Ty21a vaccine and three years for Vi vaccination.70 
Moreover, they cannot be administered to newborns and pre-school aged children. 
That’s why only two countries, China and Vietnam, have incorporated typhoid 
fever vaccination into their routine immunization programs. In order to overcome 
the inherent limitations associated with a T-independent antigen-based vaccine,71,72 
  
29 
Vi has been conjugated to carrier proteins such as tetanus toxoid (Pedatyph) and the 
nontoxic recombinant exotoxin A of Pseudomonas aeruginosa (Vi-rEPA),73,74 
giving rise to the third generation of typhoid vaccine. Although no efficacy data are 
available for Pedatyph, which is a licensed vaccine only in India,75 Vi-rEPA was 
shown to be safe in all ages including infants and provided excellent and long 
lasting immunity with 92% protection over two years post vaccination in a 
randomized, two-dose placebo controlled trial in 2 to 5-year-old children in 
Vietnam, and with 89% protection over 46 months.76-80 More recently, Novartis 
Vaccines reported about the development of a conjugate vaccine suitable for infant 
immunization.81 They conjugated the Vi polysaccharide to CRM197, a non-toxic 
variant of diphtheria toxin. The source of the Vi antigen is a low risk and high Vi-
yielding organism, Citrobacter freundii WR7011. Vi polysaccharide from 
Citrobacter is structurally similar and immunologically indistinguishable to Vi 
from S. typhi.82 The immunogenicity and safety of Vi-CRM197 conjugate was 
assessed in two randomized phase 2 trials in Pakistan, India, and Philippines. Vi-
CRM197 was found to be safe and well tolerated and one dose of Vi-CRM197 
significantly increased concentrations of anti-Vi antibody in adults, children, and 
older infants. However, in children and older infants, a second dose of conjugate 
vaccine had no incremental effect on antibody titres and, at all ages, concentrations 
of antibodies increased substantially 6 months after vaccination.83 
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3.1 Introduction 
As already mentioned, typhoid fever is a public health concern because of the 
growing resistance of Salmonella typhi against the antibiotics used for the 
treatments and the absence of a routine immunization. The population which is 
mainly at risk consists of pre-school- and school aged children in the endemic areas. 
For all these reasons it is necessary to find a vaccine that possess two 
characteristics: 
- it must contain T-dependent antigens so that it can induce the immunological 
memory;  
- it must be effective in children. 
The new conjugated Vi vaccines seem to fulfill all these requirements but they are 
still under development (see 2.3.3). Moreover, their production has some 
drawbacks. The biological extraction of Vi antigen from Salmonella typhi 
(controlled depolymerization) is complicated and does not lead to a product with an 
high degree of purity, thus resulting in a decrease of the efficacy. In addition, it is 
difficult to obtain large amounts of the antigen from the causative agent. In order to 
overcome these difficulties, it would be interesting to find an efficient synthetic 
route to Vi fragments of variable length. In addition, we aim at investigating if the 
introduction of the zwitterionic motif into a naturally non-zwitterionic 
polysaccharide confers to the resulting ZPS the ability to activate T cells without 
protein conjugation (see 1.3.6). The structure of the Vi CPS makes it an ideal 
candidate for a careful investigation of the biological behavior of synthetic 
zwitterionic oligomers. In fact, Vi fragments can be easily converted into 
zwitterionic derivatives by formal N-deacetylation, without introducing huge 
structural modifications. With these compounds in hand it would be possible to 
correlate the structural and conformational properties of the ZPS with their 
biological activity, both in terms of charge pattern and minimum molecular weight 
required for immunogenicity. 
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3.2 State of the art 
Only two syntheses of Vi antigen oligomers have been reported in the literature so 
far. The first one dates back to 1999, from Sinaÿ and co-workers.84 They 
synthesized Vi oligosaccharides up to hexasaccharide bearing a methyl group both 
at the anomeric position of the reducing end and at position 4 of the non-reducing 
end. The starting point was the glycal 1. The azido functionality was introduced by 
azidonitration reaction, leading to the formation of both the - and -glycosylnitrate 
in moderate yield. The former was converted into donor 2, bearing a xanthate as the 
leaving group, and the latter into acceptor 3. Glycosylation reaction afforded both  
and  anomer (Figure 13). 
 
 
Figure 13: retrosynthetic analysis. 
 
The drawbacks of this synthetic procedure are: 
- the azidonitration reaction is a laborious reaction that leads to the production of 
both anomers in only moderate yield; 
- the glycosylation reaction was not stereoselective and provided a mixture of 
anomers (/ = 3.3:1). Purification of anomeric mixtures is often difficult and 
causes a significant drop of the yield; 
- the oligosaccharides bear a non-natural 4-O-methyl group at the non-reducing 
end; 
- the methyl group at C-1 of the reducing end does not allow the conjugation of 
Vi fragments to a protein 
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Another synthesis was reported recently by Ye and co-workers.85 They prepared 
fragments up to the tetrasaccharide carrying a methyl group at the reducing end and 
a non-natural 4-O-acetyl group at the non-reducing end (Figure 14). The synthesis 
was characterized by the use of N-acetyloxazolidinone-protected thioglycoside 
donor 4 and acceptor 5. Oxazolidinone acts as a non-participating group in 
glycosylation reaction enhancing the  stereoselectivity and leading, in this case, to 
the formation of only the  anomer. 
 
 
Figure 14: retrosynthetic approach. 
 
The drawbacks of this synthetic strategy are: 
- the presence of an unnatural acetyl group at C-4 of the non-reducing end that 
cannot be selectively removed. 
- the methyl group at C-1 of the reducing end does not allow the conjugation to 
multivalent scaffolds, including proteins. 
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3.3 Aim of the work 
Our work is aimed at finding an alternative, more efficient and versatile synthesis of 
Vi fragments, that could circumvent the main drawbacks and challenges evidenced 
by Sinaÿ’s and Ye’s approaches. In particular:  
- it should ensure the exclusive formation of -glycosidic bonds;  
- it should provide versatile oligosaccharide building blocks in order to allow 
protein conjugation at the reducing-end as well as chain elongation at C-4 of the 
non-reducing end;  
- it should allow direct access both to natural Vi fragments and their zwitterionic 
analogues.  
With the final aim to perform comprehensive biological and immunological studies, 
we directed our attention on the synthesis of two distinct series of Vi-related 
oligosaccharides: the one corresponding to the natural structure and their 
zwitterionic derivatives. Moreover, the role of 3-O-acetylation will be also taken 
into account by the synthesis of both fully 3-O-acetylated and fully non-3-O-
acetylated oligosaccharides. In addition, all the oligosaccharides will be endowed 
with a suitable linker at C-1 of the reducing end to facilitate subsequent conjugation 
to multivalent scaffolds (Figure 15). 
 
 
Figure 15: structure of the target Vi oligomers. 
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4.1 First synthetic route 
In the first part of the work, we focused on the synthesis of oligomers non 
acetylated at position 3. We designed a flexible synthetic strategy based on versatile 
intermediates suitably protected for the systematic introduction of charge centers on 
each repeating unit, and containing non-participating protecting groups onto 2-
amino functions to allow the formation of 1,2-cis glycosidic linkages. The use of 
the azide group at C-2 allows the formation, in the late stages of the synthesis, of 
either an amino group (like in the ZPS) or an acetamido function (as in the natural 
Vi CPS). Moreover, the acceptor contains a suitable linker at the anomeric position 
in order to facilitate subsequent conjugation to multivalent scaffolds. Both 
intermediates are easily attainable from commercially available galactosamine 
hydrochloride (Figure 16).  
 
Figure 16: retrosynthetic analysis. 
 
Initially, we selected a propargyl group as the linker moiety and, after some 
preliminary optimization, we identified the N-phenyltrifluoroacetimidate moiety as 
the best leaving group, as it was less prone to give rearrangement by-products 
during the glycosylation reaction.86 The synthetic strategy has been optimized on 
both gram and multi-gram quantities. The synthesis of the two building blocks 
started from galactosamine hydrochloride, which was subjected to one-pot copper-
catalyzed diazotransfer reaction and acetylation using imidazolyl sulfonyl azide 
hydrochloride as the azide source. This type of reagent is less expensive and safer 
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than the classical triflic azide.87,88 Compound 8 was then selectively deprotected at 
the anomeric position, furnishing intermediate 9 (Scheme 1). 
 
Scheme 1: preparation of common intermediate 9 
 
4.1.1 Acceptor synthesis 
The synthesis of the acceptor started from compound 9, which is activated as 
trichloroacetimidate (10). Glycosylation with propargyl alcohol and catalytic 
TMSOTf afforded a mixture of the corresponding glycosides 11. The / ratio 
ranged from a good 9:1 to a moderate 3:1 when the reaction was performed on 
small and large batches, respectively. The two anomers were inseparable, so they 
were subjected to Zemplén deacetylation and benzylidene formation and, at this 
stage, they could be easily separated by flash chromatography. The 3-OH of the 
pure α anomer 13 was then benzylated. The benzylidene was cleaved by means of a 
transacetalization with ethanethiol and selective acetylation with acetyl chloride and 
sym-collidine at low temperature afforded acceptor 7a in 22% overall yield over 7 
steps (Scheme 2). We also tried to recycle the undesired beta anomer, but the 
removal of the propargyl group by treatment with potassium tert-butoxide followed 
by catalytic osmium tetroxide and N-methylmorpholine N-oxide did not take 
place.89 
 
4.1.2 Donor synthesis 
The synthesis of the donor started from compound 9, which was protected at the 
anomeric position as a silyl ether, then subjected to Zemplén deacetylation and 
installation of 4,6-O-benzylidene, affording compound 18. The 3-OH was then 
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benzylated and the anomeric silyl group was cleaved. The last step was the 
formation of the imidate by the treatment with cesium carbonate and N-
phenyltrifluoroacetimidoyl chloride, furnishing the desired donor 6 in good 65% 
overall yield over 6 steps (Scheme 3). 
 
Scheme 2: synthesis of acceptor 7a. 
 
 
Scheme 3: synthesis of donor 6. 
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4.1.3 Glycosylation and deprotection 
Then, we optimized the glycosylation between these two building blocks (Scheme 
5). As we had in hand a reactive donor and a less reactive acceptor, we decided to 
use an excess of the former to promote the reaction.  
Table 1 summarizes the results obtained. Gratifyingly, all the tested reaction 
conditions gave stereoselectively the desired  product. The first attempt was 
performed using 1.5 eq of donor and 0.2 eq of TMSOTf as the acidic promoter at -
20 °C but the yield was low. We thought that this result could be explained by the 
high acidity of the reaction medium. So we tried a weaker Lewis acid like AgOTf, 
obtaining only traces of the product. The next attempt was made employing only 
0.1 eq of TMSOTf and increasing the amount of donor up to 2 equivalents. In this 
condition the yield was good, 58% of the α disaccharide 21. We explored also an 
“inverse glycosylation” procedure,90 but we could detect the -(16)-dimer as by-
product, probably deriving from 6-OH to 4-OH acetyl migration in the acceptor 
under prolonged acidic conditions. The best result were obtained by a slow addition 
via a syringe pump, over 1 hour, of a diluted solution (0.055 M) of the Lewis acid. 
This methodology permitted the use of only 1.5 eq of donor, instead of 2, with 
comparable yield and the same stereoselectivity. 
In order to deprotect the primary positions the benzylidene acetal must be 
regioselectively opened and the acetyl group must be removed. Unfortunately, 
when we attempted regioselective reductive opening of the benzylidene ring on the 
acetylated dimer 21 (Scheme 4) we obtained complex reaction mixtures with 
various reagents combinations and no product was formed (Table 2).91-94 
 
Scheme 4: regioselective reductive benzylidene ring opening on dimer 21. 
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Scheme 5: glycosylation reaction. 
 
 
Table 1: glycosylation reaction conditions. 
 
 Conditions Don.eq. 
Acc.
eq. Lewis acid T (ºC) Yield 
1 
Direct glycosylation 
1.5 1 TMSOTf, 0.2 eq. -20 16%, α 
2 1.5 1 AgOTf, 0.6 eq. -10 trace, α 
3 2 1 TMSOTf, 0.1 eq. 0 58%, α 
4 “Inverse glycosylation” 2 1 TMSOTf, 0.1 eq. 0 45% α-(14)+ 8% α-(16)
5 Slow addition of diluted L.A. 1.5 1 TMSOTf, 0.1 eq. 0  rt 71%, α 
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Reagents T (°C) Yield
CuOTf, BH3THF 15 / 
CuOTf, BH3THF -15 / 
CoCl2, BH3THF rt / 
Et3SiH, PhBCl2 
-78  -40
-78  0 
-78  rt 
/ 
/ 
/ 
Table 2: conditions for the regioselective reductive benzylidene ring opening on dimer 21. 
 
Surprisingly, when we tried the same reaction on the deacetylated dimer 23, we 
obtained smoothly the desired product 24 in 92% yield (Scheme 6). 
 
Scheme 6: deprotection of the primary positions. 
 
4.1.4 Oxidation 
The following step is the oxidation of the primary positions. To facilitate the 
purification and the characterization of the product during the initial optimization of 
the reaction conditions we decided to isolate the corresponding bis-methyl ester 
(Scheme 7).  
 
Scheme 7: oxidation to methyl uronates. 
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Several methodologies were tested on compound 24, and the results are 
summarized in Table 3. The oxidation with RuCl3 gave a complex mixture of 
inseparable products, probably due to oxidation of the multiple bond and of the 
benzyl ethers. Also the application of the classical TEMPO-mediated reaction 
conditions gave unsatisfactory results. The use of catalytic TEMPO and BAIB as 
the stoichiometric oxidant resulted in a complex reaction mixture, presumably due 
to degradation of the triple bond. On the contrary, the reaction did not occur using 
sodium hypochlorite as the oxidant. Only a two-step procedure involving Dess-
Martin periodinane (DMP) and Pinnick oxidation95 gave the desired product in 39% 
yield, along with another major product 26 derived from intramolecular Huisgen 
cycloaddition under basic conditions. The use of IBX instead of DMP furnished 
only product 26 in low yield. 
 Oxidizing agents Temp. Yield 
1 RuCl32H2O, NaIO4 rt / 
2 TEMPO, BAIB rt / 
3 TEMPO, NaOCl, KBr, NaHCO3 0ºC n.r. 
4 DMP then NaClO2, NaH2PO4, 2-methyl-2-butene rt 39% 25 + 11% 26 
5 IBX then NaClO2, NaH2PO4, 2-methyl-2-butene 80ºC, rt 22% 26 
Table 3: oxidation conditions. 
 
4.1.5 Natural Vi disaccharide 
In order to overcome the issue related to intramolecular “click reaction”, compound 
24 was subjected to azide reduction, acetylation and deacetylation affording 
compound 27, suitable for the synthesis of the natural Vi disaccharide. In this way, 
due to the presence of the acetamido function at position 2, compound 27 could be 
oxidized by the DMP/Pinnick protocol, as the intramolecular cyclization could not 
take place. The oxidation, followed by protection of the carboxylic acids as benzyl 
esters to facilitate purification of the product, furnished the desired uronate 28 in 
moderate and non-reproducible 50% yield. Full deprotection was finally achieved 
by high pressure hydrogenolysis (Scheme 8). 
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Scheme 8: synthesis of the natural Vi disaccharide. 
 
4.1.6 Zwitterionic disaccharide derivative 
The synthesis of the zwitterionic disaccharide derivative required the application of 
special reaction conditions for the oxidation step, in order to avoid the formation of 
undesired side-products. We found in the literature a procedure specifically 
developed for the oxidation of C-C multiple bond-containing molecules, the so-
called Zhao’s modification of the TEMPO oxidation.96 The reaction takes place 
under strictly controlled buffered conditions (phosphate buffer pH 6.7) and employs 
sodium chlorite as the stoichiometric oxidant and only a catalytic amount of sodium 
hypochlorite. We employed compound 30 obtained from 23 by benzylidene 
cleavage. The oxidation under buffered conditions, followed by esterification, gave 
only the desired product 31, although in modest yield. Finally, full deprotection by 
high pressure hydrogenation furnished the zwitterionic derivative 32, isolated as the 
corresponding dihydrochloride (Scheme 9). 
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Scheme 9: synthesis of the zwitterionic disaccharide derivative. 
  
4.1.7 Biological assay 
The binding affinities of compounds 29 and 32 were preliminary evaluated by 
ELISA competitive assay using natural Vi polysaccharide as positive control. The 
results showed that both disaccharides are recognized by the antibody in a dose-
dependent manner (Figure 17). 
 
Figure 17 
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4.1.8 Disaccharide donors 
However, the elongation strategy so far described is suitable only for the synthesis 
of very short oligomers. We therefore explored a new and more efficient 
oligomerization strategy based on disaccharide donors. We designed two new 
disaccharide donors: compound 33 is the elongation block since, after the 
glycosylation, the benzylidene group can be easily manipulated in order to obtain a 
new glycosyl acceptor. Compound 34 is the capping block, as the 4-OH is protected 
with a permanent benzyl group. The use of these building blocks, along with 
compound 7 and 35 as acceptors, permits the elongation of the chain by either the 
“2n+1” or the “2n+2” approaches, two monosaccharide units at a time (Figure 18). 
The synthesis started from the common intermediate 19. The monosaccharide 
acceptor 37 was obtained in two step by benzylidene cleavage and selective 
acetylation at low temperature. The monosaccharide donor 39 was obtained by 
regioselective reductive benzylidene ring opening, acetylation, deprotection of the 
anomeric position and formation of the imidate (Scheme 10).  
 
Figure 18: glycosylation approach based on disaccharide donors.  
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Scheme 10: synthesis of the monosaccharide donor and acceptor. 
 
Glycosylation of 37 and 39 with 0.1 eq of TMSOTf afforded precursor 40, which 
was converted into donor 34 by desilylation and formation of the corresponding 
imidate in good overall yield. The same steps were applied to the synthesis of 
compound 41, precursor of the disaccharide donor 33 (Scheme 11). 
 
Scheme 11: synthesis of the disaccharide donors. 
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4.1.9 Trisaccharide derivatives 
Then, as a proof of concept, we tested disaccharide donor 34 in the synthesis of the 
trisaccharide but unfortunately, under standard glycosylation conditions, at -40 and 
0°C, we got an inseparable mixture of the -(14) and -(16) regioisomers, 
probably due to acetyl migration, as deduced by analysis of the NMR spectra 
(Scheme 12). 
 
Scheme 12: glycosylation with disaccharide donor. 
 
To overcome this problem we replaced the acetyl group at position 6 in the acceptor 
with a silyl ether, thus obtaining only the desired product 46 in 59% yield after 
desilylation (Scheme 13). 
 
Scheme 13: optimized glycosylation with disaccharide donor. 
  
51 
Firstly, we tried Zhao’s TEMPO oxidation on the triol derived from deacetylation 
of compound 46  in order to obtain the zwitterionic derivative, but the reaction did 
not take place. Thus, compound 46 was subjected to azide reduction and 
acetylation, deprotection of the primary positions and oxidation with the 
DMP/Pinnick protocol followed by benzyl esters formation to obtain the protected 
Vi trisaccharide 48, in 34% yield. Also in this case, the final deprotection was 
achieved by high pressure hydrogenolysis (Scheme 14). 
 
Scheme 14: synthesis of the natural Vi trisaccharide. 
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4.2 Second synthetic route 
The encouraging results of the ELISA test on the two disaccharide derivatives (see 
4.1.7) prompted us to improve our synthetic strategy. In particular, several 
drawbacks derived from the use of the propargyl group as the linker moiety, that 
caused a drastic drop of the overall yield during the oxidation step. We therefore 
switched to a 4-pentenyl linker (Figure 19). One advantage of this linker is that it is 
easily converted into various functional groups that can be used in the conjugation 
chemistry (such as aldehydes, amino groups and carboxylic acids). 
 
Figure 19: retrosynthetic approach. 
 
4.2.1 Building blocks synthesis 
The synthesis of the new building blocks started from the common intermediate 9. 
The anomeric position was activated as a trichloroacetimidate and glycosylation 
with 4-pentenol using catalytic TMSOTf afforded a nearly 1:1 mixture of the 
corresponding glycosides 50. The two anomers could be easily separated by flash 
chromatography after Zemplén deacetylation and installation of a 4,6-O-
benzylidene. The key advantage of the use of the pentenyl moiety is the possibility 
to exploit both anomers. In particular, the pure  anomer 52 can be converted into 
acceptor 7b by benzylation, benzylidene removal and selective acetylation at 
position 6. On the other hand, the pure  anomer 51 can be recycled through a 
halocyclization reaction followed by in situ hydrolysis and converted into donor 6 
(Scheme 15).97 This possibility contributes to keep the whole strategy as much 
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economical as possible. By comparison, in the previous strategy, the α/β ratio of the 
propargyl glycosides was higher, but the  anomer has to be discarded after 
benzylidene formation, leading to a loss of about 30% of product (see 4.1.1). 
 
Scheme 15: synthesis of donor 6 and acceptor 7b. 
 
4.2.2 Disaccharide derivatives 
The glycosylation between 6 and 7b was performed under the previously optimized 
conditions, by a slow addition of the Lewis acid, affording compound 53 with 
complete stereoselectivity, in 70% yield after deacetylation. Compound 53 was 
subjected to regioselective reductive benzylidene ring opening and then oxidized by 
the DMP/Pinnick protocol, followed by protection of the carboxylic acids as benzyl 
esters, thus obtaining the desired uronate 54 in 63% yield. The zwitterionic 
derivative 55 was simply obtained after full deprotection by hydrogenolysis. The 
disaccharide corresponding to the natural Vi structure 56 was obtained from 55 by 
neutralization of the hydrochloride and selective N-acetylation (Scheme 16). 
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Scheme 16: synthesis of the natural Vi disaccharide and its zwitterionic derivative. 
 
4.2.3 Glycosylation with disaccharide donor 
Given the above mentioned acetyl migration issue during the glycosylation with 
disaccharide donor (see 4.1.8), we decided to replace the acetyl group at position 6 
with a silyl ether also in acceptor 7b. The new acceptor 57 was then glycosylated 
with disaccharide donor 34, smoothly obtaining the desired protected trisaccharide 
59 in 83% yield after desilylation (Scheme 17).  
 
4.2.4 Trisaccharide derivatives 
Compound 59 was subjected to deprotection of the primary positions by 
saponification and then oxidized with the DMP/Pinnick protocol followed by 
benzyl esters formation to obtain the protected uronate 61, but the yield of the 
oxidation step dropped to a moderate 41%. Also in this case the zwitterionic 
derivative 62 was obtained by high pressure hydrogenolysis and the Vi 
trisaccharide 63 was obtained from 62 by selective N-acetylation (Scheme 18). 
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Scheme 17: glycosylation with disaccharide donor. 
 
 
Scheme 18: synthesis of the natural Vi trisaccharide and its zwitterionic derivative. 
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4.2.5 Biological assay 
The biological behavior of the four compounds was evaluated by ELISA 
competitive assay using horse anti-Vi polyclonal antibodies and natural Vi 
polysaccharide as the positive control. The results showed that the oligosaccharides 
are all recognized by the antibody in a dose-dependent manner (Figure 20 and 
Figure 21). In particular, both trisaccharides have a slightly higher affinity than the 
disaccharides and their IC50 values are in the same order of magnitude as that of the 
natural polysaccharide. But it is also important to notice that the zwitterionic 
derivatives have comparable values as their natural Vi counterpart, suggesting that 
the N-acetylation could not be a structural prerequisite for antibody recognition. 
However, all four compounds have a low avidity (as judged by their maximum 
inhibition values), but this could be explained by their short chain length. In fact, 
they are too small to compete efficiently with the natural polysaccharide (Table 4). 
 
Compound IC50 (mg/ml) Maximum Inhibitiona (%) 
Vi CPS (~ 4000 residues) 6.1 x 10-5 100 ± 2 
Vi disaccharide 56 1.5 x 10-4 28 ± 4 
Zwitterionic disaccharide 55 7.2 x 10-4 30 ± 5 
Vi trisaccharide 63 2.9 x 10-5 35 ± 3 
Zwitterionic trisaccharide 62 1.3 x 10-5 34 ± 7 
Table 4: a the maximum inhibition elicited by each compound at 1 mg/ml 
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5.1 First route 
As previously mentioned in chapter 2.1, the immunogenicity of Vi antigen is 
closely related to its degree of 3-O-acetylation. Accordingly, in the second part of 
this work we investigated a different synthetic strategy in order to obtain the natural 
Vi oligomers and their zwitterionic analogues fully acetylated at C-3. Initially, we 
decided to introduce the acetate ester in the early steps of the synthesis by 
acetylation of glycosides 51 and 52 (Figure 22). 
 
Figure 22: retrosynthetic analysis. 
 
Disappointingly, we got extensive acetyl migration during the benzylidene cleavage 
step (Scheme 19) under different reaction conditions (Table 5). We then explored 
the use of the p-methoxybenzyl (PMB) as a temporary protection of 3-OH, but it 
was found very labile under the acidic conditions of the glycosylation reaction, 
leading to an inseparable mixture of partially protected disaccharides in moderate 
overall yield (Scheme 20). 
 
Scheme 19: acetyl migration issue during the benzylidene cleavage step. 
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Conditions Yield 
EtSH, cat. pTSA, dry DCM, rt 60% + 15% b, c 
EtSH, cat. pTSA, dry DCM, 0°C 20% + 40% b 
80% TFA, DCM, -20°C to rt 50% + 30% b, c 
80% AcOH, 70°C 40% + 20% b, c 
Table 5: benzylidene removal conditions. 
 
 
Scheme 20: glycosylation with PMB-protected building blocks. 
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5.2 Second route 
Taking into account the previous issues, we decided to move to a totally different 
approach based on the use of uronate building blocks following an oxidation pre-
glycosylation approach (Figure 23). In this way, besides overcoming the problem 
related to protection at C-3, we also aimed at improving the dramatic drop of the 
overall yield occurring when the oxidation step is performed in the late stages of the 
synthesis. 
 
Figure 23: uronate building blocks. 
 
The presence of the electron-withdrawing ester function at C-5 makes the uronic 
acids less reactive glycosylation partners than their unoxidized counterparts. In 
particular, uronate donors are known to possess poor reactivity and/or lack of 
selectivity and therefore require excellent leaving groups for their activation.98,99 In 
order to test the feasibility of this new strategy, we carried out a preliminary 
glycosylation attempt with two readily prepared building blocks 67 and 68, and, 
although not completely stereoselective, the reaction furnished disaccharide 54 in 
good 68% yield with an α/β ratio higher than 5 to 1 (estimated by NMR, Scheme 
21). Literature data show that the  stereoselectivity in the glycosylation with 
galacturonate donors can be improved by the presence of 4-O-acyl groups, an effect 
known as remote anchimeric assistance.100-102 Therefore we designed the new 
strategy based on donor 96 and acceptor 70. Both compounds contain an acetate 
group at position 3 and the donor bears an orthogonal acyl group at position 4, 
allowing easy chain growth. Moreover, due to the high cost of the starting material 
(galactosamine hydrochloride), we decided to synthesize the new galacturonate 
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building blocks via inversion of C-4 configuration of glucosamine hydrochloride 
(Figure 24). 
 
Scheme 21: preliminary glycosylation attempt. 
 
 
Figure 24: retrosynthetic strategy. 
 
5.2.1 Building blocks synthesis 
Initially, we selected a Lev moiety as orthogonal acyl protecting group at C-4. The 
early steps of this new synthetic strategy are the same previously described for 
galactosamine, but performed on glucosamine, and led to obtain the two anomers 
72 and 73. They were separated by crystallization and used independently in the 
following steps. The two compounds were protected at position 3 with the Lev 
group, followed by benzylidene cleavage and silylation of the primary position. The 
inversion with concomitant Lev migration was obtained by treatment with triflic 
anhydride followed by addition of water and heating.103 Acetylation followed by 
simultaneous desilylation/oxidation of the primary position with Jones reagent 
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afforded uronates 76 in satisfactory yields. At this stage the pure α anomer was 
planned to be converted into acceptor 70 by selective removal of the Lev group, 
whereas the pure β anomer transformed into donor 69a through pentenyl hydrolysis 
and formation of the imidate (Scheme 22). 
 
Scheme 22: synthesis of donor 69a and acceptor 70. 
 
Disappointingly, when we attempted Lev removal on precursor 76α (Scheme 23) 
we obtained, under different reaction conditions, an inseparable mixture of the 
desired product 70 and a variable amount of the glycoside 78 derived from acetyl 
migration from C-3 to C-4 (Table 6). We ascribed this result to the rather basic 
conditions required for Lev removal. We reasoned that we could circumvent the 
acetyl migration by replacing the levulinoyl group with the chloroacetyl ester, that 
can be removed under strictly neutral conditions. As a proof of concept, we tested 
this reaction on galactoside 83. This compound was obtained in good yield starting 
from intermediate 79, which was subjected to installation of a 3,4-O-
isopropylidene, oxidation with BAIB and catalytic TEMPO under two-phases 
conditions, hydrolysis of the acetal, borinic ester-catalyzed regioselective 
acetylation104 at position 3 and chloroacetylation at position 4. ClAc removal was 
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obtained by treatment with thiourea in refluxing DCM/MeOH, providing smoothly 
acceptor 70 in 95% yield as the sole product (Scheme 24). 
 
Scheme 23: Lev removal. 
 
Conditions Yield 70/78 
NaBH4, H2O, pH 5-8 /  
NaHSO3, THF n.r.  
H2NNH2·AcOH 80% 2:1 
H2NNH2·H2O, Py/AcOH 4:1, 5%  75% 1:1 
Table 6: Lev removal conditions. 
 
 
Scheme 24: ClAc removal attempt on galactoside 83. 
 
  
  
67 
5.3 Perspectives 
Future work will concern the optimization of the synthesis of the building blocks 
starting from glucosamine hydrochloride, using the chloroacetate ester to protect 
position 4 in the donor, and the optimization of the glycosylation reaction 
conditions with building blocks 69b and 70. We will also explore the “2n+1” and 
“2n+2” glycosylation approaches employing the uronate disaccharide donor 85,   
which could be obtained from disaccharide 84 by pentenyl hydrolysis (Figure 26). 
Another important aspect we will also focus on is the elaboration of the linker 
moiety in order to allow protein or multivalent scaffold conjugation. In fact, the 
target oligomers obtained by hydrogenolysis contain a pentyl arm at the reducing 
end, and they are therefore unsuitable for conjugation. To this end, various options 
will be investigated. For example, the terminal C-C double bond of the pentenyl 
linker can be converted into an aldehyde by ozonolysis prior to global deprotection. 
Another option is to perform a chemoselective thiol-ene “click” reaction using a 
bifunctional organic thiol (Figure 25). 
 
Figure 25: manipulation of the linker moiety. 
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Figure 26: global synthetic strategy. 
 
  
6 
Experimental section 
  
70 
  
  
71 
General experimental methods 
Thin Layer Chromatography 
Thin Layer Chromatography (TLC) and High Performance Thin Layer 
Chromatography (HPTLC) were performed on Merck precoated 60F254 plates (0.25 
mm and 0.2 mm thickness, respectively). Reactions were always followed by TLC 
analysis. Compounds were visualized, when appropriate by UV light (254 nm), and 
always by spraying with: 
- molybdic solution (21 g of (NH4)4Mo4O24, 1 g of Ce(SO4)2, 31 mL of H2SO4 
98%, 970 mL H2O) 
- sulphuric acid (50 mL of H2SO4 98%, 450 mL of MeOH, 450 mL H2O) 
- ninhydrin (2.7 g of 2,2-dihydroxyindane-1,3-dione, 27 mL of AcOH, 900 mL 
of EtOH) 
with detection by charring at 196°C. 
 
Flash chromatography 
According to Still procedure,105 compounds were purified by flash chromatography, 
using Silica gel (SiO2, high-purity grade (Merck Grade 9385), pore size 60 Å, 230-
400 mesh particle size) from Sigma-Aldrich. In some cases it was also used a flash 
purification system, Biotage SP1. Normal- and reverse phase Biotage SNAP 
cartridges (sizes from 10 g to 340 g, standard 50 μm silica) were used to purify the 
compounds. 
 
NMR analysis 
NMR spectra were recorded on a Bruker AMX 400 instrument (400 and 100.6 MHz 
for 1H and 13C, respectively), and were all run at room temperature (298K), unless 
otherwise noted. The samples were prepared using deuterated solvents (CDCl3, D2O 
and CD3OD from Sigma-Aldrich). Chemical shifts (δ) are reported in ppm and the 
coupling constants (J) in Hz. Chemical shifts were referenced to the residual proton 
in the solvent (e.g. the CHCl3, 0.01 % in 99.99 % CDCl3), according to Gottlieb and 
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Nudelman.106 Multiplicities are abbreviated as: br (broad), s (singlet), d (doublet), t 
(triplet), hept (heptet), m (multiplet) or combinations thereof. 1H-NMR spectra were 
recorded for all the synthesized products. In the case of unknown structure, the 
characterization is reported by 1H-NMR and 13C-NMR. Bidimensional experiments 
(COSY, TOCSY, HSQC and HMBC) were used to better assign peaks to the 
structure. Carbon atoms and protons on each sugar residue were identified by 
numbers in accordance to Figure 27. C-6 methylene protons were labeled with 
letters “a” and “b”. 
 
Figure 27 
 
Mass analysis 
Low resolution mass analyses were recorded in negative or positive mode on a 
Thermo Finnigan LCQ Advantage equipped with an ESI source. High resolution 
mass analyses were recorded on a Waters Micromass Q-Tof micro equipped with a 
LockSpray ESI source or on a Bruker Daltonics ICR-FTMS APEX II at C.I.G.A, 
University of Milan. 
 
Optical rotatory power 
Optical rotations were measured at r.t. with a Pelkin-Elmer 241 polarimeter (589 
nm, D line from sodium lamp); the polarimeter tube was 100 mm thick and 1 ml of 
capacity. Optical rotatory powers were measured following the equation: 
[α]D20 = (10000·)/(l·c), where α is the observed rotation (on the average of 10 
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experimental values), l is the length of the observed layer in mm, c is the number of 
g of substance contained in 100 ml of solution. The optical rotation (α) can be 
expressed in angular degrees: values are given in 10-1 deg cm2 g-1 unit. 
 
Anhydrous environment 
Unless otherwise stated, all the reaction were conducted under nitrogen atmosphere. 
When stirred overnight, the reaction were put under anhydrous atmosphere by an 
Argon-balloon. 
 
Solvents 
Unless otherwise stated, all the reactions were performed using dry solvents. DCM, 
Et2O, MeOH, pyridine, toluene, DMF, CH3CN and THF over molecular sieves 
were purchased from Sigma-Aldrich and used without further purifications. 
 
Competitive ELISA assay 
96-Well flat-bottomed plates were incubated overnight at 4-8°C with a mixture of 
S. thypi Vi CPS (kindly provide by Sanofi Pasteur, Marcy L’Etoile, France) (1 
mg/mL) and methylated human serum albumin (1 mg/mL). A solution of foetal calf 
serum (5%) in phosphate-buffered saline supplemented with Brij-35 (0.1%) and 
sodium azide (0.05%) was applied to the plates for blocking of nonspecific binding 
sites. The plates were incubated overnight at 4-8°C with a solution (1:200) of horse 
anti-Vi, used as reference serum (Remel, Lenexa, USA). When Vi analogs were 
tested, they were added to each well immediately before the addition of the 
reference serum. The plates were then incubated with alkaline phosphatase 
conjugate rabbit anti-horse IgG (Sigma-Aldrich, Milan, Italy), stained with p-
nitrophenylphosphate, and the absorbance was measured at 405 nm with an 
Ultramark microplate reader (Bio-Rad Laboratories S.r.l., Milan, Italy). 
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6.1 3-non-O-Ac (3-OH) oligomers 
6.1.1 First route – propargyl linker 
 
1,3,4,6-Tetra-O-acetyl-2-azido-2-deoxy-D-galactopyranoside (8) 
 
 
 
Anhydrous K2CO3 (19.8 g, 143 mmol) was added to a suspension of D-
galactosamine hydrochloride (10.29 g, 47.7 mmol) in MeOH (250 mL) at 0°C and 
the mixture is left under vigorous stirring for 15 min. Imidazole-1-sulfonyl azide 
hydrochloride (11.99 g, 57.24 mmol) was then slowly added, followed by 
CuSO4·5H2O (120 mg, 0.48 mmol). The reaction was monitored by RPTLC 
(CH3CN/MeOH/H2O 10:5:1). After 2 h the solvent was removed, then the crude 
was coevaporated three times with toluene and kept under vacuum overnight. The 
crude was suspended in pyridine (64.4 mL, 763 mmol) and DCM (150 mL), 
catalytic DMAP was added. Ac2O (36 mL, 382 mmol) was slowly added to the 
suspension at 0°C, then the reaction was warmed to rt and stirred for 3 h until 
completion (TCL, eluent hexane/AcOEt 6:4). The mixture was quenched with 
crushed ice and the solvent evaporated. The crude was diluted with DCM and 
washed with 5% aq. HCl, satd. NaHCO3 and brine. The organic phase was dried 
over Na2SO4, filtered and concentrated in vacuo. Flash chromatography 
(hexane/AcOEt 6:4) afforded compound 8 (11.7118 g, 66%) as a white foam. 
 
Spectroscopic data were in agreement with those reported in the literature.3 
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3,4,6-Tri-O-acetyl-2-azido-2-deoxy-D-galactopyranose (9) 
 
 
 
A solution of hydrazinium acetate was prepared by slow addition of acetic acid 
(1.67 mL, 29.3 mmol) to a stirred solution of hydrazine hydrate (1.85 mL, 38.1 
mmol) in MeOH (19 mL) at 0°C. After 15 min, the solution was slowly added to 
compound 8 (10.9239 g, 29.3 mmol) dissolved in DMF (60 mL), and stirred for 1.5 
h (TLC hexane/AcOEt 6:4). The solvent was evaporated, the crude was taken up 
with AcOEt and washed with brine. The organic phase was dried with Na2SO4, 
filtered and the solvent removed. Compound 9 was obtained as a light yellow foam 
(9.693 g, quant.) and used in the following step without further purification. 
 
Spectroscopic data were in agreement with those reported in the literature.4 
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3,4,6-Tri-O-acetyl-2-azido-2-deoxy-D-galactopyranosyl trichloroacetimidate 
(10) 
 
 
 
Compound 9 (10.48 g, 31.6 mmol) was dissolved in DCM (50 mL). 
Trichloroacetonitrile (31.7 mL, 316 mmol) and catalytic DBU were added and the 
reaction mixture was stirred for 1.5 h (TLC, hexane/AcOEt 6:4). The solvent was 
removed and the crude was purified by flash chromatography (hexane/AcOEt 6:4 + 
2% TEA), affording compound 10 (12.94 g, 86%) as a white foam. 
 
Spectroscopic data were in agreement with those reported in the literature.5 
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Propargyl 3,4,6-tri-O-acetyl-2-azido-2-deoxy-D-galactopyranoside (11) 
 
 
 
Compound 10 (12.94 g, 27.2 mmol) was dissolved in Et2O (20 mL) and DCM (5 
mL) under Argon atmosphere at 0°C, and propargyl alcohol (1.9 mL, 32.6 mmol) 
was added. Then a solution of TMSOTf (0.11 M in DCM, 12.7 mL, 1.4 mmol) was 
slowly added. The reaction was monitored by HPTLC (hexane/AcOEt 6:4). After 2 
h the mixture was neutralized with TEA, filtered on a Celite pad and the solvent 
was removed. Flash chromatography (hexane/AcOEt 7:3 to 6:4) afforded pure 11 
(8.84 g, 88%, α/β 3:1) as a white foam. 
 
Spectroscopic data were in agreement with those reported in the literature.6 
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Propargyl 2-azido-2-deoxy-D-galactopyranoside (12) 
 
 
 
A solution of MeONa in MeOH (0.1 M, 2 mL, 5 mmol) was added to compound 11 
(4.78 g, 12.95 mmol) dissolved in MeOH (40 mL) and the mixture was stirred for 2 
h (TLC, DCM/MeOH 9:1). The reaction is neutralized with Amberlite IR-120, 
filtered and the solvent was removed in vacuo. The product was used in the 
following step without further purification (quant.). 
 
Spectroscopic data were in agreement with those reported in the literature.7 
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Propargyl 2-azido-4,6-O-benzylidene-2-deoxy--D-galactopyranoside (13) 
 
 
 
Compound 12 (3.15 g, 12.95 mmol) was dissolved in CH3CN (30 mL), 
benzaldehyde dimethyl acetal (5.2 mL, 34.7 mmol) and pTSA·H2O (246 mg, 1.3 
mmol) were added. The reaction was stirred overnight (TLC, hexane/AcOEt 6:4), 
then quenched with TEA and the solvent was evaporated. Flash chromatography 
(hexane/AcOEt 8:2 to 6:4) afforded compound 13 (2.22 g, 52%) as a white solid. 
 
1H NMR (400 MHz, CDCl3, 25°C): δ = 7.52 – 7.35 (m, 5H, arom.), 5.56 (s, 1H, 
PhCH), 5.19 (d, J1,2 = 3.5 Hz, 1H, H-1), 4.30 – 4.23 (m, 4H, OCH2CCH, H-6a, H-
4), 4.15 (dd, J2,3 = 10.6, J3,4 = 3.7 Hz, 1H, H-3), 4.08 (dd, J6a,6b = 12.7, J5,6b = 1.7 
Hz, 1H, H-6b), 3.78 (br d, J = 1.3 Hz, 1H, H-5), 3.65 (dd, J2,3 = 10.6, J1,2 = 3.5 Hz, 
1H, H-2), 2.48 (t, J = 2.4 Hz, 1H, OCH2CCH), 2.47 (br s, 1H, OH) ppm. 
 
13C NMR (100.6 MHz, CDCl3, 25°C): δ = 101.36 (PhCH), 97.64 (C-1), 75.45 (C-
4), 75.22 (OCH2CCH), 69.07 (C-6), 67.66 (C-3), 63.36 (C-5), 60.60 (C-2), 55.56 
(OCH2CCH) ppm. 
 
ESI HR-MS (MeOH) for [C16H17N3O5Na]+ calcd: 354.10604, found: 354.10591 
 
[α]D20 = 169.34 (c = 1 in CHCl3) 
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Propargyl 2-azido-3-O-benzyl-4,6-O-benzylidene-2-deoxy--D-
galactopyranoside (14) 
 
 
 
Compound 13 (1.2992 g, 3.92 mmol) and BnBr (930 µL, 7.84 mmol) were 
dissolved in DMF (20 mL), then NaH was slowly added portionwise over 2 h. The 
reaction was stirred for a further 1 h (TLC, hexane/AcOEt 6:4), then carefully 
quenched with MeOH and neutralized with Amberlite IR-120. The mixture is 
filtered and the solvent evaporated. The crude is taken up with AcOEt and washed 
with water and brine. The organic phase was dried with Na2SO4, filtered and 
evaporated in vacuo. Flash chromatography (hexane/AcOEt 8:2) furnished 
compound 14 (1.2224 g, 74%) as a white foam. 
 
1H NMR (400 MHz, CDCl3, 25°C): δ = 7.55 – 7.28 (m, 10H, arom.), 5.47 (s, 1H, 
PhCH), 5.19 (d, J1,2 = 2.3 Hz, 1H, H-1), 4.74 (m, 2H, OCH2Ph), 4.29 (m, 2H, 
OCH2CCH), 4.24 (m, 1H, H-6a), 4.21 (m, 1H, H-4), 4.01 (m, 3H, H-6b, H-2, H-3), 
3.69 (m, 1H, H-5), 2.46 (t, J = 2.4 Hz, 1H, OCH2CCH) ppm. 
 
13C NMR (100.6 MHz, CDCl3, 25°C): δ = 101.16 (PhCH), 97.75 (C-1), 76.21 
(OCH2CCH), 74.83 (C-3), 73.26 (C-4), 71.59 (OCH2Ph), 69.40 (C-6), 63.54(C-5), 
58.84 (C-2), 55.60 (OCH2CCH) ppm. 
 
ESI HR-MS (MeOH) for [C23H23N3O5Na]+ 444.15299, found: 444.15277 
 
[α]D20 = 152.9 (c = 1 in CHCl3) 
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Propargyl 2-azido-3-O-benzyl-2-deoxy--D-galactopyranoside (15) 
 
 
 
Compound 14 (1.3346 g, 3.17 mmol) was dissolved in DCM (20 mL). EtSH (1.4 
mL, 19 mmol) and then pTSA·H2O (120 mg, 0.63 mmol) were added. The reaction 
was stirred for 1 h (TLC, hexane/AcOEt 6:4), then quenched with TEA and the 
solvent was removed. Flash chromatography (hexane/AcOEt 5:5) afforded 
compound 15 (1.0346 g, 98%) as a white solid. 
 
1H NMR (400 MHz, CDCl3, 25°C): δ = 7.45 – 7.28 (m, 5H, arom.), 5.15 (d, J1,2 = 
3.5 Hz, 1H, H-1), 4.71 (m, 2H, OCH2Ph), 4.28 (m, 2H, OCH2CCH), 4.12 (br d, J = 
2.7 Hz, 1H, H-4), 3.95 – 3.87 (m, 2H, H-6a, H-5), 3.86 – 3.78 (m, 3H, H-3, H6b, H-
2), 2.47 (t, J = 2.4 Hz, 1H, OCH2CCH) ppm. 
 
13C NMR (100.6 MHz, CDCl3, 25°C): δ = 96.94 (C-1), 76.14 (C-3), 75.40 
(OCH2CCH), 72.28 (OCH2Ph), 70.10 (C-5), 67.69 (C-4), 62.96 (C-6), 58.98 (C-2), 
55.28 (OCH2CCH) ppm. 
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Propargyl 6-O-acetyl-2-azido-3-O-benzyl-2-deoxy--D-galactopyranoside 
(7a) 
 
 
 
Compound 15 (1.0346 g, 3.11 mmol) and sym-collidine (1.6 mL, 12.4 mmol) were 
dissolved in DCM at -40°C. AcCl (331 µL, 4.66 mmol) was slowly added and the 
reaction mixture was stirred for 3 h (TLC, hexane/AcOEt 5:5). The reaction was 
quenched with MeOH, diluted with DCM and washed with 5% aq. HCl, satd. 
NaHCO3 and brine. The organic phase was dried with Na2SO4, filtered and 
evaporated in vacuo. Flash chromatography (hexane/AcOEt 6:4) afforded 
compound 7a (894 mg, 77%) as a white solid. 
 
1H NMR (400 MHz, CDCl3, 25°C): δ = 7.44 – 7.30 (m, 5H, arom.), 5.12 (d, J1,2 = 
3.3 Hz, 1H, H-1), 4.71 (m, 2H, OCH2Ph), 4.37 – 4.21 (m, 4H, H-6a, H-6b, 
OCH2CCH), 4.01 (br d, J = 1.0 Hz, 1H, H-4), 3.96 (br t, J = 6.1 Hz, 1H, H-5), 3.90 
(dd, J2,3 = 10.4, J3,4 = 2.9 Hz, 1H, H-3), 3.78 (dd, J2,3 = 10.4, J1,2 = 3.3 Hz, 1H, H-2), 
2.48 (t, J = 2.3 Hz, 1H, OCH2CCH), 2.07 (s, 3H, OCOCH3) ppm. 
 
13C NMR (100.6 MHz, CDCl3, 25°C): δ = 170.71 (COCH3), 96.64 (C-1), 76.12 (C-
3), 74.70 (OCH2CCH), 72.33 (OCH2Ph), 68.46 (C-5), 66.36 (C-4), 63.29 (C-6), 
58.88 (C-2), 55.04 (OCH2CCH), 20,92 (COCH3) ppm. 
 
ESI HR-MS (MeOH) for [C18H21N3O6Na]+ calcd: 398.13226, found: 398.13184  
 
[α]D20 = 98.7 (c = 1 in CHCl3) 
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Thexyldimethylsilyl 3,4,6-tri-O-acetyl-2-azido-2-deoxy--D-
galactopyranoside (16) 
 
 
 
Compound 9 (7.38 g, 22 mmol) and imidazole (4.5 g, 66 mmol) were dissolved in 
DMF (20 mL). TDSCl (8.5 mL, 44 mmol) was slowly added at 0°C. After 15 min 
the reaction was warmed to rt and stirred overnight (TCL, hexane/AcOEt 6:4). The 
solvent was removed, the crude was taken up with AcOEt and washed with water 
and brine. The organic phase was dried with Na2SO4, filtered and evaporated in 
vacuo. Flash chromatography (hexane/AcOEt 8:2) afforded compound 16 (8.4088 
g, 81%) as a white solid. 
 
Spectroscopic data were in agreement with those reported in the literature.8 
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Thexyldimethylsilyl 2-azido-2-deoxy--D-galactopyranoside (17) 
 
 
 
A solution of MeONa in MeOH (0.4 M, 11 mL, 4.5 mmol) was added to compound 
16 (10.8 g, 22.8 mmol) dissolved in MeOH (80 mL). The reaction was followed by 
TLC (hexane/AcOEt 6:4). After 15 min the reaction was neutralized with Amberlite 
IR-120, filtered and the solvent was removed in vacuo, affording compound 17 
(7.6744 g, 96%) as a white foam. The product was used in the following step 
without further purification. 
 
Spectroscopic data were in agreement with those reported in the literature.8 
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Thexyldimethylsilyl 2-azido-4,6-O-benzylidene-2-deoxy--D-
galactopyranoside (18) 
 
 
 
Compound 17 (7.6744 g, 22 mmol) was dissolved in CH3CN (60 mL), then 
benzaldehyde dimethyl acetal (4.9 mL, 33 mmol) and pTSA·H2O (418 mg, 2.2 
mmol) were added. The reaction was monitored by TLC (hexane/AcOEt 7:3). After 
2 h the mixture was quenched with TEA and the solvent was evaporated. Flash 
chromatography (hexane/AcOEt 8:2 + 1% TEA) afforded compound 18 (8.6797 g, 
90%) as a white solid. 
 
Spectroscopic data were in agreement with those reported in the literature.8 
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Thexyldimethylsilyl 2-azido-3-O-benzyl-4,6-O-benzylidene-2-deoxy--D-
galactopyranoside (19) 
 
 
 
Compound 18 (8.6797 g, 19.9 mmol) was dissolved in DMF (70 mL), then BnBr 
(4.7 mL, 39.9 mmol) and TBAI (735 mg, 2 mmol) were added. NaH (799 mg, 29.9 
mmol) was added portionwise. The reaction was monitored by TLC (hexane/AcOEt 
7:3). After 15 min the mixture was quenched with MeOH and the solvent was 
removed. The crude was taken up in DCM and washed with water and brine. The 
organic phase was dried with Na2SO4, filtered and evaporated in vacuo. Flash 
chromatography (hexane/AcOEt 95:5 to 9:1) afforded compound 19 (9.834 g, 94%) 
as a white foam. 
 
1H NMR (400 MHz, CDCl3, 25°C): δ = 7.46 – 7.28 (m, 10H arom.), 5.49 (s, 1H, 
PhCH), 4.75 (s, 2H, OCH2Ph), 4.53 (d, J1,2 = 7.6 Hz, 1H, H-1), 4.25 (dd, J6a,6b = 
12.3, J5,6a = 1.6 Hz, 1H, H-6a), 4.08 (br d, J = 3.5 Hz, 1H, H-4), 4.01 (dd, J6a,6b = 
12.3, J5,6b = 1.9 Hz, 1H, H-6b), 3.78 (dd, J2,3 = 10.4, J1,2 = 7.6 Hz, 1H, H-2), 3.34 
(dd, J2,3 = 10.4, J3,4 = 3.5 Hz, 1H, H-3), 3.29 (m, 1H, H-5), 1.72 (m, 1H, 
OSiC(CH3)2CH(CH3)2), 0.94 (m, 12H, OSiC(CH3)2CH(CH3)2), 0.24 (m, 6H, 
OSi(CH3)2) ppm. 
 
ESI-MS (MeOH) for [C28H39N3O5SiNa]+ calcd: 548.26, found: 548.5 
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2-Azido-3-O-benzyl-4,6-O-benzylidene-2-deoxy-D-galactopyranose (20) 
 
 
 
Compound 19 (2.6829 g, 5 mmol) was dissolved in THF (20 mL) at -40°C. AcOH 
(875 L, 15.3 mmol) and TBAF (1.0 M in THF, 15 mL, 15 mmol) were slowly 
added. The reaction was monitored by TLC (hexane/AcOEt 5:5). After 1 h the 
solvent was concentrated, the mixture was diluted with AcOEt and washed with 
satd. NH4Cl. The organic phase was dried with Na2SO4, filtered and evaporated in 
vacuo. Flash chromatography (hexane/AcOEt 5:5) afforded compound 20 (1.9239 
g, quant.) as a white foam. 
 
Spectroscopic data were in agreement with those reported in the literature.9 
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2-Azido-3-O-benzyl-4,6-O-benzylidene-2-deoxy-α-D-galactopyranosyl N-
phenyltrifluoroacetimidate (6) 
 
 
 
Compound 20 (709.5 mg, 1.85 mmol) and N-phenyltrifluoroacetimidoyl chloride 
(600 L, 3.7 mmol) were dissolved in DCM (10 mL), then Cs2CO3 (912 mg, 2.8 
mmol) was added portionwise. The reaction was monitored by TLC (hexane/AcOEt 
5:5). After 3 h the reaction mixture was filtered on a Celite pad and the solvent was 
evaporated. Flash chromatography (hexane/AcOEt 7:3 + 0.1% TEA) afforded 
compound 6 (0.9732 g, 95%) as a white foam. 
 
1H NMR (400 MHz, CDCl3, 55°C): δ = 7.56 – 7.30 (m, 12H, arom.), 7.15 (m, 1H, 
arom.), 6.88 (m, 2H, arom.), 6.49 (br s, 1H, H-1), 5.50 (s, 1H, PhCH), 4.80 (m, 2H, 
OCH2Ph), 4.30 (m, 2H, H-4, H-6a), 4.20 (dd, J2,3 = 10.5, J1,2 = 3.4 Hz, 1H, H-2), 
4.05 (m, 2H, H-3, H-6b), 3.76 (br s, 1H, H-5) ppm. 
 
13C NMR (100.6 MHz, CDCl3, 55°C): δ = 101.00 (PhCH), 95.11 (C-1), 74.85 (C-
3), 72.68 (C-4), 71.59 (OCH2Ph), 68.96 (C-6), 65.22 (C-5), 58.36 (C-2) ppm. 
 
ESI HR-MS (MeOH) for [C28H25F3N4O5Na]+ calcd: 577.1669, found: 577.1615  
 
  
  
89 
(2-Azido-3-O-benzyl-4,6-O-benzylidene-2-deoxy--D-galactopyranosyl)-
(14)-(propargyl 6-O-acetyl-2-azido-3-O-benzyl-2-deoxy--D-
galactopyranoside) (21) 
 
 
 
Donor 6 (1.1655 g, 2.1 mmol) and acceptor 7a (526.9 mg, 1.4 mmol) were 
coevaporated together three times with toluene and kept under vacuum overnight. 
They were dissolved in DCM (8 mL) under Argon atmosphere. Freshly activated 
4Å molecular sieves (1.71 g) were added and the mixture was stirred at rt for 45 
min. Then a solution of trimethylsilyl triflate (0.055 M in DCM, 2.5 mL, 0.14 
mmol) was slowly added over 1 h at 0°C using a syringe pump. The reaction 
mixture was then warmed to rt and monitored by HPTLC (hexane/AcOEt 6:4). 
After 2 h the reaction was neutralized with TEA, filtered on a Celite pad and the 
solvent was evaporated. Flash chromatography (toluene/AcOEt 100:0 to 95:5) 
afforded compound 21 (735 mg, 71%) as a white foam. 
 
1H NMR (400 MHz, CDCl3, 25°C): δ = 7.36 (m, 15H, arom.), 5.32 (s, 1H, PhCH), 
5.22 (d, J1’,2’ = 3.6 Hz, 1H, H-1’), 5.08 (d, J1,2 = 2.7 Hz, 1H, H-1), 4.74 (m, 4H, 2 x 
OCH2Ph), 4.54 (dd, J6a,6b = 11.1, J5,6a = 6.6 Hz, 1H, H-6a), 4.37 (dd, J6a,6b = 11.1, 
J5,6b = 7.9 Hz, 1H, H-6b), 4.29 (m, 2H, OCH2CCH), 4.24 (d, J = 2.7 Hz, 1H, H-4’), 
4.15 (d, J = 1.1 Hz, 1H, H-4), 4.03 (s, 1H, H-5), 4.00 (m, 3H, H-2; H-3; H-5’), 3.92 
(dd, J2’,3’ = 10.8, J3’,4’ = 2.7 Hz, 1H, H-3’), 3.76 (dd, J2’,3’ = 10.8, J1’,2’ = 3.6 Hz, 1H, 
H-2’), 3.58 (dd, J6’a,6’b = 12.8, J5’,6’a = 1.1 Hz, 1H, H-6’a), 3.34 (dd, J6’a,6’b = 12.8, 
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J5’,6’b = 1.4 Hz, 1H, H-6’b), 2.50 (t, J = 2.3 Hz, 1H, OCH2CCH), 2.11 (s, 3H, 
COCH3) ppm.  
 
13C NMR (100.6 MHz, CDCl3, 25°C): δ = 172.31 (COCH3), 100.89 (PhCH), 99.81 
(C-1’), 96.90 (C-1), 76.05 (C-3’), 75.39 (OCH2CCH), 74.90 (C-5’ or C-3), 73.00 
(C-4’), 72.85 (C-4), 72.2 (OCH2Ph), 71.33 (OCH2Ph), 69.12 (C-6’), 69.00 (C-5’ or 
C-3), 63.27 (C-5), 61.32 (C-6), 59.65 (C-2’), 59.28 (C-2), 55.40 (OCH2CCH), 21.11 
(COCH3) ppm.  
 
ESI HR-MS (MeOH) for [C38H40N6O10Na]+ calcd: 763.26981 found: 763.26939  
 
[α]D20 = 224.90 (c = 1 in CHCl3) 
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(2-Azido-3-O-benzyl-4,6-O-benzylidene-2-deoxy--D-galactopyranosyl)-
(14)-(propargyl 2-azido-3-O-benzyl-2-deoxy--D-galactopyranoside) (23) 
 
 
 
Compound 21 (735 mg, 0.99 mmol) was dissolved in MeOH (10 mL) and THF (2 
mL), then a solution of sodium methoxide (0.4 M in MeOH, 250 L, 0.1 mmol) 
was added dropwise. The reaction was monitored by TLC (hexane/AcOEt 6:4). 
After 2 h the mixture was neutralized with Amberlite IR-120, filtered and the 
solvent was removed in vacuo, affording compound 23 (684 mg, 99%) as a white 
foam. 
 
1H NMR (400 MHz, CDCl3, 25°C): δ = 7.47 – 7.29 (m, 15H, arom.), 5.32 (s, 1H, 
PhCH), 5.22 (d, J1’,2’ = 3.6 Hz, 1H, H-1’), 5.13 (d, J1,2 = 2.9 Hz, 1H, H-1), 4.81 – 
4.65 (m, 4H, 2 x OCH2Ph), 4.32 (br d, J = 2.7 Hz, 1H, H-4’), 4.30 (m, 2H, 
OCH2CCH), 4.15 (br d, J = 1.2 Hz, 1H, H-4), 4.03 – 3.98 (m, 3H, H-2, H-3, H-5), 
3.91 (m, 4H, H-5’, H-6’a, H-6’b, H-3’), 3.75 (dd, J2’,3’ = 10.9, J1’,2’ = 3.6 Hz, 1H, H-
2’), 3.66 (m, 1H, H-6a), 3.37 (m, 1H, H-6b), 2.48 (t, J = 2.3 Hz, 1H, OCH2CCH) 
ppm. 
 
13C NMR (100.6 MHz, CDCl3, 25°C): δ = 100.82 (PhCH), 99.60 (C-1), 96.91 (C-
1’), 76.14 (C-3’), 75.24 (OCH2CCH), 74.66 (C-2 or C-3 or C-5), 72.99 (C-4’), 
72.82 (C-4), 72.08 (OCH2Ph), 71.60 (C-5’), 71.20 (OCH2Ph), 69.16 (C-6), 63.17 
(C-2 or C-3 or C-5), 60.62 (C-6’), 59.77 (C-2’), 59.29 (C-2 or C-3 or C-5), 55.30 
(OCH2CCH) ppm.  
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ESI HR-MS (MeOH) for [C36H38N6O9Na]+ calcd: 721.25925, found: 721.25935  
 
[α]D20 = 166.04 (c = 1 in CHCl3) 
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(2-Azido-3,4-di-O-benzyl-2-deoxy--D-galactopyranosyl)-(14)-(propargyl 
2-azido-3-O-benzyl-2-deoxy--D-galactopyranoside) (24) 
 
 
 
Compound 23 (242.5 mg, 0.35 mmol) was dissolved in DCM (10 mL). 3Å 
molecular sieves (1.25 g) were added and the mixture was stirred for 40 minutes. 
Triethylsilane (210 L, 1.32 mmol) was added. PhBCl2 (57 L, 0.42 mmol) was 
added at -78°C. The reaction mixture was slowly warmed to 0°C over 4 hours. 
Further triethylsilane (100 L, 0.32 mmol) and PhBCl2 (26 L 0.2, mmol) were 
added at -78°C, the reaction mixture was warmed to -30°C and stirred overnight. 
The reaction was monitored by TLC (hexane/AcOEt 6:4). The reaction was diluted 
with MeOH and neutralized with TEA, filtered on a Celite pad, diluted with DCM 
and washed with satd. NaHCO3. The organic phase was dried with Na2SO4, filtered, 
and concentrated. Flash chromatography (hexane/AcOEt 6:4) afforded compound 
24 (223 mg, 92%) as a white foam. 
 
1H NMR (400 MHz, CDCl3, 25°C): δ = 7.44 – 7.23 (m, 15H, arom.), 5.15 (d, J1’,2’ = 
3.6 Hz, 1H, H-1’), 5.04 (d, J1,2 = 2.7 Hz, 1H, H-1), 4.89 – 4.51 (m, 6H; 3 x 
OCH2Ph), 4.27 (m, 2H, OCH2CCH), 4.22 (br d, J = 1.9 Hz, 1H, H-4’), 4.03 – 3.94 
(m, 4H, H-5’, H-2, H-3, H-4), 3.92 – 3.86 (m, 2H, H-5, H-3’), 3.83 – 3.74 (m, 3H, 
H-6’a, H-6’b, H-2’), 3.43 (dd, J6a,6b = 11.2, J5,6a = 6.1 Hz, 1H, H-6a), 3.36 (dd, J6a,6b 
= 11.2, J5,6b = 5.7 Hz, 1H, H-6b), 2.48 (t, J = 2.2 Hz, 1H, OCH2CCH) ppm.  
 
13C NMR (100.6 MHz, CDCl3, 25°C): δ = 99.34 (C-1), 96.87 (C-1’), 77.55 (C-3), 
76.38 (C-3’), 75.35 (OCH2CCH), 74.83 (OCH2Ph), 74.09 (C-4’), 73.41 (C-4), 72.56 
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(OCH2Ph), 72.30 (OCH2Ph), 71.80 (C-5’), 71.27 (C-5), 62.13 (C-6), 60.89 (C-2), 
60.48 (C-6’), 59.72 (C-2’), 55.28 (OCH2CCH) ppm. 
 
ESI HR-MS (MeOH) for [C36H40N6O9Na]+ calcd: 723.27490, found: 723.27436  
 
[α]D20 = 180.2 (c = 1 in CHCl3) 
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(2-Acetamido-3,4-di-O-benzyl-2-deoxy--D-galactopyranosyl)-(14)-
(propargyl 2-acetamido-3-O-benzyl-2-deoxy--D-galactopyranoside) (27) 
 
 
 
Compound 24 (172.5 mg, 0.25 mmol) was dissolved in MeOH (15 mL). 
Propanedithiol (500 L, 5 mmol) and TEA (670 L, 5.8 mmol) were added, and the 
mixture was heated at 40°C for 24 h. The reaction was monitored by TLC 
(hexane/AcOEt 5:5). Then the solvent was removed in vacuo, the crude was 
dissolved in MeOH (10 mL) and Ac2O (472 L, 5 mmol) was added. The reaction 
was monitored by TLC (AcOEt) and stirred overnight. Then the solvent was 
removed in vacuo and flash chromatography (DCM/MeOH 98:2) afforded 
compound 27 (93.4 mg, 51%) as a white foam.  
 
The occurrence of the azide reduction was confirmed by the appearance of the 
acetamido signals in the 1H NMR spectrum. 
 
ESI-MS (MeOH) for [C40H48N2O11Na]+ calcd: 755.32, found: 755.40  
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(Benzyl 2-acetamido-3,4-di-O-benzyl-2-deoxy--D-
galactopyranosyluronate)-(14)-(benzyl (propargyl 2-acetamido-3-O-benzyl-
2-deoxy--D-galactopyranosid)uronate) (28) 
 
 
 
Compound 27 (93.4 mg, 0.13 mmol) was dissolved in DCM (5 mL) and Dess-
Martin periodinane (165 mg, 0.39 mmol) was added. The reaction was monitored 
by TLC (hexane/AcOEt 5:5). After 2 h, the mixture was quenched with 10% aq. 
Na2S2O3. The organic phase was separated and washed with satd. NaHCO3. The 
combined aqueous phases were extracted with DCM. The combined organic phases 
were dried over Na2SO4, filtered and concentrated in vacuo. The residue was 
dissolved in THF (3 mL) and tBuOH (2 mL). 2-Methylbut-2-ene (1.4 mL, 13 
mmol) and a solution of NaClO2 and NaH2PO4·2H2O (293.9 mg + 304.2 mg in 10 
mL of water, 2.6 mmol + 1.95 mmol) were then added. The reaction was monitored 
by TLC (hexane/AcOEt 4:6 + 1% AcOH). After 2 h the mixture was concentrated 
to half volume, acidified with 5% aq. HCl to pH 2, then the solvents were 
evaporated and the mixture lyophilized. The crude was dissolved in DMF (10 mL), 
BnBr (309 L, 2.6 mmol) and Cs2CO3 (423 mg, 1.3 mmol) were added. The 
reaction was monitored by TLC (hexane/AcOEt 7:3) and stirred overnight. Then the 
solvent was evaporated, the crude was taken up in DCM and washed with water and 
brine. The organic phase was dried over Na2SO4, filtered and concentrated. Flash 
chromatography (hexane/AcOEt 8:2 to 6:4) afforded compound 28 (61.1 mg, 50%) 
as a white foam. 
 
1H NMR (400 MHz, CDCl3, 25°C): δ = 7.55 – 7.11 (m, 25H, arom.), 5.39 (m, 2H, 
COOCHHPh, NHAc), 5.15 (m, 2H, H-1, NHAc), 5.06 – 4.95 (m, 3H, H-5’, 
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COOCHHPh, H-1’), 4.85 (d, J = 8.2 Hz, 2H, OCHHPh), 4.80 – 4.72 (m, 2H, 
OCHHPh, OCHHPh), 4.67 (d, J = 12.1 Hz, 2H, COOCHHPh), 4.61 – 4.49 (m, 6H, 
COOHHPh, H-2’, H-4, H-4’, OCHHPh, OCHHPh), 4.45 – 4.28 (m, 4H, H-2, H-5, 
OCHHPh, OCHHPh), 4.27 – 4.13 (m, 3H, OCH2CCH, OCHHPh), 3.75 (dd, J3’,4’ = 
11.3, J2’,3’ = 2.7 Hz, 1H, H-3’), 3.55 (dd, J3,4 = 11.3, J2,3 = 2.7 Hz, 1H, H-3), 2.33 (t, 
J = 2.4 Hz, 1H, OCH2CCH), 2.06 (s, 3H, HNCOCH3), 1.95 (s, 3H, HNCOCH3) 
ppm. 
 
ESI-MS (MeOH) for [C54H56N2O13Na]+ calcd: 963.38, found: 963.51  
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(2-Acetamido-2-deoxy--D-galactopyranosyluronic acid)-(14)-(propyl 2-
acetamido-2-deoxy--D-galactopyranosiduronic acid) (29) 
 
 
 
Compound 28 (35.6 mg, 37.8 µmol) was dissolved in H2O/MeOH/AcOEt 4:4:1 (9 
mL + 5 drops of 5% aq. HCl). Pd/C was added and the mixture was stirred under 
hydrogen (30 bar) at 40°C for 24 h. The reaction mixture was then filtered on a 
Celite pad and lyophilized. Reverse phase flash chromatography (H2O/CH3CN 
95:5) afforded compound 29 (17.3 mg, 93%) 
 
1H NMR (400 MHz, D2O, 25°C): δ = 5.09 (d, J1,2 = 3.8 Hz, 1H, H-1), 5.03 (d, J1’,2’ 
= 3.5 Hz, 1H, H-1’), 4.48 (br d, J = 2.8 Hz, 1H, H-5’), 4.38 (m, 1H, H-5), 4.27 – 
4.04 (m, 5H, H-4’, H-2, H-2’, H-3’, H-3), 3.66 (m, 1H, OCHHCH2CH3), 3.50 (dt, J 
= 9.9, 6.3 Hz, 1H, OCHHCH2CH3), 2.07 (s, 3H, NHCOCH3), 2.05 (s, 3H, 
NHCOCH3), 1.60 (m, 2H, OCH2CH2CH3), 0.91 (m, 3H, OCH2CH2CH3). 
 
13C NMR (100.6 MHz, D2O, 25°C): δ = 173.77 (COOH or NHCOCH3), 173.46 
(COOH or NHCOCH3), 97.41 (C-1), 95.51 (C-1’), 76.82 (C-5’), 71.36 (C-5), 70.18 
(OCH2CH2CH3), 69.53 (C-4’), 68.93 (C-4), 66.83 (C-3), 65.93 (C-3’), 48.85 (C-2’), 
48.21 (C-2), 21.29 (NHCOCH3), 20.78 (NHCOCH3), 20.53 (OCH2CH2CH3), 8.13 
(OCH2CH2CH3) ppm. 
 
ESI HR-MS (MeOH) for [C19H30N2O13-H]- calcd: 493.1675, found: 493.1627 
 
[]D20 = 95.3 (c = 0.5 in H2O) 
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(2-Azido-3-O-benzyl-2-deoxy--D-galactopyranosyl)-(14)-(propargyl 2-
azido-3-O-benzyl-2-deoxy--D-galactopyranoside) (30) 
 
 
 
Compound 23 (244 mg, 0.35 mmol) was dissolved in DCM (10 mL). EtSH (155 
L, 2.1 mmol) and pTSA·H2O (13 mg, 0.07 mmol) were added. The reaction was 
monitored by TLC (hexane/AcOEt 3:7). After 2 h, the mixture was neutralized with 
TEA and the solvent was evaporated. Flash chromatography (hexane/AcOEt 3:7) 
afforded compound 30 (203 mg, 95%) as a white foam. 
 
The occurrence of the benzylidene cleavage was confirmed by the disappearance of 
the benzylidene signal in the 1H NMR spectrum. 
 
ESI-MS (MeOH) for [C29H34N6O9Na]+ calcd: 633.23, found: 633.1  
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(Benzyl 2-azido-3-O-benzyl-2-deoxy--D-galactopyranosyluronate)-(14)-
(benzyl (propargyl 2-azido-3-O-benzyl-2-deoxy--D-galactopyranosid)uronate) 
(31) 
 
 
 
Compound 30 (48.8 mg, 80 mol) and TEMPO (1.3 mg, 8 mol) were dissolved in 
CH3CN (1 mL) and sodium phosphate buffer (0.67 M, pH 6.7, 500 L) and the 
mixture was heated to 35°C. Then NaClO2 (28.9 mg, 320 mol in 200 L of water) 
and bleach (1.8 L 13% NaOCl diluted in 200 L of water, 3.2 mol) were added. 
The mixture was stirred at 35°C for 24 h (TLC DCM/MeOH 7:3 + 0.1% AcOH), 
then cooled to room temperature. Water (5 mL) was added, and the pH was 
adjusted to 8.0 with 1 M NaOH. The reaction was quenched by pouring into cold 
(0°C) Na2SO3 solution, until the pH of the aqueous layer reached 8.5-9.0. After 
stirring for 0.5 h at room temperature, MTBE (5 mL) was added. The organic layer 
was separated and discarded. Then AcOEt was added, the aqueous layer was 
acidified with 5% aq. HCl to pH 3-4. The combined organic phases were dried over 
Na2SO4, filtered and concentrated in vacuo. The crude was dissolved in DMF (5 
mL), BnBr (190 L, 1.6 mmol) and KF (46.5 mg, 800 mol) were added at 0°C. 
The reaction was monitored by TLC (hexane/AcOEt 6:4) and stirred for 3 h at rt. 
The solvent was then removed, the crude was taken up with DCM and washed with 
water. The organic phase was dried over Na2SO4, filtered and concentrated. Flash 
chromatography (hexane/AcOEt 8:2 to 6:4) afforded compound 31 (21.5 mg, 33%). 
 
1H NMR (400 MHz, CDCl3, 25°C): δ = 7.49 – 7.18 (m, 20H, arom.), 5.37 (d, J = 
12.0 Hz, 1H, COOCHHPh), 5.30 (d, J1,2 = 3.7 Hz, 1H, H-1), 5.24 (d, J = 12.0 Hz, 
1H, COOCHHPh), 5.09 (d, J1’,2’ = 3.7 Hz, 1H, H-1b), 5.04 (d, J = 12.3 Hz, 1H, 
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COOHHPh), 4.92 (br d, J = 1.7 Hz, 1H, H-5’), 4.80 (d, J = 12.3 Hz, 1H, 
COOHHPh), 4.75 (d, J = 10.8 Hz, 1H, OCHHPh), 4.74 (d, J = 12.4 Hz, 1H, 
OCHHPh), 4.67 (d, J = 10.8 Hz, 1H, OCHHPh), 4.61 (br d, J = 2.0 Hz, 1H, H-4), 
4.50 (d, J = 12.4 Hz, 1H, OCHHPh), 4.45 (br s, 1H, H-5), 4.41 (m, 1H, H-4’), 4.30 
(ddd, J = 15.9, 12.8, 2.4 Hz, 2H, OCH2CCH), 3.97 (dd, J2’,3’ = 10.4, J3’,4’ = 3.1 Hz, 
1H, H-3’), 3.90 (dd, J2,3 = 10.9, J3,4 = 2.9 Hz, 1H, H-3), 3.74 (dd, J2’,3’ = 10.4, J1’,2’ = 
3.7 Hz, 1H, H-2’), 3.69 (dd, J2,3 = 10.9, J1,2 = 3.7 Hz, 1H, H-2), 2.37 (t, J = 2.4 Hz, 
1H, OCH2CCH), 2.30 (br s, 1H, OH) ppm. 
 
13C NMR (100.6 MHz, CDCl3, 25°C): δ = 167.92 (COOBn), 167.24 (COOBn), 
99.70 (C-1), 97.07 (C-1’), 78.08 (OCH2CCH), 75.98 (C-3, OCH2CCH), 75.41 (C-
4’), 74.72 (C-3’), 72.29 (OCH2Ph), 71.81 (OCH2Ph), 70.52 (C-5), 70.39 (C-5’), 
67.78 (COOCH2Ph), 67.06 (C-4), 66.94 (COOCH2Ph), 58.80 (C-2’), 58.63 (C-2), 
55.90 (OCH2CCH) ppm. 
 
ESI-MS (MeOH) for [C43H42N6O11Na]+ calcd: 841.28, found: 841.1  
 
[]D20 = 101.6 (c = 1 in CHCl3) 
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(2-Amino-2-deoxy--D-galactopyranosyluronic acid)-(14)-(propyl 2-
amino-2-deoxy--D-galactopyranosiduronic acid) dihydrochloride (32) 
 
 
 
Compound 31 (35.6 mg, 43.9 mol) was dissolved in H2O/MeOH 1:1 (8 mL + 5 
drops of 5% aq. HCl). Pd/C was added and the reaction was left under H2 (30 bar) 
at 40°C for 24 h. The mixture was then filtered on a Celite pad and lyophilized, 
affording compound 32 (20 mg, 95%) as a white solid. 
 
1H NMR (400 MHz, D2O, 25°C): δ = 5.22 (br s, 1H, H-1), 5.17 (br s, 1H, H-1’), 
5.02 (br s, 1H, H-5), 4.39 (br s, 2H, H-5’, H-4), 4.29 (br s, 1H, H-4), 4.19 (br d, J = 
11.1 Hz, 1H, H-3’), 4.10 (br d, J = 10.8 Hz, 1H, H-3), 3.70 – 3.36 (m, 4H, 
OCH2CH2CH3, H-2, H-2’), 1.54 (m, 2H, OCH2CH2CH3), 0.82 (t, J = 7.4 Hz, 3H, 
OCH2CH2CH3) ppm. 
 
13C NMR (100.6 MHz, D2O, 25°C): δ = 96.16 (C-1), 95.17 (C-1’), 77.39 (C-4’), 
71.54 (C-5), 70.69 (OCH2CH2CH3), 70.15 (C-5’), 68.88 (C-4), 65.89 (C-3), 65.79 
(C-3’), 50.54 (C-2, C-2’), 22.04 (OCH2CH2CH3), 9.90 (OCH2CH2CH3) ppm. 
 
ESI HR-MS (MeOH) for [C15H26N2O11-H]- calcd: 409.1464, found: 409.1501 
 
[]D20 = 127.1 (c = 0.5 in H2O) 
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Thexyldimethylsilyl 2-azido-3-O-benzyl-2-deoxy--D-galactopyranoside (36) 
 
 
 
Compound 19 (2.5221 g, 4.8 mmol) was dissolved in DCM (30 mL). EtSH (2.13 
mL, 28.8 mmol) and pTSA·H2O (182 mg, 0.95 mmol) were added. After 10 min 
TLC (hexane/AcOEt 5:5) showed completion of the reaction, the mixture was 
neutralized with TEA and the solvent was removed. Flash chromatography 
(hexane/AcOEt 5:5) afforded compound 36 (2.055 g, 98%) as a light yellow oil. 
 
The occurrence of the benzylidene cleavage was confirmed by the disappearance of 
the benzylidene signal in the 1H NMR spectrum. 
 
ESI-MS (MeOH) for [C21H35N3O5SiNa]+ calcd: 460.22, found: 460.3  
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Thexyldimethylsilyl 6-O-acetyl-2-azido-3-O-benzyl-2-deoxy--D-
galactopyranoside (37) 
 
 
 
Compound 36 (3.254 g, 7.44 mmol) and sym-collidine (5 ml, 37.2 mmol) were 
dissolved in DCM (20 mL) at -40°C. AcCl (690 L, 9.7 mmol) was added 
dropwise. The reaction was monitored by TLC (hexane/AcOEt 6:4). After 1 h the 
reaction was warmed to -20°C and stirred for a further 1 h. The mixture was 
quenched with MeOH, the solvent was evaporated. The crude is taken up with 
DCM and washed with 5% aq. HCl, satd. NaHCO3 and brine. The organic phase 
was dried over Na2SO4, filtered and concentrated. Flash chromatography 
(hexane/AcOEt 8:2) afforded compound 37 (3.3163 g, 83%) as a light yellow oil. 
 
1H NMR (400 MHz, CDCl3, 25°C): δ = 7.52 – 7.32 (m, 5H, arom.), 4.74 (m, 2H, 
OCH2Ph), 4.43 (d, J1,2 = 7.7 Hz, 1H, H-1), 4.38 – 4.27 (m, 2H, H-6a, H-6b), 3.88 
(m, 1H, H-4), 3.65 – 3.51 (m, 2H, H-5, H-2), 3.28 (dd, J2,3 = 10.1, J3,4 = 3.4 Hz, 1H, 
H-3), 2.40 (m, 1H, OH), 2.08 (s, 3H, OCOCH3), 1.69 (hept, J = 6.9 Hz, 1H, 
SiC(CH3)2CH(CH3)2), 0.94 (m, 12H, SiC(CH3)2CH(CH3)2), 0.21 (br d, 6H, 
Si(CH3)2) ppm. 
 
13C NMR (100.6 MHz, CDCl3, 25°C): δ = 171.43 (OCOCH3), 97.77 (C-1), 79.48 
(C-3), 73.09 (OCH2Ph), 72.77 (C-5), 66.39 (C-4), 65.81 (C-2), 63.89 (C-6), 34.59 
(SiC(CH3)2CH(CH3)2, 21.46 (OCOCH3), 20.64, 20.53 (SiC(CH3)2CH(CH3)2), 
19.16, 19.05 (SiC(CH3)2CH(CH3)2), -2.02 (Si(CH3)2) ppm. 
 
ESI-MS (MeOH) for [C23H37N3O6SiNa]+ calcd: 502.23, found: 502.4  
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Thexyldimethylsilyl 2-azido-3,4-di-O-benzyl-2-deoxy--D-galactopyranoside 
(19a) 
 
 
 
Compound 19 (534.2 mg, 1.02 mmol) was dissolved in DCM (20 mL). 4Å 
molecular sieves (2.8 g) were added and the mixture was stirred for 45 min. Et3SiH 
(623 L, 3.9 mmol) was added and the mixture was cooled to -78°C. PhBCl2 (160 
L, 1.22 mmol) was added dropwise. The reaction was monitored by TLC 
(hexane/AcOEt 6:4). After 1 h the mixture was neutralized with TEA, filtered on a 
Celite pad and the solvent was removed. The crude is taken up in DCM and washed 
with satd. NaHCO3 and brine. The organic phase was dried over Na2SO4, filtered 
and concentrated. Flash chromatography (hexane/AcOEt 8:2) afforded compound 
19a (514.4 mg, 95%) as a transparent oil. 
 
The occurrence of the regioselective benzylidene ring opening was confirmed by 
the disappearance of the benzylidene signal in the 1H NMR spectrum. 
 
ESI-MS (MeOH) for [C28H41N3O5SiNa]+ calcd: 550.27, found: 550.5 
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Thexyldimethylsilyl 6-O-acetyl-2-azido-3,4-di-O-benzyl-2-deoxy--D-
galactopyranoside (38) 
 
 
 
Compound 19a (4.322 g, 8.19 mmol), pyridine (2.7 mL, 32.8 mmol) and catalytic 
DMAP were dissolved in DCM (20 mL) at 0°C. Acetic anhydride (1.5 mL, 16.4 
mmol) was added dropwise, and the mixture was warmed to rt. The reaction was 
monitored by TLC (hexane/AcOEt 6:4). After 1 h the reaction mixture was 
quenched with crushed ice, diluted with DCM and washed with 5% aq. HCl, satd. 
NaHCO3 and brine. The organic phase was dried over Na2SO4, filtered and 
concentrated, affording compound 38 (4.5044 g, 97%) as a light yellow oil. 
 
1H NMR (400 MHz, CDCl3, 25°C): δ = 7.51 – 7.25 (m, 5H, arom.), 4.95 (d, J = 
11.6 Hz, 1H, OCHHPh), 4.76 (m, 2H, OCH2Ph), 4.64 (d, J = 11.6 Hz, 1H, 
OCHHPh), 4.42 (d, J1,2 = 7.7 Hz, 1H, H-1), 4.21 (dd, J6a,6b = 11.2, J5,6a = 7.3 Hz, 
1H, H-6a), 4.04 (dd, J6a,6b = 11.2, J5,6b = 5.3 Hz, 1H, H-6b), 3.76 (dd, J2,3 = 10.4, J1,2 
= 7.7 Hz, 1H, H-2), 3.74 (m, 1H, H-4), 3.50 (ddd, J5,6a = 7.3, J5,6b = 5.3, J4,5 = 1.1 
Hz, 1H, H-5), 3.30 (dd, J2,3 = 10.4, J3,4 = 2.9 Hz, 1H, H-3), 1.99 (s, 3H, OCOCH3), 
1.68 (hept, J = 6.9 Hz, 1H, SiC(CH3)2CH(CH3)2), 0.94 (m, 12H, 
SiC(CH3)2CH(CH3)2), 0.19 (s, 5H, Si(CH3)2) ppm. 
 
13C NMR (100.6 MHz, CDCl3, 25°C): δ = 170.56 (OCOCH3), 97.40 (C-1), 80.71 
(C-3), 74.39 (OCH2Ph), 73.06 (OCH2Ph), 72.45 (C-5), 72.17 (C-4), 65.74 (C-2), 
63.31 (C-6), 33.92 (SiC(CH3)2CH(CH3)2, 20.74 (OCOCH3), 20.00, 19.91 
(SiC(CH3)2CH(CH3)2), 18.51, 18.42 (SiC(CH3)2CH(CH3)2), -1.96 (Si(CH3)2) ppm. 
 
ESI-MS (MeOH) for [C30H43N3O6SiNa]+ calcd: 619.28, found: 619.1  
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6-O-acetyl-2-azido-3,4-di-O-benzyl-2-deoxy-D-galactopyranose (38a) 
 
 
 
Compound 38 (512.5 mg, 0.92 mmol) was dissolved in THF (15 mL) at -40°C. 
Acetic acid (158 L, 2.76 mmol) and TBAF (1 M in THF, 2.8 ml, 2.8 mmol) were 
added dropwise. The reaction was monitored by TLC (hexane/AcOEt 6:4). After 45 
min the solvent was removed, the crude was taken up with AcOEt and washed with 
satd. NH4Cl. The organic phase was dried over Na2SO4, filtered and concentrated. 
Flash chromatography (hexane/AcOEt 6:4) afforded compound 38a (383.2 mg, 
98%, mixture of anomers) as a light yellow oil. 
 
The occurrence of the desilylation was confirmed by the disappearance of the TDS 
signals in the 1H NMR spectrum. 
 
ESI-MS (MeOH) for [C22H25N3O6Na]+ calcd: 450.16, found: 450.2 
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6-O-Acetyl-2-azido-3,4-di-O-benzyl-2-deoxy--D-galactopyranosyl N-
phenyltrifluoroacetimidate (39) 
 
 
 
Compound 38a (2.4967 g, 5.84 mmol) and N-phenyltrifluoroacetimidoyl chloride 
(1.89 mL, 11.7 mmol) were dissolved in DCM (20 mL), then Cs2CO3 (2.85 g, 8.76 
mmol) was added. The reaction was monitored by TLC (hexane/AcOEt 6:4). After 
2 h the mixture was filtered on a Celite pad and the solvent removed. Flash 
chromatography (hexane/AcOEt 7:3 + 0.1% TEA) afforded compound 39 (3.5364 
g, quant.) as a white foam. 
 
1H NMR (400 MHz, CDCl3, 50°C): δ = 7.51 – 7.24 (m, 12H, arom.), 7.13 (m, 1H, 
arom.), 6.86 (m, 2H, arom.), 5.46 (br d, J1,2 = 7.8 Hz, 1H, H-1), 4.97 (d, J = 11.4 
Hz, 1H, OCHHPh), 4.80 (m, 2H, OCH2Ph), 4.64 (d, J = 11.4 Hz, 1H, OCHHPh), 
4.24 (dd, J6a,6b = 11.2, J5,6a = 6.7 Hz, 1H, H-6a), 4.14 (dd, J6a,6b = 11.2, J5,6b = 5.8 
Hz, 1H, H-6b), 4.09 (dd, J2,3 = 10.5, J1,2 = 7.8 Hz, 1H, H-2), 3.82 (m, 1H, H-4), 3.59 
(m, 1H, H-5), 3.44 (dd, J2,3 = 10.5, J3,4 = 2.2 Hz, 1H, H-3), 1.98 (s, 3H, OCOCH3) 
ppm. 
 
13C NMR (100.6 MHz, CDCl3, 50°C): δ = 96.01 (C-1), 80.91 (C-3), 74.71 
(OCH2Ph), 73.55 (C-5), 73.20 (OCH2Ph), 72.04 (C-4), 62.68 (C-6), 62.21 (C-2), 
20.53 (OCOCH3) ppm. 
 
ESI HR-MS (MeOH) for [C30H29F3N4O6Na]+ calcd: 621.1931, found: 621.1991 
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(6-O-Acetyl-2-azido-3,4-di-O-benzyl-2-deoxy--D-galactopyranosyl)-(14)-
(thexyldimethylsilyl 6-O-acetyl-2-azido-3-O-benzyl-2-deoxy--D-
galactopyranoside) (40) 
 
 
 
Donor 39 (2.0643 g, 3.45 mmol) and acceptor 37 (1.1034 g, 2.3 mmol) were 
coevaporated three times with toluene and left under vacuum overnight. They were 
dissolved in DCM (10 mL), freshly activated 4Å molecular sieves (3.5 g) were 
added and the mixture was stirred for 45 min under Argon atmosphere. A solution 
of TMSOTf (0.055 M in DCM, 4.6 mL, 0.23 mmol) was added dropwise via a 
syringe pump over 1 h. The reaction was warmed to rt and monitored by HPTLC 
(hexane/AcOEt 8:2). After 2h the mixture was quenched with TEA, filtered on a 
Celite pad and the solvent was removed. Flash chromatography (hexane/AcOEt 9:1 
to 8:2) afforded compound 40 (1.5996 g, 78%) as a white solid. 
 
1H NMR (400 MHz, CDCl3, 25°C): δ = 7.52 – 7.25 (m, 15H, arom.), 4.97 (d, J1’,2’ = 
3.5 Hz, 1H, H-1’), 4.93 (d, J = 11.2 Hz, 1H, OCHHPh), 4.86 (d, J = 11.1 Hz, 1H, 
OCHHPh), 4.81 (m, 2H, OCHHPh, OCHHPh), 4.67 (d, J = 12.5 Hz, 1H, 
OCHHPh), 4.56 (d, J = 11.2 Hz, 1H, OCHHPh), 4.49 – 4.39 (m, 2H, H-1H-6a), 
4.42 – 4.29 (m, 2H, H-5’, H-6b), 4.13 – 4.04 (m, 2H, H-3’, H-6’a), 4.03 – 3.90 (m, 
4H, H-4’, H-2’, H-4, H-6’b), 3.58 – 3.48 (m, 2H, H-2, H-5), 3.18 (dd, J2,3 = 10.6, 
J3,4 = 3.0 Hz, 1H, H-3), 2.08 (s, 3H, OCOCH3), 1.86 (s, 3H, OCOCH3), 1.70 (hept, 
J = 6.9 Hz, 1H, SiC(CH3)2CH(CH3)2), 0.92 (m, 12H, SiC(CH3)2CH(CH3)2), 0.20 (br 
d, 6H, Si(CH3)2) ppm. 
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13C NMR (100.6 MHz, CDCl3, 25°C): δ = 99.50 (C-1’), 97.33 (C-1), 78.08 (C-3), 
77.1 (C-3’), 74.70 (OCH2Ph), 72.82 (C-4), 72.58 (C-4’), 72.38 (2 x OCH2Ph), 72.26 
(C-5), 69.01 (C-5’), 65.73 (C-2), 62.36 (C-6’), 62.19 (C-6), 60.17 (C-2’), 34.01 
(SiC(CH3)2CH(CH3)2), 20.68 (2 x OCOCH3), 19.96 (SiC(CH3)2CH(CH3)2), 18.46 
(SiC(CH3)2CH(CH3)2) ppm. 
 
ESI-MS (MeOH) for [C45H60N6O11SiNa]+ calcd: 911.40, found: 911.3  
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(6-O-Acetyl-2-azido-3,4-di-O-benzyl-2-deoxy--D-galactopyranosyl)-(14)-
(6-O-acetyl-2-azido-3-O-benzyl-2-deoxy-D-galactopyranose) (40a) 
 
 
 
Compound 40 (1.3192 g, 1.48 mmol) was dissolved in THF (20 mL) at -50°C. 
TBAF (1 M in THF, 1.78 mL, 1.78 mmol) was slowly added dropwise. The 
reaction was monitored by TLC (hexane/AcOEt 6:4). After 1 h acetic acid (17 L, 
0.3 mmol) was added, the mixture was diluted with water and extracted with DCM. 
The combined organic phases were dried over Na2SO4, filtered and concentrated. 
Flash chromatography (hexane/AcOEt 7:3) afforded compound 40a (839.4 mg, 
76%) as a light yellow oil. 
 
The occurrence of the desilylation was confirmed by the disappearance of the TDS 
signals in the 1H NMR spectrum. 
 
ESI-MS (MeOH) for [C37H42N6O11Na]+ calcd: 769.28, found: 769.5  
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(6-O-Acetyl-2-azido-3,4-di-O-benzyl-2-deoxy--D-galactopyranosyl)-(14)-
(6-O-acetyl-2-azido-3-O-benzyl-2-deoxy--D-galactopyranoside) N-
phenyltrifluoroacetimidate (34) 
 
 
Compound 40a (937.5 mg, 1.26 mmol) and N-phenyltrifluoroacetimidoyl chloride 
(405 L, 2.5 mmol) were dissolved in DCM (10 mL), then Cs2CO3 (619 mg, 1.9 
mmol) was added. The reaction was monitored by TLC (hexane/AcOEt 6:4). After 
1 h the mixture was filtered on a Celite pad and the solvent removed. Flash 
chromatography (hexane/AcOEt 8:2 + 0.1% TEA) afforded compound 34 (1.1363 
g, 98%) as a white foam. 
 
1H NMR (400 MHz, CDCl3, 50°C): δ = 7.53 – 7.25 (m, 12H, arom.), 7.13 (m, 1H, 
arom.), 6.86 (m, 2H, arom.), 5.44 (br d, J1,2 = 8.2 Hz, 1H, H-1), 5.02 (br s, 1H, H-
1’), 4.94 (d, J = 11.2 Hz, 1H, OCHHPh), 4.84 (m, 3H, OCH2Ph, OCHHPh), 4.71 
(d, J = 12.4 Hz, 1H, OCHHPh), 4.58 (d, J = 11.2 Hz, 1H, OCHHPh), 4.42 (m, 2H, 
H-6a, H-6b or H-6’a, H-6’b), 4.33 (br t, J5,6a = J5,6b = 6.6 Hz, 1H, H-5’ or H-5), 4.20 
– 3.97 (m, 6H, H-6’a, H-6’b or H-6a, H-6b, H-3’, H-2’, H-4, H-4’), 3.86 (dd, J2,3 = 
10.3, J1,2 = 8.2 Hz, 1H, H-2), 3.58 (br t, J = 6.1 Hz, 1H, H-5 or H-5’), 3.33 (dd, J2,3 
= 10.3, J3,4 = 2.8 Hz, 1H, H-3), 2.05 (s, 3H, OCOCH3), 1.91 (s, 3H, OCOCH3) ppm. 
 
13C NMR (100.6 MHz, CDCl3, 50°C): δ = 99.53 (C-1’), 95.92 (C-1), 78.58 (C-3), 
77.25 (C-3’), 74.77 (OCH2Ph), 73.42 (C-5 or C-5’), 73.02 (C-4, C-4’), 72.48 (2 x 
OCH2Ph), 69.48 (C-5’ or C-5), 62.53 (C-6’ or C-6), 62.13 (C-2), 61.76 (C-6 or C-
6’), 60.57 (C-2’), 20.52 (2 x OCOCH3) ppm. 
 
ESI HR-MS (MeOH) for [C45H46F3N7O11Na]+ calcd: 940.3099, found: 940.3110 
  
113 
(2-Azido-3-O-benzyl-4,6-O-benzylidene-2-deoxy--D-galactopyranosyl)-
(14)-(thexyldimethylsilyl 6-O-acetyl-2-azido-3-O-benzyl-2-deoxy--D-
galactopyranoside) (41a) 
 
 
 
Donor 6 (319 mg, 0.57 mmol) and acceptor 37 (183 mg, 0.38 mmol) were 
coevaporated three times with toluene and left under vacuum overnight. They were 
dissolved in DCM (5 mL), freshly activated 4Å molecular sieves (0.5 g) were added 
and the mixture was stirred for 45 min under Argon atmosphere. A solution of 
TMSOTf (0.055 M in DCM, 690 L, 38 mol) was added dropwise via a syringe 
pump over 1 h. The reaction was warmed to rt and monitored by HPTLC 
(hexane/AcOEt 8:2). After 2h the mixture was quenched with TEA, filtered on a 
Celite pad and the solvent was removed. Flash chromatography (hexane/AcOEt 8:2 
to 7:3) afforded compound 41a (304.4 mg, 87%) as a light yellow oil. 
 
1H NMR (400 MHz, CDCl3, 25°C): δ = 7.53 – 7.29 (m, 15H, arom.), 5.38 (s, 1H, 
PhCH), 5.05 (d, J1’,2’ = 3.4 Hz, 1H, H-1’), 4.84 – 4.73 (m, 3H, OCH2Ph, OCHHPh), 
4.69 (d, J = 11.9 Hz, 1H, OCHHPh), 4.55 – 4.47 (m, 2H, H-6a, H-1), 4.38 (dd, J6a,6b 
= 11.1, J5,6b = 7.2 Hz, 1H, H-6b), 4.21 (br d, J = 3.3 Hz, 1H, H-4’), 4.13 – 4.04 (m, 
3H, H-5’, H-3’, H-4), 4.00 (dd, J2’,3’ = 10.7, J1’,2’ = 3.4 Hz, 1H, H-2’), 3.71 (dd, 
J6’a,6’b = 12.7, J5’,6’a = 1.5 Hz, 1H, H-6’a), 3.60 – 3.51 (m, 2H, H-5, H-2), 3.49 (dd, 
J6’a,6’b = 12.7, J5’,6’b = 1.8 Hz, 1H, H-6’b), 3.24 (dd, J2,3 = 10.6, J3,4 = 3.0 Hz, 1H, H-
3), 2.11 (s, 3H, OCOCH3), 1.72 (m, 1H, SiC(CH3)2CH(CH3)2), 0.94 (m, 12H, 
SiC(CH3)2CH(CH3)2), 0.23 (m, 6H, Si(CH3)2) ppm. 
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13C NMR (100.6 MHz, CDCl3, 25°C): δ = 170.37 (OCOCH3), 100.72 (PhCH), 
100.05 (C-1’), 97.32 (C-1), 78.88 (C-3), 74.19 (C-3’), 72.91 (C-4’), 72.56 (C-4), 
72.42 (OCH2Ph), 72.11 (C-5), 71.16 (OCH2Ph), 69.09 (C-6’), 65.71 (C-2), 63.13 
(C-5’), 61.69 (C-6), 59.00 (C-2’), 34.02 (SiC(CH3)2CH(CH3)2), 20.85 (OCOCH3), 
20.04, 19.97 (SiC(CH3)2CH(CH3)2), 18.54 (SiC(CH3)2CH(CH3)2), 18.47 
(SiC(CH3)2CH(CH3)2), -1.98 (Si(CH3)2), -3.04 (Si(CH3)2) ppm. 
 
ESI-MS (MeOH) for [C43H56N6O10SiNa]+ calcd: 867.37, found: 867.2  
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(2-Azido-3-O-benzyl-4,6-O-benzylidene-2-deoxy--D-galactopyranosyl)-
(14)-(6-O-acetyl-2-azido-3-O-benzyl-2-deoxy-D-galactopyranose) (41) 
 
 
 
Compound 41a (280 mg, 0.33 mmol) was dissolved in THF (5 mL) at -50°C. TBAF 
(1 M in THF, 400 L, 0.4 mmol) was slowly added dropwise. The reaction was 
monitored by TLC (hexane/AcOEt 6:4). After 1 h acetic acid (4 L, 0.07 mmol) 
was added, the mixture was diluted with water and extracted with DCM. The 
combined organic phases were dried over Na2SO4, filtered and concentrated. Flash 
chromatography (hexane/AcOEt 7:3) afforded compound 41a (188 mg, 82%) as a 
light yellow oil. 
 
The occurrence of the desilylation was confirmed by the disappearance of the TDS 
signals in the 1H NMR spectrum. 
 
ESI-MS (MeOH) for [C35H38N6O10Na]+ calcd: 725.25, found: 725.5  
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Propargyl 2-azido-3-O-benzyl-6-O-t-butyldimethylsilyl-2-deoxy--D-
galactopyranoside (44) 
 
 
 
Compound 15 (167.6 mg, 0.50 mmol) was dissolved in THF (5 mL). Imidazole 
(136 mg, 2 mmol) was added and the mixture was cooled to 0°C. TBDMSCl (113 
mg, 0.75 mmol) was added, the mixture was slowly warmed to rt and stirred 
overnight. The reaction was monitored by TLC (hexane/AcOEt 6:4). The solvent 
was removed, the crude was taken up in AcOEt and washed with brine. The organic 
phase was dried over Na2SO4, filtered and concentrated. Flash chromatography 
(hexane/AcOEt 85:15) afforded compound 44 (195.9 mg, 87%) as a light yellow 
oil. 
 
1H NMR (400 MHz, CDCl3, 25°C): δ = 7.47 – 7.31 (m, 5H, arom.), 5.14 (d, J1,2 = 
3.0 Hz, 1H, H-1), 4.75 (m, 2H, OCH2Ph), 4.29 (m, 2H, OCH2CCH), 4.13 (br s, 1H, 
H-4), 3.95 – 3.75 (m, 5H, H-6a, H-6b, H-5, H-3, H-2), 2.48 (t, J = 2.3 Hz, 1H, 
OCH2CCH), 0.92 (s, 9H, OSiC(CH3)3), 0.10 (s, 6H, OSi(CH3)2). 
 
ESI-MS (MeOH) for [C22H33N3O5SiNa]+ calcd: 470.21, found: 470.3  
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(6-O-Acetyl-2-azido-3,4-di-O-benzyl-2-deoxy--D-galactopyranosyl)-(14)-
(6-O-acetyl-2-azido-3-O-benzyl-2-deoxy--D-galactopyranosyl)-(14)-
(propargyl 2-azido-3-O-benzyl-2-deoxy--D-galactopyranoside) (46) 
 
 
 
Donor 34 (304 mg, 331 mol) and acceptor 44 (95.8 mg, 214 mol) were 
coevaporated three times with toluene and left under vacuum overnight. They were 
dissolved in DCM (3 mL), freshly activated 4Å molecular sieves (400 mg) were 
added and the mixture was stirred for 45 min under Argon atmosphere. A solution 
of TMSOTf (0.055 M in DCM, 420 L, 21 mol) was added dropwise via a syringe 
pump over 1 h. The reaction was warmed to rt and monitored by HPTLC 
(hexane/AcOEt 8:2). After 3 h the mixture was quenched with TEA, filtered on a 
Celite pad and the solvent was removed. Flash chromatography (hexane/AcOEt 9:1 
to 6:4) afforded crude compound 45 (193 mg) as a light yellow oil. It was dissolved 
in THF (5 mL) at -40°C. TBAF (1 M in THF, 321 L, 321 mol) was added 
dropwise. The reaction was monitored by TLC (hexane/AcOEt 6:4). After 2 h the 
mixture was allowed to warm to 0°C overnight. Then acetic acid (6 L, 107 mol) 
was added, then the mixture is diluted with AcOEt and washed with brine. Then 
organic phase was dried over Na2SO4, filtered and concentrated. Flash 
chromatography (hexane/AcOEt 8:2 to 6:4) afforded compound 46 (133.7 mg, 59% 
over two steps) as a light yellow oil. 
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1H NMR (400 MHz, CDCl3, 25°C): δ = 7.50 – 7.22 (m, 20H, arom.), 5.17 (d, J1,2 = 
3.6 Hz, 1H, H-1), 5.14 (d, J1’,2’ = 3.5 Hz, 1H, H-1’), 4.95 (d, J1’’,2’’ = 2.2 Hz, 1H, H-
1’’), 4.91 – 4.86 (m, 2H, 2 x OCHHPh), 4.85 – 4.76 (m, 3H, OCH2Ph, OCHHPh), 
4.73 (d, J = 12.1 Hz, 1H, OCHHPh), 4.66 (d, J = 12.0 Hz, 1H, OCHHPh), 4.52 (d, J 
= 11.2 Hz, 1H, OCHHPh), 4.34 – 4.22 (m, 6H, H-5’’ or H-5’, H-5’ or H-5’’, 
OCH2CCH, H-5, H-6’’a or H-6’a), 4.19 – 4.11 (m, 2H, H-4’, H-6’’b or H-6’b), 4.06 
– 3.98 (m, 3H, H-6’a or H-6’’a, H-3’’, H-2’’), 3.97 – 3.69 (m, 9H, H-4’’, H-3’, H-4, 
H-3, H-6a, H-6b, H-6’b or H-6’’b, H-2’, H-2), 2.49 (t, J = 2.4 Hz, 1H, OCH2CCH), 
1.97 (s, 3H, OCOCH3), 1.82 (s, 3H, OCOCH3) ppm. 
 
13C NMR (100.6 MHz, CDCl3, 25°C): δ = 169.86 (2 x OCOCH3), 99.10 (C-1’’), 
98.49 (C-1’), 96.78 (C-1), 78.43 (OCH2CCH), 77.27 (C-3’’), 75.52 (C-3), 75.18 
(OCH2CCH), 74.98 (C-3’), 74.67 (OCH2Ph), 72.99 (C-5), 72.51 (C-4’), 72.38 
(OCH2Ph), 72.28 (C-4’’), 72.17 (OCH2Ph), 71.82 (OCH2Ph), 71.28 (C-4), 68.89 
(C-5’ or C-5’’), 68.82 (C-5’’ or C-5’), 62.07 (C-6’’ or C-6’), 61.33 (C-6’ or C-6’’), 
60.59 (C-6), 60.45 (C-2’), 60.24 (C-2’’), 59.64 (C-2), 55.12 (OCH2CCH), 20.71 
(OCOCH3), 20.63 (OCOCH3) ppm. 
 
ESI-MS (MeOH) for [C53H59N9O15Na]+ calcd: 1084.40, found: 1084.5 
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(2-Acetamido-6-O-acetyl-3,4-di-O-benzyl-2-deoxy--D-galactopyranosyl)-
(14)-(2-acetamido-6-O-acetyl-3-O-benzyl-2-deoxy--D-galactopyranosyl)-
(14)-(propargyl 2-acetamido-6-O-acetyl-3-O-benzyl-2-deoxy--D-
galactopyranoside) (46a) 
 
 
 
Compound 46 (68.1 mg, 64 mol) was dissolved in MeOH (5 mL). Propanedithiol 
(193 L, 1.9 mmol) and TEA (267 L, 1.9 mmol) were added, and the mixture was 
heated at 40°C for 24 h. The reaction was monitored by TLC (hexane/AcOEt 6:4 
and H2O/MeOH 5:5 + 5 drops of 25% aq. NH3). Then the solvent was removed in 
vacuo, the crude was dissolved in pyridine (5 mL) and cooled to 0°C. Catalytic 
DMAP and Ac2O (180 L, 1.9 mmol) were added and the mixture was warmed to 
rt. The reaction was monitored by TLC (AcOEt) and stirred overnight. Then the 
solvent was removed in vacuo and flash chromatography (hexane/AcOEt 1:9 to 
AcOEt/MeOH 9:1) afforded compound 46a (38 mg, 52%) as a colorless oil. 
 
1H NMR (400 MHz, CDCl3, 25°C): δ = 7.45 – 7.22 (m, 20H, arom.), 5.35 (d, J2’,NH 
= 8.9 Hz, 1H, NHAc), 5.22 (d, J2,NH = 9.4 Hz, 1H, NHAc), 5.17 (d, J2’’,NH = 8.9 Hz, 
1H, NHAc), 5.00 (d, J1,2 = 3.7 Hz, 1H, H-1), 4.98 – 4.72 (m, 7H, H-1’, H-1’’, 4 x 
OCHHPh, H-2’), 4.61 – 4.37 (m, 8H, 4 x OCHHPh, H-2, H-2’, H-5, H-5’ or H-5’’), 
4.29 – 4.18 (m, 4H, H-6’’a or H-6a, H-4’’, OCH2CCH), 4.17 – 4.08 (m, 2H, H-4, 
H-6a or H-6’’a), 4.07 – 3.80 (m, 7H, H-6’a, H-6’b, H-6’’b or H-6b, H-4’, H-5’’ or 
H-5’, H-3’, H-3’’), 3.66 (t, J5,6a = J5,6b = 10.1 Hz, 1H, H-6b or H-6’’b), 3.53 (dd, J2,3 
= 11.1, J3,4 = 2.6 Hz, 1H, H-3), 2.48 (t, J = 2.4 Hz, 1H, OCH2CCH), 2.11 (s, 3H, 
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OCOCH3), 1.95 (m, 6H, OCOCH3, HNCOCH3), 1.90 (m, 6H, 2 x HNCOCH3), 1.85 
(s, 3H, OCOCH3) ppm. 
 
13C NMR (100.6 MHz, CDCl3, 25°C): δ = 170.41 – 169.6 (6 x COCH3), 98.71 (C-
1’ or C-1’’), 98.46 (C-1’’ or C-1’), 96.73 (C-1), 76.80 (C-3’), 75.19 (C-3), 75.10 
(OCH2CCH), 74.37 (C-3’’), 74.21 (OCH2Ph), 71.94 (OCH2Ph), 71.87 (C-4’), 71.78 
(OCH2Ph), 71.54 (C-4), 71.33 (C-4’), 69.30 (C-5’’ or C-5’), 69.04 (C-5), 68.92 (C-
5’ or C-5’’), 62.06 (C-6’), 61.74 (C-6’’ or C-6), 60.35 (C-6 or C-6’’), 54.99 
(OCH2CCH), 49.22 (C-2’), 48.94 (C-2’’), 48.33 (C-2), 23.38 (3 x HNCOCH3), 
20.72 (3 x OCOCH3) ppm. 
 
ESI-MS (MeOH) for [C61H73N3O19Na]+ calcd: 1174.47, found: 1174.2  
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(2-Acetamido-3,4-di-O-benzyl-2-deoxy--D-galactopyranosyl)-(14)-(2-
acetamido-3-O-benzyl-2-deoxy--D-galactopyranosyl)-(14)-(propargyl 2-
acetamido-3-O-benzyl-2-deoxy--D-galactopyranoside) (47) 
 
 
 
Compound 46a (38 mg, 33 mol) was dissolved in H2O/MeOH/THF 1:2.5:0.5 (4 
mL). LiOH·H2O (4 mg, 100 mol) was added and the mixture was stirred for 24 h. 
The reaction was monitored by TLC (AcOEt/MeOH 9:1). After completion, the 
mixture was quenched with Amberlite IR-120, filtered and the solvent was 
removed. Flash chromatography (AcOEt/MeOH 100:0 to 9:1) afforded compound 
47 (27.6 mg, 82%). 
 
The occurrence of complete deacetylation was confirmed by the disappearance of 
the acetyl signals in the 1H NMR spectrum. 
 
ESI-MS (MeOH) for [C55H67N3O16Na]+ calcd: 1048.44, found: 1048.3  
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(Benzyl 2-acetamido-3,4-di-O-benzyl-2-deoxy--D-
galactopyranosyluronate)-(14)-(benzyl 2-acetamido-3-O-benzyl-2-deoxy--D-
galactopyranosyluronate)-(14)-(benzyl (propargyl 2-acetamido-3-O-benzyl-
2-deoxy-galactopyranosid)uronate) (48) 
 
 
 
Compound 47 (27.6 mg, 27 mol) was dissolved in DCM (2.5 mL) and Dess-
Martin periodinane (51.7 mg, 122 mol) was added. The reaction was monitored by 
HPTLC (AcOEt/MeOH 9:1). After 3 h, the mixture was quenched with 10% aq. 
Na2S2O3. The organic phase was separated and washed with satd. NaHCO3. The 
combined aqueous phases were extracted with DCM. The combined organic phases 
were dried over Na2SO4, filtered and concentrated in vacuo. The residue was 
dissolved in THF (1 mL) and tBuOH (2 mL). 2-Methylbut-2-ene (424 L) and a 
solution of NaClO2 and NaH2PO4·2H2O (73 mg + 95 mg in 1 mL of water, 810 
mol + 608 mol) were then added. The reaction was monitored by TLC 
(DCM/MeOH 8:2 + 1% AcOH). After 1 h the mixture was concentrated to half 
volume, acidified with 5% aq. HCl to pH 2, then the solvents were evaporated in 
vacuo. The crude was dissolved in DMF (3 mL), BnBr (100 L, 810 mol) and 
Cs2CO3 (132 mg, 405 mol) were added. The reaction was monitored by TLC 
(hexane/AcOEt 2:8) and stirred overnight. Then the solvent was evaporated, the 
crude was taken up in DCM and washed with water and brine. The organic phase 
was dried over Na2SO4, filtered and concentrated. Flash chromatography 
hexane/AcOEt 3:7 to 2:8) afforded compound 48 (17.3 mg, 34%) as a white foam. 
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1H NMR (400 MHz, CDCl3, 25°C): δ = 7.49 – 7.11 (m, 35H, arom.), 5.39 (m, 3H, 2 
x NHAc, COOCHHPh), 5.11 (m, 2H, H-1, NHAc), 5.04 – 4.94 (m, 5H, H-5’, H-
5’’, H-1’, H-1’’, COOCHHPh), 4.89 – 4.71 (m, 6H, COOCH2Ph, 3 x OCHHPh, H-
2’), 4.66 (d, J = 12.2 Hz, 1H, COOCHHPh), 4.59 – 4.48 (m, 6H, COOCHHPh, H-4, 
H-4’’, H-2’’, OCHHPh, OCHHPh), 4.45 – 4.33 (m, 4H, H-2, H-5, OCHHPh, H-4’), 
4.30 (d, J = 12.8 Hz, 1H, OCHHPh), 4.26 – 4.13 (m, 3H, OCH2CCH, OCHHPh), 
3.82 (dd, J3’,4’ = 11.1, J2’,3’ = 2.5 Hz, 1H, H-3’), 3.73 (dd, J3’’,4’’ = 11.4, J2’’,3’’ = 2.6 
Hz, 1H, H-3’’), 3.52 (dd, J3,4 = 11.2, J2,3 = 2.8 Hz, 1H, H-3), 2.33 (t, J = 2.4 Hz, 1H, 
OCH2CCH), 2.06 (s, 3H, HNCOCH3), 2.05 (s, 3H, HNCOCH3), 1.92 (s, 3H, 
HNCOCH3) ppm. 
 
13C NMR (100.6 MHz, CDCl3, 25°C): δ = 170.64, 170.31, 169.81 (3 x NHCOCH3), 
168.54, 168.44, 167.41 (3 x COOBn), 100.11 (C-1’), 99.57 (C-1’’), 97.20 (C-1), 
77.02 (C-3’), 75.15 (OCH2CCH), 75.08 (C-3’’), 74.80 (C-3 or C-4’ or C-4), 74.75 
(C-4’ or C-4 or C-3), 74.68 (C-4 or C-4’ or C-3), 74.22 (OCH2Ph), 74.13 (C-4’’), 
72.07 (OCH2Ph), 71.85 (C-5’’), 71.59 (OCH2Ph), 71.29 (OCH2Ph), 71.22 (C-5’), 
70.43 (C-5), 67.65 (COOCH2Ph), 67.42 (COOCH2Ph), 66.43 (COOCH2Ph), 55.96 
(OCH2CCH), 48.32 (C-2’), 47.92 (C-2 or C-2’’), 47.87 (C-2’’ or C-2), 23.62, 23.54, 
23.29 (3 x HNCOCH3) ppm. 
 
ESI HR-MS (MeOH) for [C76H79N3O19Na]+ calcd: 1360.5205, found: 1360.6083 
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(2-Acetamido-2-deoxy--D-galactopyranosyluronic acid)-(14)-(2-
acetamido-2-deoxy--D-galactopyranosyluronic acid)-(14)-(propyl 2-
acetamido-2-deoxy--D-galactopyranosiduronic acid) (49) 
 
Compound 48 (13 mg, 6.9 mol) was dissolved in H2O/MeOH/AcOEt 3:3:1 (7 mL 
+ 5 drops of 5% aq. HCl). Pd/C was added and the mixture was stirred under 
hydrogen (25 bar) at 40°C overnight. The reaction mixture was then filtered on a 
Celite pad and lyophilized, affording compound 49 (8.7 mg, quant.). 
 
1H NMR (400 MHz, D2O, 25°C): δ = 5.01 (m, 5H, H-1, H-1’, H-1’’, H-5, H-5’), 
4.60 (br s, 1H, H-5’’), 4.42 (m, 2H, H-4, H-4’), 4.30 (br s, 1H, H-4’’), 4.18 – 3.95 
(m, 6H, H-3, H-3’, H-3’’, H-2, H-2’, H-2’’), 3.59 (m, 1H, OCHHCH2CH3), 3.42 
(m, 1H, OCHHCH2CH3), 1.98 (m, 9H, 3 x HNCOCH3), 1.52 (m, 2H, 
OCH2CH2CH3), 0.83 (t, J = 7.1 Hz, 3H, OCH2CH2CH3) ppm. 
 
13C NMR (100.6 MHz, D2O, 25°C): δ = 174.73, 172.64, 171.68 (3 x COOH, 3 x 
NHCOCH3), 98.50, 98.42, 96.99 (C-1, C-1’, C-1’’), 77.51 (C-4 or C-4’), 77.46 (C-
4’ or C-4), 71.33 (C-5 or C-5’), 71.05 (OCH2CH2CH3), 70.65 (C-5’ or C-5), 69.55 
(C-5’’), 69.17 (C-4’’), 66.72, 66.22, 65.90 (C-3, C-3’, C-3’’), 49.60, 49.30 (C-2, C-
2’, C-2’’), 22.16 (2 x NHCOCH3), 21.98 (OCH2CH2CH3), 21.90 (NHCOCH3), 9.80 
(OCH2CH2CH3) ppm. 
 
ESI HR-MS (MeOH) for [C27H41N3O19-H]- calcd: 710.2261, found: 710.2290 
 
[]D20 = 63.8 (c = 0.26 in H2O)  
  
125 
6.1.2 Second route – pentenyl linker 
 
4-Pentenyl 3,4,6-tri-O-acetyl-2-azido-2-deoxy-D-galactopyranoside (50) 
 
 
 
Compound 10 (9.4214 g, 19.8 mmol) and 4-pentenol (2.45 mL, 23.8 mmol) were 
dissolved in DCM (5 mL) and Et2O (10 mL). TMSOTf (2 M in DCM, 1.9 mmol) 
was then added dropwise at rt. The reaction was monitored by HPTLC 
(hexane/AcOEt 6:4). After 2 h the mixture was neutralized with TEA and the 
solvent evaporated. Flash chromatography (hexane/AcOEt 7:3) afforded compound 
50 (7.908 g, quant., α/β = 1:1). 
 
Spectroscopic data were in agreement with those reported in the literature.10 
 
  
  
126 
4-Pentenyl 2-azido-4,6-O-benzylidene-2-deoxy-D-galactopyranoside (51 and 
52) 
 
 
 
Crude 50 (19.8 mmol) was dissolved in MeOH (25 mL), then a solution of sodium 
methoxide (0.4 M in MeOH, 5 mL, 2 mmol) was added dropwise. The reaction was 
monitored by TLC (hexane/AcOEt 5:5). After 1 h the mixture was neutralized with 
Amberlite IR-120, filtered and the solvent was removed in vacuo. The residue was 
dissolved in CH3CN (20 mL), benzaldehyde dimethyl acetal (6 mL, 40 mmol) and 
pTSA·H2O (380 mg, 2 mmol) were added. The reaction was stirred overnight 
(TLC, hexane/AcOEt 7:3), then quenched with TEA and the solvent was 
evaporated. Flash chromatography (hexane/AcOEt 8:2 to 6:4 + 0.1% TEA) afforded 
compound 51 (3.22 g, 45%) and 52 (2.862 g, 40%) as white foams. 
 
Spectroscopic data were in agreement with those reported in the literature.11 
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4-Pentenyl 2-azido-3-O-benzyl-4,6-O-benzylidene-2-deoxy--D-
galactopyranoside (52a) 
 
 
 
Compound 52 (2.862 g, 7.9 mmol) and BnBr (1.9 mL, 16 mmol) were dissolved in 
DMF (15 mL). NaH (240 mg, 10 mmol) was added portionwise. The reaction was 
monitored by TLC (hexane/AcOEt 7:3). After 2h the mixture was quenched with 
MeOH and the solvent was removed. The crude was taken up in DCM and washed 
with water and brine. The organic phase was dried over Na2SO4, filtered and 
concentrated. Flash chromatography (hexane/AcOEt 8:2) afforded compound 52a 
(3.3885 g, 95%) as a white foam. 
 
1H NMR (400 MHz, CDCl3, 25°C): δ = 7.59 – 7.30 (m, 10H, arom.), 5.84 (ddt, J = 
16.9, 10.2, 6.7 Hz, 1H, O(CH2)3CHCH2), 5.50 (s, 1H, PhCH–), 5.13 – 4.98 (m, 3H, 
O(CH2)3CHCH2, H-1), 4.77 (m, 2H, OCH2Ph), 4.30 – 4.23 (m, 2H, H-6a, H-4), 
4.09 – 4.02 (m, 2H, H-3, H-6b), 3.91 (dd, J2,3 = 10.7, J1,2 = 3.4 Hz, 1H, H-2), 3.74 
(dt, J = 9.8, 6.6 Hz, 1H, OCHH(CH2)2CHCH2), 3.66 (br d, J = 1.2 Hz, 1H, H-5), 
3.55 (dt, J = 9.8, 6.4 Hz, 1H, OCHH(CH2)2CHCH2), 2.18 (m, 2H, 
O(CH2)2CH2CHCH2), 1.76 (m, 2H, OCH2CH2CH2CHCH2) ppm. 
 
13C NMR (100.6 MHz, CDCl3, 25°C): δ = 138.07 (O(CH2)3CHCH2), 115.20 
(O(CH2)3CHCH2), 101.10 (PhCH–), 98.83 (C-1), 74.54 (C-3), 73.35 (C-4), 71.43 
(OCH2Ph), 69.57 (C-6), 68.07 (OCH2(CH2)2CHCH2), 63.03 (C-5), 58.93 (C-2), 
30.38 (O(CH2)3CH2CHCH2), 28.76 (OCH2CH2CH2CHCH2) ppm. 
 
ESI HR-MS (MeOH) for [C25H29N3O5Na]+ calcd: 474.2005, found: 473.9853 
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4-Pentenyl 2-azido-3-O-benzyl-2-deoxy--D-galactopyranoside (52b) 
 
 
 
Compound 52a (1.7992 g, 4.0 mmol) was dissolved in DCM (10 mL). EtSH (1.8 
mL, 24 mmol) and then pTSA·H2O (152 mg, 0.8 mmol) were added. The reaction 
was stirred for 1 h (TLC hexane/AcOEt 6:4), then quenched with TEA and the 
solvent was removed. Flash chromatography (hexane/AcOEt 5:5) afforded 
compound 52b (1.38 g, 95%) as a white solid. 
 
1H NMR (400 MHz, CDCl3, 25°C): δ = 7.46 – 7.34 (m, 5H, arom.), 5.84 (ddt, J = 
16.9, 10.2, 6.6 Hz, 1H, O(CH2)3CHCH2), 5.11 – 4.98 (m, 2H, O(CH2)3CHCH2), 
4.97 (d, J1,2 = 3.5 Hz, 1H, H-1), 4.85 – 4.66 (m, 2H, OCH2Ph), 4.16 (br dd, J = 3.2, 
1.0 Hz, 1H, H-4), 4.00 – 3.92 (m, 2H, H-6a, H-3), 3.87 – 3.81 (m, 2H, H-5, H-6b), 
3.74 (dt, J = 9.8, 6.6 Hz, 1H, OCHH(CH2)2CHCH2), 3.69 (dd, J2,3 = 10.4, J1,2 = 3.5 
Hz, 1H, H-2), 3.51 (dt, J = 9.7, 6.4 Hz, 1H, OCHH(CH2)2CHCH2), 2.17 (m, 2H, 
O(CH2)2CH2CHCH2), 1.85 (br s, 1H), 1.76 (m, 2H, OCH2CH2CH2CHCH2) ppm. 
 
13C NMR (100.6 MHz, CDCl3, 25°C): δ = 138.01 (O(CH2)3CHCH2), 115.23 
(O(CH2)3CHCH2), 98.27 (C-1), 75.98 (C-3), 72.28 (OCH2Ph), 96.56 (C-5), 67.92 
(OCH2(CH2)2CHCH2), 67.83 (C-4), 63.15 (C-6), 59.21 (C-2), 30.36 
(O(CH2)3CH2CHCH2), 28.71 (OCH2CH2CH2CHCH2) ppm. 
 
ESI-MS (MeOH) for [C18H25N3O5Na]+ calcd: 386.17, found: 386.2  
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4-Pentenyl 6-O-acetyl-2-azido-3-O-benzyl-2-deoxy--D-galactopyranoside 
(7b) 
 
 
 
Compound 52b (1.2781 g, 3.52 mmol) was dissolved in DCM (5 mL). Sym-
collidine (2.3 mL, 17.6 mmol) was added and the mixture was cooled to -40°C. 
AcCl (326 µL, 4,6 mmol) was added dropwise. The reaction was followed by TLC 
(hexane/AcOEt 6:4). After 2 h, the mixture was quenched with MeOH, diluted with 
DCM and washed with 5% aq. HCl, satd. NaHCO3 and brine. Then organic phase 
was dried over Na2SO4, filtered and concentrated. Flash chromatography 
(hexane/AcOEt 6:4) afforded compound 7b (1.3838 g, 97%) as a light yellow oil. 
 
1H NMR (400 MHz, CDCl3, 25°C): δ = 7.47 – 7.33 (m, 5H, arom.), 5.84 (ddt, J = 
16.9, 10.2, 6.6 Hz, 1H, O(CH2)3CHCH2), 5.10 – 4.98 (m, 2H, O(CH2)3CHCH2), 
4.94 (d, J1,2 = 3.5 Hz, 1H, H-1), 4.75 (m, 2H, OCH2Ph), 4.36 (dd, J6a,6b = 11.6, J5,6a 
= 5.0 Hz, 1H, H-6a), 4.28 (dd, J6a,6b = 11.6, J5,6b = 7.3 Hz, 1H, H-6b), 4.06 (br dd, 
J3,4 = 3.2, J4,5 = 1.4 Hz, 1H, H-4), 4.01 – 3.96 (m, 1H), 3.94 (dd, J2,3 = 10.4, J3,4 = 
3.2 Hz, 1H, H-3), 3.71 (dt, J = 9.5, 6.5 Hz, 1H, OCHH(CH2)2CHCH2), 3.67 (dd, J2,3 
= 10.4, J1,2 = 3.5 Hz, 1H, H-2), 3.53 (dt, J = 9.8, 6.4 Hz, 1H, OCHH(CH2)2CHCH2), 
2.17 (m, 2H, O(CH2)2CH2CHCH2), 2.10 (s, 3H, OCOCH3), 1.76 (m, 2H, 
OCH2CH2CH2CHCH2) ppm. 
 
13C NMR (100.6 MHz, CDCl3, 25°C): δ = 137.98 (O(CH2)3CHCH2), 115.24 
(O(CH2)3CHCH2), 98.21 (C-1), 76.00 (C-3), 72.35 (OCH2Ph), 68.02 
(OCH2(CH2)2CHCH2), 67.99 (C-5), 66.57 (C-4), 63.63 (C-6), 59.16 (C-2), 30.38 
(O(CH2)3CH2CHCH2), 28.71 (OCOCH3), 20.96 (OCH2CH2CH2CHCH2) ppm. 
 
ESI HR-MS (MeOH) for [C20H27N3O6Na]+ calcd: 428.1792, found: 428.1750 
  
130 
4-Pentenyl 2-azido-3-O-benzyl-4,6-O-benzylidene-2-deoxy--D-
galactopyranoside (51a) 
 
 
 
Compound 51 (419 mg, 1.16 mmol) and BnBr (207 L, mmol) were dissolved in 
DMF (20 mL). NaH (33.6 mg, 1.4 mmol) was added portionwise and the mixture 
was stirred for 2h (TLC hexane/AcOEt 6:4). Then the solvent was removed, the 
crude was taken up in DCM and washed with water and brine. The organic phase 
was dried over Na2SO4, filtered and concentrated. Flash chromatography 
(hexane/AcOEt 7:3) afforded compound 51a (494 mg, 1.1 mmol, 95%) as a white 
foam. 
 
ESI-MS (MeOH) for [C25H29N3O5Na]+ calcd: 474.20, found: 474.1 
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2-Azido-3-O-benzyl-4,6-O-benzylidene-2-deoxy-D-galactopyranose (51b) 
 
 
 
Compound 51a (494 mg, 1.1 mmol) was dissolved in 1% aq. CH3CN (10 mL), 
freshly recrystallized NBS (587 mg, 3.3 mmol) was added and the mixture was 
stirred for 2 h in the dark (TLC hexane/AcOEt 1:1). Then the reaction mixture was 
diluted with Et2O and washed with 10% aq. Na2S2O3. The organic phase was dried 
over Na2SO4, filtered and concentrated. Flash chromatography (hexane/AcOEt 1:1) 
afforded compound 51b (413 mg, 98%, mixture of anomers) as a white foam. 
 
Spectroscopic data were in agreement with those reported in the literature.9 
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(2-Azido-3-O-benzyl-4,6-O-benzylidene-2-deoxy--D-galactopyranosyl)-
(14)-(4-pentenyl 2-azido-3-O-benzyl-2-deoxy--D-galactopyranoside) (53) 
 
 
 
Donor 6 (300 mg, 0.54 mmol) and acceptor 7b (145.9 mg, 0.36 mmol) were 
coevaporated together three times with toluene and kept under vacuum overnight. 
They were dissolved in DCM (4 mL) under Argon atmosphere. Freshly activated 
4Å molecular sieves (450 mg) were added and the mixture was stirred at rt for 45 
min. Then a solution of trimethylsilyl triflate (0.055 M in DCM, 654 L, 36 mol) 
was slowly added over 1 h at 0°C using a syringe pump. The reaction mixture was 
then warmed to rt and monitored by HPTLC (hexane/AcOEt 7:3). After 2 h the 
reaction was neutralized with TEA, filtered on a Celite pad and the solvent was 
evaporated. Flash chromatography (hexane/AcOEt 7:3) afforded the crude 
disaccharide. It was then dissolved in MeOH (2 mL) and THF (2 mL) and treated 
with a solution of MeONa (0.4 M in MeOH, 1.1 mL, 0.4 mmol). The reaction was 
monitored by TLC (hexane/AcOEt 6:4). After 5 h the mixture was neutralized with 
Amberlite IR-120, filtered and the concentrated. Flash chromatography 
(hexane/AcOEt 7:3) afforded compound 53 (184.5 mg, 70%) as a white foam. 
 
1H NMR (400 MHz, CDCl3, 25°C): δ = 7.51 – 7.30 (m, 15H, arom.), 5.84 (ddt, J = 
16.9, 10.2, 6.6 Hz, 1H, O(CH2)3CHCH2), 5.34 (s, 1H, PhCH–), 5.15 (d, J1,2 = 2.8 
Hz, 1H, H-1), 5.11 – 4.99 (m, 3H, O(CH2)3CHCH2, H-1’), 4.83 (d, J = 11.7 Hz, 1H, 
OCHHPh), 4.75 (br s, 2H, OCH2Ph), 4.71 (d, J = 11.7 Hz, 1H, OCHHPh), 4.34 (br 
d, J = 2.8 Hz, 1H, H-4), 4.17 (m, 1H, H-4’), 4.07 – 3.89 (m, 7H, H-5, H-3, H-2, H-
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3’, H-6’a, H-6’b, H-5’), 3.75 (dt, J = 9.7, 6.6 Hz, 1H, OCHH(CH2)2CHCH2), 3.71 – 
3.63 (m, 2H, H-6a, H-2’), 3.53 (dt, J = 9.7, 6.4 Hz, 1H, OCHH(CH2)2CHCH2), 3.40 
(dd, J6a,6b = 12.8, J5,6b = 1.8 Hz, 1H, H-6b), 2.18 (m, 2H, O(CH2)2CH2CHCH2), 1.76 
(m, 2H, OCH2CH2CH2CHCH2) ppm. 
 
13C NMR (100.6 MHz, CDCl3, 25°C): δ = 138.03 (O(CH2)3CHCH2), 115.24 
(O(CH2)3CHCH2), 100.82 (PhCH–), 99.63 (C-1), 98.29 (C-1’), 75.91 (C-3), 74.75 
(C-3’), 73.18 (C-4’), 72.84 (C-4), 71.95 (OCH2Ph), 71.23 (OCH2Ph), 71.09 (C-5’), 
69.19 (C-6), 67.96 (OCH2(CH2)2CHCH2), 63.14 (C-5), 60.81 (C-6’), 59.85 (C-2’), 
59.32 (C-2), 30.40 (O(CH2)3CH2CHCH2), 28.75 (OCH2CH2CH2CHCH2) ppm. 
 
ESI-MS (MeOH) for [C38H44N6O9Na]+ calcd: 751.31, found: 751.2 
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(2-Azido-3,4-di-O-benzyl-2-deoxy--D-galactopyranosyl)-(14)-(4-pentenyl 
2-azido-3-O-benzyl-2-deoxy--D-galactopyranoside) (53a) 
 
 
 
Compound 53 (320.7 mg, 0.44 mmol) was dissolved in DCM (10 mL). 4Å 
molecular sieves (1.5 g) were added and the mixture was stirred for 45 min at rt. 
Et3SiH (267 L, 1.67 mmol) was added and the mixture was cooled to -78°C. 
PhBCl2 (69 L, 0.53 mmol) was added dropwise and the mixture was slowly 
warmed to 0°C. The reaction was monitored by TLC (hexane/AcOEt 5:5). After 1 h 
the mixture was quenched with TEA at -78°C, filtered and concentrated. The crude 
was taken up in DCM, washed with satd. NaHCO3 and brine. The organic phase 
was dried over Na2SO4, filtered and concentrated. Flash chromatography 
(hexane/AcOEt 7:3) afforded compound 53a (300.8 mg, 93%) as a white foam. 
 
1H NMR (400 MHz, CDCl3, 25°C): δ = 7.51 – 7.26 (m, 15H, arom.), 5.84 (ddt, J = 
16.9, 10.1, 6.6 Hz, 1H, O(CH2)3CHCH2), 5.05 (m, 3H, O(CH2)3CHCH2, H-1’), 4.96 
(d, J1,2 = 3.6 Hz, 1H, H-1), 4.89 (d, J = 11.3 Hz, 1H, OCHHPh), 4.82 (d, J = 11.0 
Hz, 1H, OCHHPh), 4.79 (d, J = 11.3 Hz, 1H, OCHHPh), 4.73 (d, J = 11.3 Hz, 1H, 
OCHHPh), 4.70 (d, J = 11. Hz, 1H, OCHHPh), 4.57 (d, J = 11.3 Hz, 1H, 
OCHHPh), 4.25 (br d,J = 2.7 Hz, 1H, H-4), 4.08 – 3.76 (m, 8H, H-5’, H-2’, H-3’, 
H-4’, H-3, H-5, H-6a, H-6b), 3.76 – 3.64 (m, 2H, OCHH(CH2)2CHCH2, H-2), 3.51 
(dt, J = 9.7, 6.4 Hz, 1H, OCHH(CH2)2CHCH2), 3.45 (dd, J6’a,6’b = 11.3, J5’,6’a = 6.0 
Hz, 1H, H-6’a), 3.39 (dd, J6’a,6’b = 11.3, J5’,6’b = 5.8 Hz, 1H, H-6’b), 2.37 (br s, 1H, 
OH), 2.17 (m, 2H, O(CH2)2CH2CHCH2), 1.76 (m, 2H, OCH2CH2CH2CHCH2) ppm. 
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13C NMR (100.6 MHz, CDCl3, 25°C): δ = 137.89 (O(CH2)3CHCH2), 115.08 
(O(CH2)3CHCH2), 99.25 (C-1’), 98.13 (C-1), 77.53 (C-3’), 76.03 (C-3), 74.72 
(OCH2Ph), 74.19 (C-4), 73.40 (C-4’), 72.35 (OCH2Ph), 72.21 (OCH2Ph), 71.69 (C-
5’), 70.68 (C-5), 67.82 (OCH2(CH2)2CHCH2), 62.02 (C-6’), 60.83 (C-2’), 60.59 (C-
6), 59.77 (C-2), 30.24 (O(CH2)3CH2CHCH2), 28.61 (OCH2CH2CH2CHCH2) ppm. 
 
ESI-MS (MeOH) for [C38H46N6O9Na]+ calcd: 753.32, found: 753.1 
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(Benzyl 2-azido-3,4-di-O-benzyl-2-deoxy--D-galactopyranosyluronate)-
(14)-(benzyl (4-pentenyl 2-azido-3-O-benzyl-2-deoxy--D-
galactopyranosid)uronate) (54) 
 
 
 
Compound 53a (84.8 mg, 0.12 mmol) was dissolved in DCM (5 mL) and Dess-
Martin periodinane (153 mg, 0.36 mmol) was added. The reaction was monitored 
by TLC (hexane/AcOEt 6:4). After 1 h, the mixture was quenched with 10% aq. 
Na2S2O3. The organic phase was separated and washed with satd. NaHCO3. The 
combined aqueous phases were extracted with DCM. The combined organic phases 
were dried over Na2SO4, filtered and concentrated in vacuo. The residue was 
dissolved in THF (3 mL) and tBuOH (6 mL). 2-Methylbut-2-ene (1.3 mL) and a 
solution of NaClO2 and NaH2PO4·2H2O (271 mg + 280 mg in 7 mL of water, 2.4 
mmol + 1.8 mmol) were then added. The reaction was monitored by TLC 
(DCM/MeOH 9:1 + 1% AcOH). After 1 h the mixture was concentrated to half 
volume, acidified with 5% aq. HCl to pH 2, then the solvents were evaporated and 
the mixture lyophilized. The crude was dissolved in DMF (5 mL), BnBr (285 L, 
2.4 mmol) and Cs2CO3 (782 mg, 2.4 mmol) were added. The reaction was 
monitored by TLC (hexane/AcOEt 7:3) and stirred overnight. Then the solvent was 
evaporated, the crude was taken up in DCM and washed with water and brine. The 
organic phase was dried over Na2SO4, filtered and concentrated. Flash 
chromatography (toluene/acetone 98:2 to 95:5) afforded compound 54 (70.7 mg, 
63%) as a white foam. 
 
1H NMR (400 MHz, CDCl3, 25°C): δ = 7.50 – 7.08 (m, 25H, arom.), 5.78 (ddt, J = 
16.9, 10.2, 6.6 Hz, 1H, O(CH2)3CHCH2), 5.30 (m, 2H, COOCH2Ph), 5.15 (d, J1’,2’ = 
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3.6 Hz, 1H, H-1’), 5.12 (d, J1,2 = 3.6 Hz, 1H, H-1), 4.99 (m, 2H, O(CH2)3CHCH2), 
4.90 (d, J = 1.5 Hz, 1H, H-5’), 4.85 – 4.71 (m, 5H, OCH2Ph, 2 x OCHHPh, 
COOHHPh), 4.66 (d, J = 12.1 Hz, 1H, COOHHPh), 4.63 (br d, J = 1.9 Hz, 1H, H-
4), 4.50 (d, J = 12.4 Hz, 1H, OCHHPh), 4.41 (br s, 1H, H-5), 4.34 (m, 2H, 
OCHHPh, H-4’), 4.02 (dd, J2’,3’ = 10.7, J3’,4’ = 2.6 Hz, 1H, H-3’), 3.94 (m, 2H, H-2’, 
H-3), 3.74 (dt, J = 9.9, 6.6 Hz, 1H, OCHH(CH2)2CHCH2), 3.58 (m, 2H, H-2, 
OCHH(CH2)2CHCH2), 2.12 (m, 2H, O(CH2)2CH2CHCH2), 1.72 (m, 2H, 
OCH2CH2CH2CHCH2) ppm. 
 
13C NMR (100.6 MHz, CDCl3, 25°C): δ = 168.22 (COOBn), 167.78 (COOBn), 
137.92 (O(CH2)3CHCH2), 115.32 (O(CH2)3CHCH2), 100.13 (C-1’), 98.34 (C-1), 
77.23 (C-3’), 75.53 (C-4), 74.97 (C-4’), 74.81 (C-3), 74.69 (OCH2Ph), 72.54 
(OCH2Ph), 71.85 (OCH2Ph), 71.57 (C-5’), 70.34 (C-5), 68.59 
(OCH2(CH2)2CHCH2), 67.98 (COOCH2Ph), 67.06 (COOCH2Ph), 59.42 (C-2’), 
59.13 (C-2), 30.31 (O(CH2)3CH2CHCH2), 28.30 (OCH2CH2CH2CHCH2) ppm. 
 
ESI HR-MS (MeOH) for [C52H54N6O11Na]+ calcd: 961.3743, found: 961.3825 
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(2-Amino-2-deoxy--D-galactopyranosyluronic acid)-(14)-(pentyl 2-
amino-2-deoxy--D-galactopyranosiduronic acid) dihydrochloride (55) 
 
 
Compound 54 (31.5 mg, 33.5 mol) was dissolved in H2O/THF 3:1 (8 mL + 5 
drops of 5% aq. HCl). Pd/C was added and the mixture was left under hydrogen (30 
bar) at 30°C for 24 h. Then the mixture was filtered and lyophilized. Reversed-
phase flash chromatography (H2O/CH3CN 95:5) afforded compound 55 (15.4 mg, 
90%) as a white solid. 
 
1H NMR (400 MHz, D2O, 25°C): δ = 5.24 (d, J1’,2’ = 3.7 Hz, 1H, H-1’), 5.19 (d, J1,2 
= 3.7 Hz, 1H, H-1), 4.78 (br s, 1H, H-5’), 4.42 (d, J = 3.1 Hz, 1H, H-4), 4.32 (br s, 
1H, H-5), 4.30 (br d, J = 2.9 Hz, 1H, H-4’), 4.22 (dd, J2,3 = 11.1, J3,4 = 3.0 Hz, 1H, 
H-3), 4.12 (dd, J2’,3’ = 11.1, J3’,4’ = 3.2 Hz, 1H, H-3’), 3.74 (dt, J = 9.7, 6.7 Hz, 1H, 
OCHH(CH2)3CH3), 3.55 (m, 3H, OCHH(CH2)3CH3, H-2, H-2’), 1.61 (m, 2H, 
OCH2CH2(CH2)2CH3), 1.31 (m, 4H, O(CH2)2CH2CH2CH3), 0.86 (m, 3H, 
O(CH2)4CH3) ppm. 
 
13C NMR (100.6 MHz, D2O, 25°C): δ = 174.83 (2 x COOH), 96.32 (C-1’), 95.42 
(C-1), 77.55 (C-4), 72.59 (C-5’), 70.75 (C-5), 69.62 (C-4’), 69.05 
(OCH2(CH2)3CH3), 66.83 (C-3’), 66.29 (C-3), 50.87 (C-2 or C-2’), 50.80 (C-2’ or 
C-2), 28.41 (OCH2CH2(CH2)2CH3), 27.69 (O(CH2)2CH2CH2CH3), 21.74 
(O(CH2)2CH2CH2CH3), 13.37 (O(CH2)4CH3) ppm. 
 
ESI HR-MS (MeOH) for [C17H30N2O11-H]- calcd: 437.1777, found: 437.1820 
 
[]D20 = 139.9 (c = 0.39 in H2O)  
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(2-Acetamido-2-deoxy--D-galactopyranosyluronic acid)-(14)-(pentyl 2-
acetamido-2-deoxy--D-galactopyranosiduronic acid) (56) 
 
 
 
Compound 55 (5.9 mg, 11.5 mol) was dissolved in MeOH (2 mL). NaHCO3 (3.9 
mg, 31.2 mol) was added and the mixture was stirred for 15 min. Then Ac2O (30 
L, 300 mol) was added and the mixture was stirred overnight. The reaction was 
monitored by RPTLC (H2O/CH3CN 8:2 + 1% AcOH). The mixture was quenched 
with water and neutralized with Amberlite IR-120, filtered and concentrated in 
vacuo. Reverse phase flash chromatography (H2O/CH3CN 95:5 to 7:3) afforded 
compound 56 (6 mg, quant.). 
 
1H NMR (400 MHz, D2O, 25°C): δ = 4.98 (br s, 1H, H-1), 4.91 (d, J1’,2’ = 3.5 Hz, 
1H, H-1’), 4.68 (br s, 1H, H-5), 4.35 (br s, 1H, H-5’), 4.25 (br d, J = 3.1 Hz, 1H , H-
4), 4.20 (m, 2H, H-4’, H-2), 4.13 – 3.94 (m, 3H, H-2’, H-3’, H-3), 3.65 (dt, J = 
10.0, 6.5 Hz, 1H, OCHH(CH2)3CH3), 3.46 (dt, J = 10.0, 6.0 Hz, 1H, 
OCHH(CH2)3CH3), 2.04 (s, 3H, HNCOCH3), 1.98 (s, 3H, HNCOCH3), 1.53 (m, 
2H, OCH2CH2(CH2)2CH3), 1.27 (m, 4H, O(CH2)2CH2CH2CH3), 0.82 (m, 3H, 
O(CH2)4CH3) ppm. 
 
13C NMR (100.6 MHz, D2O, 25°C): δ = 174.96 (COOH or NHCOCH3), 174.62 
(COOH or NHCOCH3), 98.56 (C-1), 96.67 (C-1’), 77.97 (C-5’), 72.52 (C-5), 70.68 
(C-4’), 70.08 (C-4), 68.50 (OCH2(CH2)3CH3), 67.98 (C-3), 67.08 (C-3’), 50.00 (C-
2’), 49.36 (C-2), 28.22 (OCH2CH2(CH2)2CH3), 27.62 (O(CH2)2CH2CH2CH3), 22.43 
(NHCOCH3), 21.92 (NHCOCH3), 21.68 (O(CH2)2CH2CH2CH3), 13.36 
(O(CH2)4CH3) ppm. 
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ESI HR-MS (MeOH) for [C21H34N2O13-H]- calcd: 521.1988, found: 521.1942 
 
[α]D20 = 82.1 (c = 0.4 in H2O) 
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4-Pentenyl 2-azido-3-O-benzyl-6-O-t-butyldimethylsilyl-2-deoxy--D-
galactopyranoside (57) 
 
 
 
Compound 52b (130 mg, 0.37 mmol) was dissolved in THF (5 mL). Imidazole 
(100.6 mg, 1.48 mmol) was added and the mixture was cooled to 0°C. TBDMSCl 
(83 mg, 0.55 mmol) was added, the mixture was slowly warmed to rt and stirred 
overnight. The reaction was monitored by TLC (hexane/AcOEt 6:4). The solvent 
was removed, the crude was taken up in AcOEt and washed with brine. The organic 
phase was dried over Na2SO4, filtered and concentrated. Flash chromatography 
(hexane/AcOEt 8:2) afforded compound 57 (148.5 mg, 84%) as a light yellow oil. 
 
1H NMR (400 MHz, CDCl3, 25°C): δ = 7.47 – 7.32 (m, 5H, arom.), 5.84 (ddt, J = 
16.9, 10.2, 6.6 Hz, 1H, O(CH2)3CHCH2), 5.10 – 4.97 (m, 2H, O(CH2)3CHCH2), 
4.92 (d, J1,2 = 3.6 Hz, 1H, H-1), 4.76 (m, 2H, OCH2Ph), 4.14 (br d, J = 2.6 Hz, 1H, 
H-4), 3.92 (dd, J2,3 = 10.4, J3,4 = 3.0 Hz, 1H, H-3), 3.89 (dd, J6a,6b = 9.4 Hz, J5,6a = 
5.2 Hz, 1H, H-6a), 3.84 – 3.67 (m, 4H, H-6b, H-5, H-2, OCHH(CH2)2CHCH2), 3.49 
(dt, J = 9.7, 6.5 Hz, 1H, OCHH(CH2)2CHCH2), 2.57 (br s, 1H, OH), 2.17 (m, 2H, 
O(CH2)2CH2CHCH2), 1.75 (m, 2H, OCH2CH2CH2CHCH2), 0.93 (s, 9H, 
SiC(CH3)3), 0.10 (s, 3H, Si(CH3)2) ppm. 
 
13C NMR (100.6 MHz, CDCl3, 25°C): δ = 137.96 (O(CH2)3CHCH2), 115.02 
(O(CH2)3CHCH2), 98.05 (C-1), 76.23 (C-3), 71.92 (OCH2Ph), 70.03 (C-5), 67.56 
(OCH2(CH2)2CHCH2), 66.45 (C-4), 62.67 (C-6), 59.20 (C-2), 30.28 
(O(CH2)3CH2CHCH2), 28.60 (OCH2CH2CH2CHCH2), 25.86 (SiC(CH3)3), 18.29 
(SiC(CH3)3), -5.41 (Si(CH3)2) ppm. 
 
ESI-MS (MeOH) for [C24H39N3O5Na]+ calcd: 500.26, found: 500.3
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(6-O-Acetyl-2-azido-3,4-di-O-benzyl-2-deoxy--D-galactopyranosyl)-(14)-
(6-O-acetyl-2-azido-3-O-benzyl-2-deoxy--D-galactopyranosyl)-(14)-(4-
pentenyl 2-azido-3-O-benzyl-6-O-t-butyldimethylsilyl-2-deoxy--D-
galactopyranoside) (58) 
 
 
 
Donor 34 (405 mg, 0.44 mmol) and acceptor 57 (137 mg, 0.29 mmol) were 
coevaporated together three times with toluene and kept under vacuum overnight. 
They were dissolved in DCM (4 mL) under Argon atmosphere. Freshly activated 
4Å molecular sieves (545 mg) were added and the mixture was stirred at rt for 45 
min. Then a solution of trimethylsilyl triflate (0.055 M in DCM, 527 L, 0.03 
mmol) was slowly added over 1 h at 0°C using a syringe pump. The reaction 
mixture was then warmed to rt and monitored by TLC (hexane/AcOEt 7:3). After 3 
h the reaction was neutralized with TEA, filtered on a Celite pad and the solvent 
was evaporated. Flash chromatography (hexane/AcOEt 9:1) afforded compound 58 
(303.2 mg, 86%) as a white foam. 
 
1H NMR (400 MHz, CDCl3, 25°C): δ = 7.50 – 7.22 (m, 20H, arom.), 5.81 (ddt, J = 
16.9, 10.2, 6.6 Hz, 1H, O(CH2)3CHCH2), 5.21 (d, J1’,2’ = 3.6 Hz, 1H, H-1’), 5.08 – 
4.96 (m, 2H, O(CH2)3CHCH2), 4.94 (d, J1,2 = 3.6 Hz, 1H, H-1), 4.92 (d, J1’’,2’’ = 3.6 
Hz, 1H, H-1’’), 4.90 – 4.85 (m, 3H, 3 x OCHHPh), 4.82 (d, J = 11.2 Hz, 1H, 
OCHHPh), 4.76 (d, J = 11.2 Hz, 1H, OCHHPh), 4.73 (d, J = 12.2 Hz, 1H, 
OCHHPh), 4.67 (d, J = 11.9 Hz, 1H, OCHHPh), 4.50 (d, J = 11.2 Hz, 1H, 
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OCHHPh), 4.38 (br dd, J = 9.8, 5.3 Hz, 1H, H-5’), 4.31 (br d, J = 2.8 Hz, 1H, H-4), 
4.30 – 4.22 (m, 2H, H-5’’, H-6’a), 4.20 (br d, J = 5.6 Hz, 1H, H-4’), 4.07 – 3.92 (m, 
7H, H-6’b, H-3’’, H-6’’a, H-3’’, H-6b, H-4’’, H-2’’), 3.89 (dd, J2,3 = 10.9 Hz, J3,4 = 
3.0 Hz, 1H, H-3), 3.79 – 3.65 (m, 5H, H-6b, H-5, H-6’’b, H-2’, 
OCHH(CH2)2CHCH2), 3.57 (dd, J2,3 = 10.8, J1,2 = 3.6 Hz, 1H, H-2), 3.49 (dt, J = 
9.8, 6.3 Hz, 1H, OCHH(CH2)2CHCH2), 2.14 (m, 2H, O(CH2)2CH2CHCH2), 1.93 (s, 
3H, OCOCH3), 1.77 (s, 3H, OCOCH3), 1.73 (m, 2H, OCH2CH2CH2CHCH2), 0.94 
(s, 9H, SiC(CH3)3), 0.12 (s, 3H, Si(CH3)2), 0.11 (s, 3H, Si(CH3)2) ppm. 
 
13C NMR (100.6 MHz, CDCl3, 25°C): δ = 169.81 (OCOCH3), 169.61 (OCOCH3), 
137.92 (O(CH2)3CHCH2), 115.03 (O(CH2)3CHCH2), 99.11 (C-1’), 98.46 (C-1), 
98.16 (C-1’’), 76.86 (C-3’’), 75.01 (C-3’, C-3), 74.65 (OCH2Ph), 72.28 (OCH2Ph), 
72.20 (C-4’, C-4’’), 71.93 (2 x OCH2Ph), 71.74 (C-4), 70.93 (C-5), 68.76 (C-5’’), 
68.27 (C-5’), 67.66 (OCH2(CH2)2CHCH2), 62.01 (C-6’’), 61.07 (C-6’), 60.41 (C-6), 
60.07, 59.96, 59.83 (C-2’’, C-2’, C-2), 30.27 (O(CH2)3CH2CHCH2), 28.60 
(OCH2CH2CH2CHCH2), 25.85 (SiC(CH3)3), 20.71 (OCOCH3), 20.61 (OCOCH3), 
18.19 (SiC(CH3)3), -5.37 (SiCH3), -5.49 (SiCH3) ppm. 
 
ESI HR-MS (MeOH) for [C61H79N9O15SiNa]+ calcd: 1228.5363, found: 1228.5380 
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(6-O-Acetyl-2-azido-3,4-di-O-benzyl-2-deoxy--D-galactopyranosyl)-(14)-
(6-O-acetyl-2-azido-3-O-benzyl-2-deoxy--D-galactopyranosyl)-(14)-(4-
pentenyl 2-azido-3-O-benzyl-2-deoxy--D-galactopyranoside) (59) 
 
 
 
Compound 58 (303 mg, 0.25 mmol) was dissolved in THF (5 mL) at -40°C. TBAF 
(1.0 M in THF, 325 L, 0.33 mmol) was slowly added. The reaction was monitored 
by TLC (hexane/AcOEt 6:4) and slowly warmed to 0°C overnight. Then the solvent 
was concentrated, the mixture was diluted with AcOEt and washed with satd. 
NH4Cl. The organic phase was dried with Na2SO4, filtered and evaporated in vacuo. 
Flash chromatography (hexane/AcOEt 7:3) afforded compound 59 (260.8 mg, 96%) 
as a white foam. 
 
1H NMR (400 MHz, CDCl3, 25°C): δ = 7.49 – 7.23 (m, 20H, arom.), 5.82 (ddt, J = 
16.9, 10.2, 6.6 Hz, 1H, O(CH2)3CHCH2), 5.13 (d, J1’,2’ = 3.5 Hz, 1H, H-1’), 5.08 – 
4.97 (m, 2H, O(CH2)3CHCH2), 4.94 (m, 2H, H-1, H-1’’), 4.90 – 4.80 (m, 4H, 4 x 
OCHHPh), 4.77 (d, J = 11.2 Hz, 1H, OCHHPh), 4.72 (d, J = 12.0 Hz, 1H, 
OCHHPh), 4.65 (d, J = 12.0 Hz, 1H, OCHHPh), 4.52 (d, J = 11.2 Hz, 1H, 
OCHHPh), 4.34 – 4.23 (m, 4H, H-5’’, H-5’, H-6’a, H-4), 4.17 (br d, J = 2.7 Hz, 1H, 
H-4’), 4.12 (br dd, J = 10.8 Hz, 5.8 Hz, 1H, H-6’b), 4.05 – 3.98 (m, 3H, H-6’’a, H-
2’’, H-3’’), 3.97 – 3.66 (m, 9H, H-4’’, H-3’, H-3, H-5, H-6a, H-6’’b, H-2’, H-6b, 
OCHH(CH2)2CHCH2), 3.59 (dd, J2,3 = 10.8, J1,2 = 3.6 Hz, 1H, H-2), 3.49 (dt, J = 
9.7, 6.4 Hz, 1H, OCHH(CH2)2CHCH2), 2.15 (m, 2H, O(CH2)2CH2CHCH2), 1.96 (s, 
3H, OCOCH3), 1.80 (s, 3H, OCOCH3), 1.73 (m, 2H, OCH2CH2CH2CHCH2) ppm. 
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13C NMR (100.6 MHz, CDCl3, 25°C): δ = 169.87 (2 x OCOCH3), 137.91 
(O(CH2)3CHCH2), 115.07 (O(CH2)3CHCH2), 99.09 (C-1’), 98.50 (C-1), 98.16 (C-
1’’), 77.33 (C-3’’), 75.28 (C-3 or C-3’), 75.08 (C-3’ or C-3), 74.67 (OCH2Ph), 
73.08 (C-4), 72.49 (C-4’), 72.38 (OCH2Ph), 72.22 (C-4’’), 72.07 (OCH2Ph), 71.84 
(OCH2Ph), 70.77 (C-5), 68.86 (C-5’’ or C-5’), 68.78 (C-5’ or C-5’’), 67.76 
(OCH2(CH2)2CHCH2), 62.05 (C-6’’ or C-6’), 61.32 (C-6’ or C-6’’), 60.73 (C-6), 
60.45 (C-2’), 60.22 (C-2’’), 59.73 (C-2), 30.24 (O(CH2)3CH2CHCH2), 28.57 
(OCH2CH2CH2CHCH2), 20.72 (OCOCH3), 20.46 (OCOCH3) ppm. 
 
ESI HR-MS (MeOH) for [C55H65N9O15Na]+ calcd: 1114.4498, found: 1114.4502 
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(2-Azido-3,4-di-O-benzyl-2-deoxy--D-galactopyranosyl)-(14)-(2-azido-3-
O-benzyl-2-deoxy--D-galactopyranosyl)-(14)-(4-pentenyl 2-azido-3-O-
benzyl-2-deoxy--D-galactopyranoside) (60) 
 
 
 
Compound 59 (260 mg, 0.24 mmol) was dissolved in THF/MeOH/H2O 1:5:1 (7 
mL) and LiOH·H2O (20 mg, 0.48 mmol) was added. The reaction was monitored 
by TLC (hexane/AcOEt 4:6). After 24 h the mixture was neutralized with 
Amberlite IR-120, filtered and the solvent was evaporated in vacuo, affording 
compound 60 (245 mg, quant.) as a colorless oil. 
 
1H NMR (400 MHz, CDCl3, 25°C): δ = 7.51 – 7.23 (m, 20H, arom.), 5.84 (ddt, J = 
16.9, 10.2, 6.6 Hz, 1H, O(CH2)3CHCH2), 5.12 – 4.98 (m, 4H, H-1’, H-1’’, 
O(CH2)3CHCH2), 4.96 (d, J1,2 = 3.6 Hz, 1H, H-1), 4.87 (d, J = 11.3 Hz, 1H, 
OCHHPh), 4.85 (d, J = 11.7 Hz, 1H, OCHHPh), 4.83 (d, J = 11.5 Hz, 1H, 
OCHHPh), 4.78 (d, J = 11.3 Hz, 1H, OCHHPh), 4.74 (d, J = 11.6 Hz, OCHHPh), 
4.71 (d, J = 11.3 Hz, OCHHPh), 4.67 (d, J = 11.7 Hz, OCHHPh), 4.56 (d, J = 11.3 
Hz, 1H, OCHHPh), 4.28 (br d, J = 2.8 Hz, 1H, H-4), 4.24 (br d, J = 2.2 Hz, 1H, H-
4’), 4.07 (br t, J = 7.0 Hz, 1H, H-5’), 4.04 – 3.56 (m, 13H, H-5’’, H-4’’, H-3’, H-
3’’, H-3, H-2’’, H-5, H-6a, H-6b, H-2’, OCHH(CH2)2CHCH2, H-2, H-6’a), 3.51 (dt, 
J = 9.7, 6.4 Hz, 1H, OCHH(CH2)2CHCH2), 3.44 – 3.31 (m, 3H, H-6’b, H-6’’a, H-
6’’b), 2.32 (br s, 1H, OH), 2.17 (m, 2H, O(CH2)2CH2CHCH2), 1.75 (m, 2H, 
OCH2CH2CH2CHCH2) ppm. 
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13C NMR (100.6 MHz, CDCl3, 25°C): δ = 137.89 (O(CH2)3CHCH2), 115.10 
(O(CH2)3CHCH2), 98.92 (C-1’), 98.82 (C-1’’), 98.10 (C-1), 77.13 (C-3’ or C-3’’), 
76.01 (C-3’’ or C-3’), 75.88 (C-3), 74.72 (OCH2Ph), 73.57 (C-4), 73.33 (C-4’’), 
72.56 (C-3’), 72.35 (OCH2Ph), 72.14 (OCH2Ph), 71.80 (OCH2Ph), 71.34 (C-5’), 
71.22 (C-5’’), 70.72 (C-5), 67.82 (OCH2(CH2)2CHCH2), 61.80 (C-6’’), 60.68 (C-6), 
60.54 (C-2’’), 60.37 (C-2’), 60.37 (C-6’), 59.81 (C-2), 30.24 (O(CH2)3CH2CHCH2), 
28.59 (OCH2CH2CH2CHCH2) ppm. 
 
ESI HR-MS (MeOH) for [C51H61N9O13Na]+ calcd: 1030.4287, found: 1030.4807 
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(Benzyl 2-azido-3,4-di-O-benzyl-2-deoxy--D-galactopyranosyluronate)-
(14)-(benzyl 2-azido-3-O-benzyl-2-deoxy--D-galactopyranosyluronate)-
(14)-(benzyl (4-pentenyl 2-azido-3-O-benzyl-2-deoxy-
galactopyranosid)uronate) (61) 
 
 
 
Compound 60 (242 mg, 0.24 mmol) was dissolved in DCM (10 mL) and Dess-
Martin periodinane (467 mg, 1.1 mmol) was added. The reaction was monitored by 
TLC (tol/AcOEt 7:3). After 8 h, the mixture was quenched with 10% aq. Na2S2O3. 
The organic phase was separated and washed with satd. NaHCO3. The combined 
aqueous phases were extracted with DCM. The combined organic phases were 
dried over Na2SO4, filtered and concentrated in vacuo. The residue was dissolved in 
THF (5 mL) and tBuOH (10 mL). 2-Methylbut-2-ene (3.8 mL) and a solution of 
NaClO2 and NaH2PO4·2H2O (814 mg + 842 mg in 20 mL of water, 7.2 mmol + 5.4 
mmol) were then added. The reaction was monitored by TLC (DCM/MeOH 8:2 + 
1% AcOH). After 1 h the mixture was concentrated to half volume, acidified with 
5% aq. HCl to pH 2, then the solvents were evaporated and the mixture lyophilized. 
The crude was dissolved in DMF (20 mL), BnBr (856 L, 7.2 mmol) and K2CO3 
(1.0 g, 7.2 mmol) were added. The reaction was monitored by TLC (hexane/AcOEt 
6:4) and stirred overnight. Then the solvent was evaporated, the crude was taken up 
in DCM and washed with water and brine. The organic phase was dried over 
Na2SO4, filtered and concentrated. Flash chromatography (toluene/acetone 98:2 to 
95:5) afforded compound 61 (130 mg, 41%) as a white foam. 
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1H NMR (400 MHz, CDCl3, 25°C): δ = 7.52 – 7.04 (m, 35H, arom.), 5.75 (ddt, J = 
16.9, 10.2, 6.6 Hz, 1H, O(CH2)3CHCH2), 5.32 (s, 2H, COOCH2Ph), 5.23 (d, J1’,2’ = 
3.7 Hz, 1H, H-1’), 5.10 – 4.91 (m, 4H, H-1, COOCHHPh, H-1’’, O(CH2)3CHCH2), 
4.91 – 4.66 (m, 10H, H-5’, OCHHPh, H-5’’, COOCHHPh, OCHHPh, OCHHPh, 
OCH2Ph, COOCHHPh, H-4), 4.62 – 4.44 (m, 4H, H-4’, COOCHHPh, OCHHPh, 
OCHHPh), 4.42 – 4.26 (m, 3H, H-5, OCHHPh, H-4), 4.03 – 3.85 (m, 4H, H-3’’, H-
3’, H-2’’, H-3), 3.71 (dt, J = 10.4, 6.5 Hz, 1H, OCHH(CH2)2CHCH2), 3.65 – 3.45 
(m, 3H, H-2’, OCHH(CH2)2CHCH2, H-2), 2.08 (m, 2H, O(CH2)2CH2CHCH2), 1.96 
(m, 2H, OCH2CH2CH2CHCH2) ppm. 
 
13C NMR (100.6 MHz, CDCl3, 25°C): δ = 167.83 (COOBn), 167.69 (COOBn), 
167.27 (COOBn), 137.72 (O(CH2)3CHCH2), 115.12 (O(CH2)3CHCH2), 99.86 (C-
1’’), 99.27 (C-1’), 98.15 (C-1), 77.05 (C-3’’), 75.34 (C-4’), 75.01 (C-3’), 74.79 (C-
4’’), 74.66 (C-4), 74.49 (OCH2Ph), 74.28 (C-3), 72.37 (OCH2Ph), 71.84 (OCH2Ph), 
71.57 (OCH2Ph), 71.40 (C-5’’), 70.79 (C-5’), 70.04 (C-5), 68.41 
(OCH2(CH2)2CHCH2), 67.74 (COOBn), 67.65 (COOBn), 66.85 (COOBn), 59.20 
(C-2’’), 59.07 (C-2’), 58.93 (C-2), 30.13 (O(CH2)3CH2CHCH2), 28.45 
(OCH2CH2CH2CHCH2) ppm. 
 
ESI HR-MS (MeOH) for [C72H73N9O16Na]+ calcd: 1342.5067, found: 1342.4950 
 
[α]D20 = 143.6 (c = 1 in CHCl3) 
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(2-Amino-2-deoxy--D-galactopyranosyluronic acid)-(14)-(2-amino-2-
deoxy--D-galactopyranosyluronic acid)-(14)-(pentyl 2-amino-2-deoxy--D-
galactopyranosiduronic acid) tris-trifluoroacetate salt (62) 
 
 
 
Compound 61 (23 mg, 17.4 mol) was dissolved in H2O/THF 3:1 (8 mL + 5 drops 
of 5% aq. HCl). Pd/C was added and the mixture was stirred under hydrogen (35 
bar) at 35°C for 24 h. The reaction mixture was filtered on a Celite pad and 
lyophilized. Reverse phase flash chromatography (H2O/CH3CN + 0.1% TFA 95:5 
to 9:1) afforded compound 62 (15 mg, 90%) as a white solid. 
 
1H NMR (400 MHz, D2O, 25°C): δ = 5.24 (d, J1’’,2’’ = 3.8 Hz, 1H, H-1’’), 5.20 (d, 
J1’,2’ = 3.8 Hz, 1H, H-1’), 5.16 (d, J1,2 = 3.7 Hz, 1H, H-1), 4.98 (s, 1H, H-5’), 4.85 
(s, 1H, H-5’’), 4.39 (m, 2H, H-4, H-4’’), 4.34 (s, 1H, H-5), 4.30 (m, 1H, H-4’), 4.26 
– 4.17 (m, 2H, H-3’’, H-3), 4.11 (dd, J2’,3’ = 11.1, J3’,4’ = 3.2 Hz, 1H, H-3’), 3.70 (dt, 
J = 9.7, 6.7 Hz, 1H, OCHHCH2CH2CH2CH3), 3.59 – 3.45 (m, 4H, H-2’’, 
OCHHCH2CH2CH2CH3, H-2, H-2’), 1.56 (m, 2H, OCH2CH2CH2CH2CH3), 1.26 (m, 
4H, OCH2CH2CH2CH2CH3), 0.81 (m, 3H, OCH2CH2CH2CH2CH3) ppm. 
 
13C NMR (400 MHz, D2O, 25°C): δ = 174.53 (COOH’), 174.20 (COOH’’), 173.08 
(COOH), 95.92 (C-1’’, C-1’), 95.21 (C-1), 77.29 (C-4 or C-4’’), 77.15 (C-4’’ or C-
4), 71.53 (C-5’), 71.05 (C-5’’), 70.34 (C-5), 69.02 (OCH2(CH2)3CH3), 68.95 (C-4’), 
66.03 (C-3’), 65.79 (C-3), 65.44 (C-3’’), 50.51 (C-2, C-2’, C-2’’), 28.30 
(OCH2CH2(CH2)2CH3), 27.57 (O(CH2)2CH2CH2CH3), 21.66 
(O(CH2)2CH2CH2CH3), 13.28 (O(CH2)4CH3) ppm. 
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ESI HR-MS (MeOH) for [C23H39N3O16-H]- calcd: 612.2257, found: 612.2310 
 
[α]D20 = 143.6 (c = 1 in H2O) 
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(2-Acetamido-2-deoxy--D-galactopyranosyluronic acid)-(14)-(2-
acetamido-2-deoxy--D-galactopyranosyluronic acid)-(14)-(pentyl 2-
acetamido-2-deoxy--D-galactopyranosiduronic acid) (63) 
 
 
 
Compound 62 (5 mg, 5.2 mol) was dissolved in MeOH (2 mL). NaHCO3 (2.6 mg, 
31.2 mol) was added and the mixture was stirred for 15 min. Then Ac2O (30 L, 
300 mol) was added and the mixture was stirred overnight. The reaction was 
monitored by RPTLC (H2O/CH3CN 7:3). The mixture was quenched with water 
and neutralized with Amberlite IR-120, filtered and concentrated in vacuo. HPLC 
purification (H2O/CH3CN + 0.1% TFA 95:5 to 7:3) afforded compound 63 (3.7 mg, 
97%). 
 
1H NMR (400 MHz, D2O, 25°C): δ = 5.15 – 4.88 (m, 5H, H-1, H-1’, H-1’’, H-5, H-
5’), 4.50 – 4.40 (m, 3H, H-5’’, H-4, H-4’), 4.31 (br s, 1H, H-4’’), 4.23 – 3.99 (m, 
6H, H-2, H-2’, H-2’’, H-3, H-3’, H-3’’), 3.67 (m, 1H, OCHH(CH2)3CH3), 3.49 (m, 
1H, OCHH(CH2)3CH3), 1.98 (m, 9H, 3 x NHCOCH3), 1.54 (m, 2H, 
OCH2CH2CH2CH2CH3), 1.26 (m, 4H, OCH2CH2CH2CH2CH3), 0.83 (m, 3H, 
OCH2CH2CH2CH2CH3) ppm. 
 
13C NMR (100.6 MHz, D2O, 25°C): δ = 174.66, 172.56 (3 x COOH, 3 x 
NHCOCH3), 98.57, 98.46, 96.88 (C-1, C-1’, C-1’’), 77.71 (C-4 or C-4’), 77.64 (C-
4’ or C-4), 71.38 (C-5 or C-5’), 71.24 (C-5’ or C-5), 70.25 (C-5’’), 69.38 (C-4’’) , 
68.77 (OCH2(CH2)3CH3), 67.05, 66.50, 66.27 (C-3, C-3’, C-3’’), 49.74, 49.36 (C-2, 
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C-2’ C-2’’), 28.20 (OCH2CH2(CH2)2CH3), 27.57 (O(CH2)2CH2CH2CH3), 22.23 (3 x 
NHCOCH3), 21.68 (O(CH2)2CH2CH2CH3), 13.33 (O(CH2)4CH3) ppm. 
 
ESI HR-MS (MeOH) for [C29H45N3O19-H]- calcd: 738.2574, found: 738.2632 
 
[α]D20 = 52.3 (c = 0.26 in H2O) 
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6.2 3-O-Ac oligomers 
 
Benzyl (thexyldimethylsilyl 2-azido-3,4-di-O-benzyl-2-deoxy--D-
galactopyranosiduronate) (38a) 
 
 
 
Compound 19a (216 mg, 0.41 mmol) was dissolved in acetone (20 mL) and 5% aq. 
NaHCO3 (10 mL), and the mixture was cooled to 0°C. KBr (97 mg, 0.82 mmol), 
TEMPO (90 mg, 0.57 mmol) and NaOCl 13% (1.7 mL) were added sequentially. 
After 30 min TLC analysis (DCM/MeOH 8:2 + 1% AcOH) showed complete 
consumption of the starting material. The solvent was removed in vacuo and co-
evaporated three times with toluene. The crude was left under vacuum overnight, 
then it was dissolved in DMF (10 mL). BnBr (240 L, 2.1 mmol) and K2CO3 (280 
mg, 2.1 mmol) were added. The reaction was monitored by TLC (hexane/AcOEt 
7:3). After 5 h the solvent was evaporated, the crude was taken up in AcOEt and 
washed with water and brine. The organic phase was dried over Na2SO4, filtered 
and concentrated. Flash chromatography (hexane/AcOEt 8:2) afforded compound 
38a (217.4 mg, 84%) as a light yellow oil. 
 
1H NMR (400 MHz, CDCl3, 25°C): δ = 7.45 – 7.22 (m, 15H, arom.), 5.14 (m, 2H, 
COOCH2Ph), 4.84 (d, J = 11.7 Hz, 1H, OCHHPh), 4.72 (s, 2H, OCH2Ph), 4.57 (d, J 
= 11.7 Hz, 1H, OCHHPh), 4.46 (d, J1,2 = 7.7 Hz, 1H, H-1), 4.24 (dd, J3,4 = 3.0, J4,5 
= 1.3 Hz, 1H, H-4), 4.00 (d, J4,5 = 1.3 Hz, 1H, H-5), 3.80 (dd, J2,3 = 10.4, J1,2 = 7.7 
Hz, 1H, H-2), 3.34 (dd, J2,3 = 10.4, J3,4 = 3.0 Hz, 1H, H-3), 1.70 (hept, J = 6.8 Hz, 
1H, SiC(CH3)2CH(CH3)2), 0.92 (m, 12H, SiC(CH3)2CH(CH3)2), 0.24 (s, 3H, 
Si(CH3)2), 0.21 (s, 3H, Si(CH3)2) ppm. 
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13C NMR (100.6 MHz, CDCl3, 25°C): δ = 167.68 (COOBn), 97.22 (C-1), 79.83 (C-
3), 74.53 (OCH2Ph), 74.11 (C-5), 74.06 (C-4), 72.69 (OCH2Ph), 67.07 
(COOCH2Ph), 65.24 (C-2), 33.94 (SiC(CH3)2CH(CH3)2), 20.00 
(SiC(CH3)2CH(CH3)2), 19.94 (SiC(CH3)2CH(CH3)2), 18.50 (SiC(CH3)2CH(CH3)2), 
18.44 (SiC(CH3)2CH(CH3)2), -1.91 (Si(CH3)2), -3.22 (Si(CH3)2) ppm. 
 
ESI-MS (MeOH) for [C35H45N3O6SiNa]+ calcd: 654.30, found: 654.2 
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Benzyl 2-azido-3,4-di-O-benzyl-2-deoxy-D-galactopyranuronate (38b) 
 
 
 
Compound 38a (217 mg, 0.34 mmol) was dissolved in THF (5 mL) at -40°C. 
AcOH (26 L, 0.44 mmol) and TBAF (1.0 M in THF, 440 L, 0.44 mmol) were 
added dropwise. The reaction was monitored by TLC (hexane/AcOEt 7:3). After 3 
h the solvent was concentrated, the mixture was diluted with AcOEt and washed 
with satd. NH4Cl. The organic phase was dried with Na2SO4, filtered and 
evaporated in vacuo. Flash chromatography (hexane/AcOEt 7:3) afforded 
compound 38b (140 mg, 85%, mixture of anomers) as a pale yellow oil. 
 
The occurrence of the desilylation was confirmed by the disappearance of the TDS 
signals in the 1H NMR spectrum. 
 
ESI-MS (MeOH) for [C27H27N3O6Na]+ calcd: 512.17, found: 512.2 
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(Benzyl 2-azido-3,4-di-O-benzyl-2-deoxy-D-galactopyranuronate) N-
phenyltrifluoroacetimidate (67) 
 
 
 
Compound 38b (140 mg, 0.29 mmol) and N-phenyltrifluoroacetimidoyl chloride 
(92 L, 0.57 mmol) were dissolved in DCM (5 mL), then Cs2CO3 (140 mg, 0.43 
mmol) was added portionwise. The reaction was monitored by TLC (hexane/ethyl 
actetate 6:4) and stirred overnight. Then the mixture was filtered on a Celite pad 
and the solvent was evaporated. Flash chromatography (hexane/AcOEt 8:2 + 0.1% 
TEA) afforded compound 67 (187.5 mg, 97%) as a white foam. 
 
1H NMR (400 MHz, CDCl3, 25°C): δ = 7.44 – 7.19 (m, 12H, arom.), 7.09 (m, 1H, 
arom.), 6.83 (m, 2H, arom.), 5.43 (s, 1H, H-1), 5.15 (m, 2H, COOCH2Ph), 4.82 (d, 
J = 11.5 Hz, 1H, OCHHPh), 4.74 (s, 2H, OCH2Ph), 4.53 (d, J = 11.5 Hz, 1H, 
OCHHPh), 4.25 (br s, 1H, H-4), 4.12 (m, 1H, H-2), 3.93 (br s, 1H, H-5), 3.45 (dd, 
J2,3 = 10.4, J3,4 = 2.8 Hz, 1H, H-3) ppm. 
 
13C NMR (100.6 MHz, CDCl3, 25°C): δ = 95.81 (C-1), 80.30 (C-3), 74.88 
(OCH2Ph), 74.79 (C-5), 73.89 (C-4), 73.08 (OCH2Ph), 67.39 (COOCH2Ph), 61.94 
(C-2) ppm. 
 
ESI-MS (MeOH) for [C35H31F3N4O6Na]+ calcd: 683.21, found: 683.1 
 
  
  
158 
Benzyl (4-pentenyl 2-azido-3-O-benzyl-2-deoxy--D-
galactopyranosiduronate) (68) 
 
Compound 52b (109.6 mg, 0.31 mmol) was dissolved in DCM/H2O 2:1 (10 mL), 
then BAIB (300 mg, 0.93 mmol) and TEMPO (15 mg, 0.1 mmol) were added. The 
reaction was monitored by TLC (DCM/MeOH 8:2 + 1% AcOH). After 3 h the 
mixture was quenched with 5% aq. Na2S2O3, diluted with water and extracted with 
AcOEt. The organic phase was washed with brine, dried over Na2SO4, filtered and 
concentrated in vacuo. The crude was dissolved in DMF (7 mL) at 0°C. KF (180 
mg, 3.1 mmol) and BnBr (184 µL, 1.6 mmol) were added, and the mixture was 
stirred overnight at rt (TLC hexane/AcOEt 6:4). Then the solvent was removed, the 
crude was taken up in DCM and washed with water and brine. The organic phase 
was dried over Na2SO4, filtered and concentrated. Flash chromatography 
(hexane/AcOEt 7:3) afforded compound 68 (121.5 mg 82%) as a white foam. 
 
1H NMR (400 MHz, CDCl3, 25°C): δ = 7.45 – 7.33 (m, 10H, arom.), 5.81 (ddt, J = 
16.9, 10.2, 6.7 Hz, 1H, O(CH2)3CHCH2), 5.30 (s, 2H, COOCH2Ph), 5.08 – 4.95 (m, 
3H, H-1, O(CH2)3CHCH2), 4.75 (m, 2H, OCH2Ph), 4.45 (m, 2H, H-4, H-5), 4.00 
(dd, J2,3 = 10.4, J3,4 = 3.1 Hz, 1H, H-3), 3.74 (m, 2H, OCHH(CH2)2CHCH2, H-2), 
3.55 (dt, J = 9.8, 6.5 Hz, 1H, OCHH(CH2)2CHCH2), 2.45 (br s, 1H, OH), 2.15 (m, 
2H, O(CH2)2CH2CHCH2), 1.74 (m, 2H, OCH2CH2CH2CHCH2) ppm. 
13C NMR (100.6 MHz, CDCl3, 25°C): δ = 168.28 (COOBn), 137.87 
(O(CH2)3CHCH2), 115.31 (O(CH2)3CHCH2), 98.39 (C-1), 75.52 (C-3), 72.38 
(OCH2Ph), 70.04 (C-4), 68.54 (OCH2(CH2)2CHCH2), 67.53 (C-5), 67.38 
(COOCH2Ph), 58.70 (C-2), 30.27 (O(CH2)3CH2CHCH2), 28.63 
(OCH2CH2CH2CHCH2) ppm. 
ESI-MS (MeOH) for [C25H29N3O6Na]+ calcd: 490.19, found: 490.3 
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Glycosylation with uronate building blocks 67 and 68 
 
 
 
Donor 67 (60.4 mg, 91.5 µmol) and acceptor 68 (25 mg, 61 µmol) were 
coevaporated three times with toluene and kept under vacuum overnight. They were 
dissolved in toluene/Et2O 1:2 (750 µL) under Argon atmosphere. Freshly activated 
4Å molecular sieves (85 mg) were added and the mixture was stirred at rt for 45 
min. Then a solution of trimethylsilyl triflate (0.1 M in toluene, 120 µL, 12 µmol) 
was slowly added over 1 h at -30°C. The reaction was monitored by HPTLC 
(hexane/AcOEt 7:3). After 2 h the reaction was neutralized with TEA, filtered on a 
Celite pad and the solvent was evaporated. Flash chromatography (hexane/AcOEt 
85:25 to 75:25) afforded compound 54 (38.6 mg, 68%, mixture of anomers) as a 
white foam. 
 
  
  
160 
1,3,4,6-Tetra-O-acetyl-2-azido-2-deoxy-D-glucopyranoside (Glc1) 
 
 
 
Anhydrous K2CO3 (29.65 g, 214.5 mmol) was added to a suspension of D-
glucosamine hydrochloride (15.42 g, 71.5 mmol) in MeOH (250 mL) at 0°C and the 
mixture is left under vigorous stirring for 15 min. Imidazole-1-sulfonyl azide 
hydrochloride (17.90 g, 85.8 mmol) was then slowly added, followed by 
CuSO4·5H2O (179 mg, 0.715 mmol). The reaction was monitored by TLC 
(DCM/MeOH 7:3). After 4 h the solvent was removed, then the crude was 
coevaporated with toluene and kept under vacuum overnight. The crude was 
suspended in pyridine (96.5 mL, 1.144 mol), catalytic DMAP was added. Ac2O (54 
mL, 0.572 mol) was slowly added to the suspension at 0°C, then the reaction was 
warmed to rt and stirred overnight until completion (TCL, eluent hexane/AcOEt 
6:4). The mixture was quenched with crushed ice and concentrated in vacuo, then 
the residue was taken up with DCM and washed with 5% aq. HCl, satd. NaHCO3 
and brine. The organic phase was dried over Na2SO4, filtered and concentrated in 
vacuo. Flash chromatography (hexane/AcOEt 7:3) afforded compound Glc1 (16.62 
g, 62%) as a white foam. 
 
Spectroscopic data were in agreement with those reported in the literature.12 
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3,4,6-Tri-O-acetyl-2-azido-2-deoxy-D-glucopyranosyl trichloroacetimidate 
(Glc2) 
 
1) H2NNH2 AcOH
DMF O
AcO N3
AcO
OAc
O
Glc2
CCl3
NHO
AcO N3
AcO
OAc
OAc
Glc1
2) Cl3CCN, cat. DBU
DCM  
 
A solution of hydrazinium acetate was prepared by slow addition of acetic acid (6.6 
mL, 78 mmol) to a stirred solution of hydrazine hydrate (2.9 mL, 60 mmol) in 
MeOH (30 mL) at 0°C. After 15 min, the solution was slowly added to compound 
Glc1 (16.62 g, 44.2 mmol) dissolved in DMF (200 mL), and stirred for 2 h (TLC 
hexane/AcOEt 6:4). The solvent was evaporated, the crude was taken up with DCM 
and washed with brine. The organic phase was dried with Na2SO4, filtered and the 
solvent removed. The residue was dissolved in DCM (200 mL), trichloroacetonitrile 
(26.6 mL, 265.2 mmol) and catalytic DBU were added and the reaction mixture was 
stirred overnight (TLC, hexane/AcOEt 6:4). The solvent was removed and the 
crude was purified by flash chromatography (hexane/AcOEt 6:4 + 1% TEA), 
affording compound Glc2 (16.44 g, 78% over two steps) as a white foam. 
 
Spectroscopic data were in agreement with those reported in the literature.12 
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4-Pentenyl 3,4,6-tri-O-acetyl-2-azido-2-deoxy-D-glucopyranoside (71) 
 
 
 
Compound Glc2 (16.44 g, 34.6 mmol) was dissolved in DCM (150 mL) under 
Argon atmosphere and 4-pentenol (3.57 mL, 34.6 mmol) was added. Then a 
solution of TMSOTf (0.5 M in DCM, 6.92 mL, 3.46 mmol) was slowly added. The 
reaction was monitored by TLC (hexane/AcOEt 6:4). After 1 h the mixture was 
neutralized with TEA, filtered on a Celite pad and the solvent was removed. Flash 
chromatography (hexane/AcOEt 8:2) afforded pure 71 (13.819 g, quant., α/β 1:1) as 
a white foam. 
 
Spectroscopic data were in agreement with those reported in the literature.12 
 
  
  
163 
4-Pentenyl 2-azido-4,6-O-benzylidene-2-deoxy-D-glucopyranoside (72 and 
73) 
 
 
 
A solution of MeONa in MeOH (0.4 M, 7.8 mL, 3.12 mmol) was added to 
compound 71 (8.33 g, 20.8 mmol) dissolved in MeOH (100 mL) and the mixture 
was stirred for 15 min (TLC, hexane/AcOEt 6:4). The reaction is neutralized with 
Amberlite IR-120, filtered and the solvent was removed in vacuo. The product 
(5.68 g, 20.8 mmol) was dissolved in CH3CN (200 mL), benzaldehyde dimethyl 
acetal (6.2 mL, 41.6 mmol) and pTSA·H2O (400 mg, 2.08 mmol) were added. The 
reaction was stirred for 4 h (TLC, hexane/AcOEt 6:4), then quenched with TEA and 
the solvent was evaporated. The residue was dissolved in DCM (100 mL), pyridine 
(6.3 mL, 77.6 mmol), catalytic DMAP and Ac2O (3.7 mL, 38.8 mmol) were 
sequentially added to the solution at 0°C. The reaction was warmed to rt and stirred 
for 3 h (TLC hexane/AcOEt 8:2). The mixture was quenched with water and the 
solvent was removed. The crude was taken up in DCM and washed with 5% aq. 
HCl, satd. NaHCO3 and brine. The organic phase was dried over Na2SO4, filtered 
and concentrated. Pure compound 72a was obtained by crystallization 
(hexane/AcOEt). Pure compound 73a was obtained after flash chromatography 
(hexane/AcOEt 9:1) of the concentrated mother liquor. The two compounds were 
independently subjected to Zémplen deactylation, affording compound 72 (3.83 g, 
52%) and 73 (2.023 g, 27%) as white foams. 
 
Spectroscopic data were in agreement with those reported in the literature.12 
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4-Pentenyl 2-azido-4,6-O-benzylidene-2-deoxy-3-O-levulinoyl--D-
glucopyranoside (72a) 
 
 
 
A solution of MeONa in MeOH (0.4 M, 3.55 mL, 1.42 mmol) was added to 
compound 72 (1.912 g, 4.74 mmol) dissolved in MeOH (45 mL). The reaction was 
followed by TLC (hexane/AcOEt 8:2). After 3 h the reaction was neutralized with 
Amberlite IR-120, filtered and the solvent was removed in vacuo. The crude was 
dissolved in DCM (90 mL), levulinic acid (0.73 mL, 7.11 mmol), DCC (1.66 g, 8.1 
mmol), and DMAP (116 mg, 0.95 mmol) were sequentially added and the mixture 
was stirred for 3 h at rt (TLC hexane/AcOEt 7:3). The reaction mixture was filtered 
on a Celite pad and the solvent evaporated. Flash chromatography (hexane/AcOEt 
8:2 to 7:3) afforded compound 72a (1.045 g, 48%) as a white foam. 
 
1H NMR (400 MHz, CDCl3, 25°C): δ = 7.53 – 7.34 (m, 5H, arom.), 5.84 (ddt, J = 
16.9, 10.2, 6.7 Hz, 1H, O(CH2)3CHCH2), 5.62 (dd, J2,3 = 10.4, J3,4 = 9.5 Hz, 1H, H-
3), 5.54 (s, 1H, PhCH), 5.17 – 4.94 (m, 3H, O(CH2)3CHCH2, H-1), 4.31 (dd, J5,6a = 
10.3, J6a,6b = 4.9 Hz, 1H, H-6a), 3.98 (m, 1H, H-5), 3.85 – 3.73 (m, 2H, H-6b, 
OCHH(CH2)2CHCH2), 3.66 (t, J3,4 = J4,5 = 9.5 Hz, 1H, H-4), 3.54 (dt, J = 9.6, 6.4 
Hz, 1H, OCHH(CH2)2CHCH2), 3.22 (dd, J2,3 = 10.4, J1,2 = 3.6 Hz, 1H, H-2), 2.81 
(m, 2H, H3CCOCH2CH2COO), 2.69 (m, 2H, H3CCOCH2CH2COO), 2.20 (m, 5H, 
O(CH2)2CH2CHCH2, H3CCOCH2CH2COO), 1.80 (m, 2H, OCH2CH2CH2CHCH2) 
ppm. 
 
13C NMR (100.6 MHz, CDCl3, 25°C): δ = 171.90 (OCOCH2CH2COCH3), 137.85 
(O(CH2)3CHCH2), 115.42 (O(CH2)3CHCH2), 101.75 (PhCH), 99.14 (C-1), 79.68 
(C-4), 69.36 (C-3), 68.96 (C-6), 68.23 (OCH2(CH2)2CHCH2), 62.94 (C-5), 61.74 
(C-2), 38.18 (H3CCOCH2CH2COO), 30.32 (O(CH2)3CH2CHCH2), 29.89 
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(H3CCOCH2CH2COO), 28.96 (OCH2CH2CH2CHCH2), 28.14 
(H3CCOCH2CH2COO) ppm. 
 
ESI-MS (MeOH) for [C23H29N3O7Na]+ calcd: 482.19, found: 482.1 
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4-Pentenyl 2-azido-2-deoxy-3-O-levulinoyl-6-O-thexyldimethylsilyl--D-
glucopyranoside (74α) 
 
 
 
Compound 72a (1.045 g, 2.27 mmol) was dissolved in 80% aq. AcOH (25 mL) and 
the mixture was stirred at 60°C (TLC hexane/AcOEt 7:3). After 1 h, the reaction 
mixture was neutralized with solid K2CO3, diluted with water and extracted with 
DCM. The organic phase was dried over Na2SO4, filtered and concentrated in 
vacuo. The residue was dissolved in DMF (20 mL). Imidazole (0.464 g, 6.81 mmol) 
was added and the mixture was cooled to 0°C. TDSCl (0.67 mL, 3.41 mmol) was 
added, and the mixture was warmed to rt. The reaction was monitored by TLC 
(hexane/AcOEt 3:7). After 2 h the solvent was removed, the crude was taken up in 
DCM and washed with water. The organic phase was dried over Na2SO4, filtered 
and concentrated. Flash chromatography (hexane/AcOEt 8:2) afforded compound 
74α (1.062 g, 91%) as a light yellow oil. 
 
1H NMR (400 MHz, CDCl3, 25°C): δ = 5.83 (ddt, J = 16.9, 10.2, 6.6 Hz, 1H, 
O(CH2)3CHCH2), 5.41 (dd, J2,3 = 10.7, J3,4 = 8.6 Hz, 1H, H-3), 5.11 – 4.97 (m, 2H, 
O(CH2)3CHCH2), 4.93 (d, J1,2 = 3.5 Hz, 1H, H-1), 3.86 (br d, J = 4.2 Hz, 2H, H-6a, 
H-6b), 3.82 – 3.64 (m, 3H, OCHH(CH2)2CHCH2, H-5, H-4), 3.49 (dt, J = 9.6, 6.4 
Hz, 1H, OCHH(CH2)2CHCH2), 3.14 (dd, J2,3 = 10.7, J1,2 = 3.5 Hz, 1H, H-2), 3.00 – 
2.77 (m, 2H, H3CCOCH2CH2COO), 2.75 – 2.57 (m, 2H, H3CCOCH2CH2COO), 
2.25 – 2.13 (m, 5H, H3CCOCH2CH2COO, O(CH2)2CH2CHCH2), 1.76 (m, 2H, 
OCH2CH2CH2CHCH2), 1.64 (hept, 1H, OSiC(CH3)2CH(CH3)2), 0.89 (m, 12H, 
OSiC(CH3)2CH(CH3)2), 0.14 (s, 6H, OSi(CH3)2) ppm. 
 
13C NMR (100.6 MHz, CDCl3, 25°C): δ = 207.54 (OCOCH2CH2COCH3), 173.02 
(OCOCH2CH2COCH3), 138.00 (O(CH2)3CHCH2), 115.22 (O(CH2)3CHCH2), 98.06 
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(C-1), 73.80 (C-3), 71.64 (C-5), 70.82 (C-4), 67.72 (OCH2(CH2)2CHCH2), 63.21 
(C-6), 60.86 (C-2), 38.56 (H3CCOCH2CH2COO), 34.28 (OSiC(CH3)2CH(CH3)2), 
30.37 (O(CH2)3CH2CHCH2), 29.88 (H3CCOCH2CH2COO), 28.71 
(OCH2CH2CH2CHCH2), 28.39 (H3CCOCH2CH2COO), 20.45 
(OSiC(CH3)2CH(CH3)2), 18.65 (OSiC(CH3)2CH(CH3)2), -3.30 (OSi(CH3)2) ppm. 
 
ESI-MS (MeOH) for [C24H43N3O7SiNa]+ calcd: 536.28, found: 536.2 
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4-Pentenyl 3-O-acetyl-2-azido-2-deoxy-4-O-levulinoyl-6-O-
thexyldimethylsilyl--D-galactopyranoside (75α) 
 
 
 
Compound 74α (100 mg, 0.195 mmol) was dissolved in DCM (2 mL) and the 
mixture was cooled to 0°C. Pyridine (32 µL, 0.39 mmol) and Tf2O (39 µL, 0.234 
mmol) were added dropwise. The mixture was monitored by TLC (hexane/AcOEt 
8:2). After 30 min, more pyridine (1 mL) and water (193 µL, 10.7 mmol) were 
added, and the mixture was stirred overnight at 40°C. The reaction mixture was 
then diluted with DCM and washed with 5% aq. HCl. The organic phase was dried 
over Na2SO4, filtered and concentrated. The crude was dissolved in DCM (2 mL), 
pyridine (63 µL, 0.78 mmol), catalytic DMAP and Ac2O (37 µL, 0.39 mmol) were 
sequentially added at rt. After 1 h the mixture was quenched with water, diluted 
with DCM and washed with 5% aq. HCl, satd. NaHCO3 and brine. The organic 
phase was dried over Na2SO4, filtered and concentrated. Flash chromatography 
(hexane/AcOEt 9:1) afforded compound 75α (65 mg, 60%) as a light yellow oil. 
 
1H NMR (400 MHz, CDCl3, 25°C): δ = 7.42 – 7.32 (m, 5H, arom.), 5.80 (m, 2H, 
O(CH2)3CHCH2, H-4), 5.41 (dd, J2,3 = 11.1, J3,4 = 3.4 Hz, 1H, H-3), 5.27 (d, J = 
11.9 Hz, 1H, COOCHHPh), 5.17 – 5.12 (m, 2H, COOCHHPh), 5.08 – 4.97 (m, 2H, 
O(CH2)3CHCH2), 4.65 (br d, J = 1.6 Hz, 1H, H-5), 3.79 (dt, J = 9.7, 6.5 Hz, 1H, 
OCHH(CH2)2CHCH2), 3.66 (dd, J2,3 = 11.1, J1,2 = 3.4 Hz, 1H, H-2), 3.58 (dt, J = 
9.7, 6.5 Hz, 1H, OCHH(CH2)2CHCH2), 2.68 – 2.47 (m, 3H, H3CCOCH2CH2COO, 
H3CCOCH2CHHCOO), 2.33 – 2.24 (m, 1H, H3CCOCH2CHHCOO), 2.22 – 2.13 
(m, 5H, H3CCOCH2CH2COO, O(CH2)2CH2CHCH2), 2.06 (s, 3H, OCOCH3), 1.76 
(m, 2H, OCH2CH2CH2CHCH2) ppm. 
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13C NMR (100.6 MHz, CDCl3, 25°C): δ = 205.99 (OCOCH2CH2COCH3), 171.45 
(OCOCH2CH2COCH3), 170.07 (COOBn or OCOCH3), 166.78 (OCOCH3 or 
COOBn), 137.73 (O(CH2)3CHCH2), 115.44 (O(CH2)3CHCH2), 98.47 (C-1), 68.91 
(C-5), 68.87 (OCH2(CH2)2CHCH2), 68.81(C-4), 67.82 (C-3), 67.74 (COOCH2Ph), 
57.1 (C-2), 37.75 (H3CCOCH2CH2COO), 30.21 (O(CH2)3CH2CHCH2), 29.86 
(H3CCOCH2CH2COO), 28.58 (OCH2CH2CH2CHCH2), 27.66 
(H3CCOCH2CH2COO), 20.69 (OCOCH3) ppm. 
 
ESI-MS (MeOH) for [C26H45N3O8SiNa]+ calcd: 578.29, found: 578.3 
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Benzyl (4-pentenyl 3-O-acetyl-2-azido-2-deoxy-4-O-levulinoyl--D-
galactopyranosiduronate) (76α) 
 
 
 
Compound 75α (300 mg, 0.54 mmol) was dissolved in acetone (4 mL) at -15°C. 
Jones reagent (3 mL) was added dropwise. The reaction was monitored by TLC 
(hexane/AcOEt 6:4). After 20 min the mixture was quenched carefully with EtOH, 
neutralized with satd. NaHCO3 and washed with chloroform. The aqueous phase 
was acidified to pH 2 with 5% aq. HCl and extracted with chloroform. The organic 
phase was dried over Na2SO4, filtered and concentrated. The crude was dissolved in 
DMF (5 mL), KF (0.29 g, 5 mmol) and BnBr (0.3 mL, 2.5 mmol) were added at 
0°C. The mixture was warmed to rt and stirred overnight (TLC hexane/AcOEt 8:2). 
The solvent was evaporated, the crude was taken up in DCM and washed with 
water. The organic phase was dried over Na2SO4, filtered and concentrated. Flash 
chromatography (hexane/AcOEt 8:2) afforded compound 76α (177 mg, 54%) as a 
pale yellow oil. 
 
ESI-MS (MeOH) for [C25H31N3O9Na]+ calcd: 540.20, found: 540.1 
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4-Pentenyl 2-azido-4,6-O-benzylidene-2-deoxy-3-O-levulinoyl--D-
glucopyranoside (73a) 
 
 
 
A solution of MeONa in MeOH (0.4 M, 2.75 mL, 1.1 mmol) was added to 
compound 73 (1.481 g, 3.67 mmol) dissolved in MeOH (35 mL). The reaction was 
followed by TLC (hexane/AcOEt 8:2). After 2 h the reaction was neutralized with 
Amberlite IR-120, filtered and the solvent was removed in vacuo. The crude was 
dissolved in DCM (35 mL), levulinic acid (0.56 mL, 5.51 mmol), DCC (1.287 g, 
6.24 mmol), and DMAP (90 mg, 0.73 mmol) were sequentially added and the 
mixture was stirred for 3 h at rt (TLC hexane/AcOEt 8:2). The reaction mixture was 
filtered on a Celite pad and the solvent evaporated. Flash chromatography 
(hexane/AcOEt 8:2 to 7:3) afforded compound 73a (1.96 g, quant.) as a white foam. 
 
1H NMR (400 MHz, CDCl3, 25°C): δ = 7.49 – 7.34 (m, 5H, arom.), 5.84 (ddt, J = 
16.9, 10.2, 6.7 Hz, 1H, O(CH2)3CHCH2), 5.52 (s, 1H, PhCH), 5.18 – 4.99 (m, 3H, 
H-3, O(CH2)3CHCH2), 4.50 (d, J1,2 = 8.0 Hz, 1H, H-1), 4.37 (dd, J6a,6b = 10.5, J5,6a = 
5.0 Hz, 1H, H-6a), 3.97 (dt, J = 9.5, 6.4 Hz, 1H, OCHH(CH2)2CHCH2), 3.81 (t, J5,6b 
= J6a,6b = 10.3 Hz, 1H, H-6b), 3.74 – 3.60 (m, 2H, H-4, OCHH(CH2)2CHCH2), 3.55 
– 3.43 (m, 2H, H-2, H-5), 2.79 (m, 2H, H3CCOCH2CH2COO), 2.69 (m, 2H, 
H3CCOCH2CH2COO), 2.27 – 2.15 (m, 5H, O(CH2)2CH2CHCH2, 
H3CCOCH2CH2COO), 1.78 (m, 2H, OCH2CH2CH2CHCH2) ppm. 
 
13C NMR (100.6 MHz, CDCl3, 25°C): δ = 206.10 (OCOCH2CH2COCH3), 171.79 
(OCOCH2CH2COCH3), 137.86 (O(CH2)3CHCH2), 115.33 (O(CH2)3CHCH2), 
102.85 (PhCH), 101.57 (C-1), 78.81 (C-4), 71.54 (C-3), 70.71 
(OCH2(CH2)2CHCH2), 68.63 (C-6), 66.55 (C-5), 64.99 (C-2), 38.13 
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(H3CCOCH2CH2COO), 30.09 (O(CH2)3CH2CHCH2), 29.89 (H3CCOCH2CH2COO), 
28.88 (OCH2CH2CH2CHCH2), 28.12 (H3CCOCH2CH2COO) ppm. 
 
ESI-MS (MeOH) for [C23H29N3O7Na]+ calcd: 482.19, found: 482.3 
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4-Pentenyl 2-azido-2-deoxy-3-O-levulinoyl--D-glucopyranoside (73b) 
 
 
 
Compound 73a (0.1.686 g, 3.67 mmol) was dissolved in 80% aq. AcOH (30 mL) 
and the mixture was stirred at 60°C (TLC hexane/AcOEt 7:3). After 1 h, the 
reaction mixture was neutralized with solid K2CO3, diluted with water and extracted 
with DCM. The organic phase was dried over Na2SO4, filtered and concentrated. 
Flash chromatography (hexane/AcOEt 3:7) afforded compound 73b (1.295 g, 95%) 
as a pale yellow oil. 
 
1H NMR (400 MHz, CDCl3, 25°C): δ = 5.67 (ddt, J = 16.9, 10.2, 6.6 Hz, 1H, 
O(CH2)3CHCH2), 4.95 – 4.82 (m, 2H, O(CH2)3CHCH2), 4.73 (dd, J3,4 = 10.4, J2,3 = 
9.1 Hz, 1H, H-3), 4.27 (d, J1,2 = 8.0 Hz, 1H, H-1), 3.80 (m, 2H, 
OCHH(CH2)2CHCH2, H-6a), 3.69 (dd, J = 11.9, 4.6 Hz, 1H, H-6b), 3.56 (t, J3,4 = 
J4,5 = 9.4 Hz, 1H, H-4), 3.45 (dt, J = 9.5, 6.7 Hz, 1H, OCHH(CH2)2CHCH2), 3.27 
(m, 2H, H-2, H-5), 2.82 (ddd, J = 18.6, 9.1, 5.0 Hz, 1H, H3CCOCHHCH2COO), 
2.65 (ddd, J = 18.6, 6.2, 4.6 Hz, 1H, H3CCOCHHCH2COO), 2.52 (ddd, J = 16.6, 
9.1, 4.5 Hz, 1H, , H3CCOCH2CHHCOO), 2.42 (ddd, J = 16.6, 6.2, 5.0 Hz, 1H, 
H3CCOCH2CHHCOO), 2.09 – 1.98 (m, 5H, H3CCOCH2CH2COO, 
O(CH2)2CH2CHCH2), 1.61 (m, 2H, OCH2CH2CH2CHCH2) ppm. 
 
ESI-MS (MeOH) for [C16H25N3O7Na]+ calcd: 394.16, found: 394.1 
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4-Pentenyl 2-azido-2-deoxy-3-O-levulinoyl-6-O-thexyldimethylsilyl--D-
glucopyranoside (74β) 
 
 
 
Compound 73b (1.363 g, 3.67 mmol) was dissolved in DMF (35 mL). Imidazole 
(0.75 g, 11 mmol) was added and the mixture was cooled to 0°C. TDSCl (1.08 mL, 
5.51 mmol) was added, and the mixture was warmed to rt. The reaction was 
monitored by TLC (hexane/AcOEt 3:7). After 2 h the solvent was removed, the 
crude was taken up in DCM and washed with water. The organic phase was dried 
over Na2SO4, filtered and concentrated. Flash chromatography (hexane/AcOEt 8:2) 
afforded compound 74β (1.603 g, 85%) as a light yellow oil. 
 
1H NMR (400 MHz, CDCl3, 25°C): δ = 5.83 (ddt, J = 16.9, 10.1, 6.7 Hz, 1H, 
O(CH2)3CHCH2), 5.13 – 4.95 (m, 2H, O(CH2)3CHCH2)), 4.88 (dd, J2,3 = 10.4, J3,4 = 
9.1 Hz, 1H, H-3), 4.38 (d, J1,2 = 8.0 Hz, 1H, H-1), 3.98 – 3.86 (m, 3H, 
OCHH(CH2)2CHCH2, H-6a, H-6b), 3.65 (t, J3,4 = J4,5 = 9.1 Hz, 1H, H-4), 3.58 (dt, J = 
9.6, 6.6 Hz, 1H, OCHH(CH2)2CHCH2), 3.43 – 3.34 (m, 2H, H-2, H-5), 2.96 – 2.77 
(m, 2H, H3CCOCH2CH2COO), 2.74 – 2.55 (m, 2H, H3CCOCH2CH2COO), 2.25 – 
2.13 (m, 5H, H3CCOCH2CH2COO, O(CH2)2CH2CHCH2), 1.76 (m, 2H, 
OCH2CH2CH2CHCH2), 1.64 (m, 1H, OSiC(CH3)2CH(CH3)2), 0.89 (m, 12H, 
OSiC(CH3)2CH(CH3)2), 0.14 (m, 6H, OSi(CH3)2) ppm. 
 
13C NMR (101 MHz, CDCl3, 25°C): δ = 207.49 (OCOCH2CH2COCH3), 172.86 
(OCOCH2CH2COCH3), 138.01 (O(CH2)3CHCH2), 115.17 (O(CH2)3CHCH2), 
101.98 (C-1), 75.92 (C-3), 75.28 (C-5), 70.88 (C-4), 69.54 (OCH2(CH2)2CHCH2), 
63.84 (C-2), 63.57 (C-6), 38.51 (H3CCOCH2CH2COO), 34.30 
(OSiC(CH3)2CH(CH3)2), 30.17 (O(CH2)3CH2CHCH2), 29.90 
(H3CCOCH2CH2COO), 28.90 (OCH2CH2CH2CHCH2), 28.36 
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(H3CCOCH2CH2COO), 20.47 (OSiC(CH3)2CH(CH3)2), 18.65 
(OSiC(CH3)2CH(CH3)2), -3.31 (OSi(CH3)2) ppm. 
 
ESI-MS (MeOH) for [C24H43N3O7SiNa]+ calcd: 536.28, found: 536.3 
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4-Pentenyl 3-O-acetyl-2-azido-2-deoxy-4-O-levulinoyl-6-O-
thexyldimethylsilyl--D-galactopyranoside (75β) 
 
 
 
Compound 74β (200 mg, 0.39 mmol) was dissolved in DCM (4 mL) and the 
mixture was cooled to 0°C. Pyridine (63 µL, 0.78 mmol) and Tf2O (79 µL, 0. 47 
mmol) were added dropwise. The mixture was monitored by TLC (hexane/AcOEt 
8:2). After 30 min, more pyridine (2 mL) and water (700 µL, 39 mmol) were added, 
and the mixture was stirred overnight at 40°C. The reaction mixture was then 
diluted with DCM and washed with 5% aq. HCl. The organic phase was dried over 
Na2SO4, filtered and concentrated. The crude was dissolved in DCM (4 mL), 
pyridine (315 µL, 3.9 mmol), catalytic DMAP and Ac2O (185 µL, 1.95 mmol) were 
sequentially added at rt. After 1 h the mixture was quenched with water, diluted 
with DCM and washed with 5% aq. HCl, satd. NaHCO3 and brine. The organic 
phase was dried over Na2SO4, filtered and concentrated. Flash chromatography 
(hexane/AcOEt 9:1) afforded compound 75β (173.4 mg, 80%) as a light yellow oil. 
 
1H NMR (400 MHz, CDCl3, 25°C): δ = 7.42 – 7.31 (m, 5H, arom.), 5.84 (ddt, J = 
16.9, 10.2, 6.7 Hz, 1H, O(CH2)3CHCH2), 5.68 (dd, J3,4 = 3.5, J4,5 = 1.4 Hz, 1H, H-
4), 5.27 (d, J = 11.9 Hz, 1H, COOCHHPh), 5.13 (d, J = 11.9 Hz, 1H, 
COOCHHPh), 5.11 – 4.97 (m, 2H, O(CH2)3CHCH2), 4.79 (dd, J2,3 = 10.9, J3,4 = 3.5 
Hz, 1H, H-3), 4.38 (d, J1,2 = 8.0 Hz, 1H, H-1), 4.27 (d, J4,5 = 1.4 Hz, 1H, H-5), 4.08 
(dt, J = 9.4, 6.4 Hz, 1H, OCHH(CH2)2CHCH2), 3.71 (dd, J2,3 = 10.9, J1,2 = 8.0 Hz, 
1H, H-2), 3.60 (dt, J = 9.5, 6.8 Hz, 1H, OCHH(CH2)2CHCH2), 2.72 – 2.50 (m, 3H, 
H3CCOCH2CH2COO, H3CCOCH2CHHCOO), 2.37 – 2.25 (m, 1H, 
H3CCOCH2CHHCOO), 2.25 – 2.15 (m, 5H, H3CCOCH2CH2COO, 
O(CH2)2CH2CHCH2), 2.06 (s, 3H, OCOCH3), 1.80 (m, 2H, OCH2CH2CH2CHCH2) 
ppm. 
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13C NMR (100.6 MHz, CDCl3, 25°C): δ = 205.96 (OCOCH2CH2COCH3), 171.53 
(OCOCH2CH2COCH3), 170.08 (COOBn or OCOCH3), 165.81 (OCOCH3 or 
COOBn), 137.97 (O(CH2)3CHCH2), 115.26 (O(CH2)3CHCH2), 102.32 (C-1), 72.36 
(C-5), 70.66 (C-3), 70.14 (OCH2(CH2)2CHCH2), 67.75 (C-4), 67.73 (COOCH2Ph), 
60.64 (C-2), 37.72 (H3CCOCH2CH2COO), 30.10 (O(CH2)3CH2CHCH2), 29.91 
(H3CCOCH2CH2COO), 28.77 (OCH2CH2CH2CHCH2), 27.67 
(H3CCOCH2CH2COO), 20.64 (OCOCH3) ppm. 
 
ESI-MS (MeOH) for [C26H45N3O8SiNa]+ calcd: 578.29, found: 578.1 
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Benzyl (4-pentenyl 3-O-acetyl-2-azido-2-deoxy-4-O-levulinoyl--D-
galactopyranosiduronate) (76β) 
 
 
Compound 75β (100 mg, 0.17 mmol) was dissolved in acetone (2 mL) at -15°C. 
Jones reagent (1 mL) was added dropwise. The reaction was monitored by TLC 
(hexane/AcOEt 6:4). After 15 min the mixture was quenched carefully with EtOH, 
neutralized with satd. NaHCO3 and washed with chloroform. The aqueous phase 
was acidified to pH 2 with 5% aq. HCl and extracted with chloroform. The organic 
phase was dried over Na2SO4, filtered and concentrated. The crude was dissolved in 
DMF (2 mL), KF (87 mg, 1.5 mmol) and BnBr (90 µL, 0.75 mmol) were added at 
0°C. The mixture was warmed to rt and stirred overnight (TLC hexane/AcOEt 8:2). 
The solvent was evaporated, the crude was taken up in DCM and washed with 
water. The organic phase was dried over Na2SO4, filtered and concentrated. Flash 
chromatography (hexane/AcOEt 8:2) afforded compound 76β (50 mg, 57%) as a 
pale yellow oil. 
 
1H NMR (400 MHz, CDCl3, 25°C): δ = 7.40 – 7.32 (m, 5H, arom.), 5.83 (ddt, J = 
16.9, 10.2, 6.7 Hz, 1H, O(CH2)3CHCH2), 5.68 (dd, J3,4 = 3.5, J4,5 = 1.5 Hz, 1H, H-
4), 5.26 (d, J = 11.9 Hz, 1H, COOCHHPh), 5.13 (d, J = 11.9 Hz, 1H, COOHHPh), 
5.10 – 4.96 (m, 2H, O(CH2)3CHCH2), 4.79 (dd, J2,3 = 10.9, J3,4 = 3.5 Hz, 1H, H-3), 
4.37 (d, J1,2 = 8.0 Hz, 1H, H-1), 4.27 (d, J4,5 = 1.5 Hz, 1H, H-5), 4.08 (dt, J = 9.4, 
6.3 Hz, 1H, OCHH(CH2)2CHCH2), 3.70 (dd, J2,3 = 10.9, J1,2 = 8.0 Hz, 1H, H-2), 
3.60 (dt, J = 9.5, 6.8 Hz, 1H, OCHH(CH2)2CHCH2), 2.70 – 2.49 (m, 3H, 
H3CCOCH2CH2COO, H3CCOCH2CHHCOO), 2.35 – 2.25 (m, 1H, 
H3CCOCH2CHHCOO), 2.25 – 2.13 (m, 5H, O(CH2)2CH2CHCH2, 
H3CCO(CH2)2COO), 1.79 (m, 2H, OCH2CH2CH2CHCH2) ppm. 
ESI-MS (MeOH) for [C25H31N3O9Na]+ calcd: 540.20, found: 540.2 
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4-Pentenyl 2-azido-2-deoxy-3,4-di-O-isopropylidene--D-galactopyranoside 
(80) 
 
 
 
Compound 79 (200 mg, 0.73 mmol) was dissolved in 2,2-dimethoxypropane (7 
mL). CSA (17 mg, 0.073 mmol) was added and the mixture was refluxed for 3 h 
(TLC hexane/AcOEt 6:4). Then the reaction mixture was quenched with TEA, 
stirred of 15 min, the solvent was evaporated and the crude was coevaporated with 
toluene. The residue was dissolved in MeOH/H2O 10:1 (11 mL) and the mixture 
was refluxed for 2.5 h. Then the solvent was evaporated in vacuo and the residue 
was purified by flash chromatography (hexane/AcOEt 7:3 + 0.1% TEA), yielding 
compound 80 (190.9 mg, 83%) as a pale yellow oil. 
 
ESI-MS (MeOH) for [C14H23N3O5Na]+ calcd: 336.15, found: 336.1 
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Benzyl (4-pentenyl 2-azido-2-deoxy-3,4-di-O-isopropylidene--D-
galactopyranosiduronate) (81) 
 
 
 
Compound 80 (0.91 g, 2.7 mmol) was dissolved in DCM/H2O 2:1 (15 mL), then 
BAIB (1.305 g, 4.05 mmol) and TEMPO (42 mg, 0.27 mmol) were added. The 
reaction was monitored by TLC (DCM/MeOH 7:3). After 3 h the mixture was 
quenched with ethanol, the solvent was evaporated and the residue was 
coevaporated with toluene. The crude was dissolved in DMF (30 mL) at 0°C. KF 
(1.74 g, 3 mmol) and BnBr (1.78 mL, 1.5 mmol) were added, and the mixture was 
stirred overnight at rt (TLC hexane/AcOEt 7:3). Then the solvent was removed, the 
crude was taken up in DCM and washed with water. The organic phase was dried 
over Na2SO4, filtered and concentrated. Flash chromatography (hexane/AcOEt 9:1) 
afforded compound 81 (1.0288 g 91%) as a pale yellow oil. 
 
1H NMR (400 MHz, CDCl3, 25°C): δ = 7.44 – 7.32 (m, 5H, arom.), 5.81 (ddt, J = 
16.9, 10.2, 6.7 Hz, 1H, O(CH2)3CHCH2), 5.42 (d, J = 12.3 Hz, 1H, COOCHHPh), 
5.22 (d, J = 12.3 Hz, 1H, COOCHHPh), 5.10 – 4.96 (m, 3H, O(CH2)3CHCH2, H-1), 
4.70 (d, J4,5 = 2.9 Hz, 1H, H-5), 4.57 (dd, J3,4 = 5.4, J4,5 = 2.9 Hz, 1H, H-4), 4.45 
(dd, J2,3 = 8.4, J3,4 = 5.4 Hz, 1H, H-3), 3.77 (dt, J=9.8, 6.6 Hz, 1H, 
OCHH(CH2)2CHCH2), 3.53 (dt, J=9.8, 6.4 Hz, 1H, OCHH(CH2)2CHCH2), 3.43 
(dd, J2,3 = 8.4, J1,2 = 3.3 Hz, 1H, H-2), 2.15 (m, 2H, O(CH2)2CH2CHCH2), 1.73 (m, 
2H, OCH2CH2CH2CHCH2), 1.53 (s, 3H, C(CH3)2), 1.35 (s, 3H, C(CH3)2) ppm. 
 
13C NMR (100.6 MHz, CDCl3, 25°C): δ = 167.49 (COOBn), 137.68 
(O(CH2)3CHCH2), 115.25 (O(CH2)3CHCH2), 110.20 (C(CH3)2), 98.16 (C-1), 73.31 
(C-3), 73.17 (C-4), 68.51 (OCH2(CH2)2CHCH2), 67.67 (C-5), 67.06 (COOCH2Ph), 
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60.54 (C-2), 30.09 (O(CH2)3CH2CHCH2), 28.46 (OCH2CH2CH2CHCH2), 28.12 
(C(CH3)2), 26.14 (C(CH3)2) ppm. 
 
ESI-MS (MeOH) for [C21H27N3O6Na]+ calcd: 440.18, found: 440.2 
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Benzyl (4-pentenyl 2-azido-2-deoxy--D-galactopyranosiduronate) (82) 
 
 
 
Compound 81 (1.0 g, 2.4 mmol) was dissolved in 80% aq. AcOH (15 mL) and 
heated at 70°C. The reaction was monitored by TLC (hexane/AcOEt 6:4). After 4 h 
the mixture was cooled to rt, neutralized with K2CO3, diluted with water and 
extracted with AcOEt. The organic phase was dried over Na2SO4, filtered and 
concentrated, affording compound 82 (905.7 mg, quant.) as a pale yellow oil. 
 
ESI-MS (MeOH) for [C18H23N3O6Na]+ calcd: 400.15, found: 400.2 
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Benzyl (4-pentenyl 3-O-acetyl-2-azido-2-deoxy--D-
galactopyranosiduronate) (70) 
 
 
 
Compound 82 (127 mg, 0.34 mmol) was dissolved in CH3CN (5 mL), 2-
aminoethyldiphenilborinate (8 mg, 34 µmol), DIPEA (118 µL, 0.68 mmol) and 
AcCl (36 µL, 0.51 mmol) were sequentially added. The reaction was monitored by 
TLC (hexane/AcOEt 6:4). After 2 h the mixture was diluted with water and 
extracted with DCM. The organic phase was dried over Na2SO4, filtered and 
concentrated. Flash chromatography (hexane/AcOEt 7:3) afforded compound 70 
(111.9 mg, 80%) as a pale yellow oil. 
 
1H NMR (400 MHz, CDCl3, 25°C): δ = 7.44 – 7.34 (m, 5H, arom.), 5.81 (ddt, J = 
16.9, 10.2, 6.6 Hz, 1H, O(CH2)3CHCH2), 5.37 (dd, J2,3 = 11.1, J3,4 = 3.1 Hz, 1H, H-
3), 5.34 – 5.23 (m, 2H, COOCH2Ph), 5.13 (d, J1,2 = 3.5 Hz, 1H, H-1), 5.09 – 4.96 
(m, 2H, O(CH2)3CHCH2), 4.57 (br d, J4,5 = 1.5 Hz, 1H, H-5), 4.53 (dd, J3,4 = 3.1, 
J4,5 = 1.5 Hz, 1H, H-4), 3.80 (dt, J = 9.7, 6.6 Hz, 1H, OCHH(CH2)2CHCH2), 3.74 
(dd, J2,3 = 11.0, J1,2 = 3.5 Hz, 1H, H-2), 3.58 (dt, J = 9.7, 6.5 Hz, 1H, 
OCHH(CH2)2CHCH2), 2.23 – 2.13 (m, 5H, OCOCH3), 1.77 (m, 2H, 
OCH2CH2CH2CHCH2) ppm. 
 
13C NMR (100.6 MHz, CDCl3, 25°C): δ = 115.27 (O(CH2)3CHCH2), 98.42 (C-1), 
69.96 (C-4), 69.82 (C-3), 68.60 (OCH2(CH2)2CHCH2), 68.39 (C-5), 67.43 
(COOCH2Ph), 56.83 (C-2), 30.11 (O(CH2)3CH2CHCH2), 28.46 
(OCH2CH2CH2CHCH2), 20.93 (OCOCH3) ppm. 
 
ESI HR-MS (MeOH) for [C20H25N3O7Na]+ calcd: 442.1585, found: 442.1602 
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Benzyl (4-pentenyl 3-O-acetyl-2-azido-4-O-chloroacetyl-2-deoxy--D-
galactopyranosiduronate) (83) 
 
 
 
Compound 70 (110 mg, 0.27 mmol) was dissolved in DCM (3 mL), chloroacetic 
acid (38 mg, 0.41 mmol), DCC (95 mg, 0.46 mmol) and DMAP (6 mg, 5 µmol) 
were sequentially added. The reaction was monitored by TLC (hexane/AcOEt 6:4). 
After 30 min the mixture was filtered on a Celite pad and the solvent was 
evaporated. Flash chromatography (hexane/AcOEt 9:1) afforded compound 83 (119 
mg, 89%) as a pale yellow oil. 
 
ESI-MS (MeOH) for [C22H26ClN3O8Na]+ calcd: 518.13, found: 518.2 
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ClAc removal on compound 83 
 
 
 
Compound 83 (30 mg, 60 µmol) was dissolved in DCM/MeOH 4:1 (5 mL), 
thiourea (23 mg, 300 µmol) was added and the mixture was refluxed overnight 
(TLC hexane/AcOEt 6:4). Then the solvent was concentrated and the crude was 
purified by flash chromatography (hexane/AcOEt 7:3), affording compound 70 
(23.9 mg, 95%) as a pale yellow oil. 
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6.3 NMR spectra 
 
1H NMR spectrum (400 Mhz, CDCl3) of compound 13 
 
13C NMR spectrum (100.6 MHz, CDCl3) 
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1H NMR spectrum (400 Mhz, CDCl3) of compound 14 
 
13C NMR spectrum (100.6 MHz, CDCl3) 
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1H NMR spectrum (400 Mhz, CDCl3) of compound 15 
 
13C NMR spectrum (100.6 MHz, CDCl3) 
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1H NMR spectrum (400 Mhz, CDCl3) of compound 7a 
 
13C NMR spectrum (100.6 MHz, CDCl3) 
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1H NMR spectrum (400 Mhz, CDCl3) of compound 19 
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1H NMR spectrum (400 Mhz, CDCl3, 55°C) of compound 6 
 
13C NMR spectrum (100.6 MHz, CDCl3, 55°C) 
 
  
  
192 
1H NMR spectrum (400 Mhz, CDCl3) of compound 21 
 
13C NMR spectrum (100.6 MHz, CDCl3) 
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1H NMR spectrum (400 Mhz, CDCl3) of compound 23 
 
13C NMR spectrum (100.6 MHz, CDCl3) 
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1H NMR spectrum (400 Mhz, CDCl3) of compound 24 
 
13C NMR spectrum (100.6 MHz, CDCl3) 
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1H NMR spectrum (300 Mhz, CDCl3) of compound 27 
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1H NMR spectrum (400 Mhz, CDCl3) of compound 28 
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1H NMR spectrum (400 Mhz, CDCl3) of compound 29 
 
13C NMR spectrum (100.6 MHz, CDCl3) 
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1H NMR spectrum (400 Mhz, CDCl3) of compound 30 
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1H NMR spectrum (400 Mhz, CDCl3) of compound 31 
 
13C NMR spectrum (100.6 MHz, CDCl3) 
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1H NMR spectrum (400 Mhz, D2O) of compound 32 
 
13C NMR spectrum (100.6 MHz, D2O) 
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1H NMR spectrum (400 Mhz, CDCl3) of compound 36 
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1H NMR spectrum (400 Mhz, CDCl3) of compound 37 
 
13C NMR spectrum (100.6 MHz, CDCl3) 
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1H NMR spectrum (400 Mhz, CDCl3) of compound 19a 
 
  
  
204 
1H NMR spectrum (400 Mhz, CDCl3) of compound 38 
 
13C NMR spectrum (100.6 MHz, CDCl3) 
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1H NMR spectrum (300 Mhz, CDCl3) of compound 38a 
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1H NMR spectrum (400 Mhz, CDCl3, 50°C) of compound 39 
 
13C NMR spectrum (100.6 MHz, CDCl3, 50°C) 
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1H NMR spectrum (400 Mhz, CDCl3) of compound 40 
 
13C NMR spectrum (100.6 MHz, CDCl3) 
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1H NMR spectrum (400 Mhz, CDCl3) of compound 40a 
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1H NMR spectrum (400 Mhz, CDCl3, 50°C) of compound 34 
 
13C NMR spectrum (100.6 MHz, CDCl3, 50°C) 
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1H NMR spectrum (400 Mhz, CDCl3) of compound 41a 
 
13C NMR spectrum (100.6 MHz, CDCl3) 
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1H NMR spectrum (400 Mhz, CDCl3) of compound 41 
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1H NMR spectrum (400 Mhz, CDCl3) of compound 44 
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1H NMR spectrum (400 Mhz, CDCl3) of compound 46 
 
13C NMR spectrum (100.6 MHz, CDCl3) 
 
  
  
214 
1H NMR spectrum (400 Mhz, CDCl3) of compound 46a 
 
13C NMR spectrum (100.6 MHz, CDCl3) 
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1H NMR spectrum (300 Mhz, CDCl3) of compound 47 
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1H NMR spectrum (400 Mhz, CDCl3) of compound 48 
 
13C NMR spectrum (100.6 MHz, CDCl3) 
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1H NMR spectrum (400 Mhz, D2O) of compound 49 
 
13C NMR spectrum (100.6 MHz, D2O) 
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1H NMR spectrum (400 Mhz, CDCl3) of compound 52a 
 
13C NMR spectrum (100.6 MHz, CDCl3) 
 
  
  
219 
1H NMR spectrum (400 Mhz, CDCl3) of compound 52b 
 
13C NMR spectrum (100.6 MHz, CDCl3) 
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1H NMR spectrum (400 Mhz, CDCl3) of compound 7b 
 
13C NMR spectrum (100.6 MHz, CDCl3) 
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1H NMR spectrum (400 Mhz, CDCl3) of compound 51a 
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1H NMR spectrum (400 Mhz, CDCl3) of compound 53 
 
13C NMR spectrum (100.6 MHz, CDCl3) 
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1H NMR spectrum (400 Mhz, CDCl3) of compound 53a 
 
13C NMR spectrum (100.6 MHz, CDCl3) 
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1H NMR spectrum (400 Mhz, CDCl3) of compound 54 
 
13C NMR spectrum (100.6 MHz, CDCl3) 
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1H NMR spectrum (400 Mhz, D2O) of compound 55 
 
13C NMR spectrum (100.6 MHz, D2O) 
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1H NMR spectrum (400 Mhz, D2O) of compound 56 
 
13C NMR spectrum (100.6 MHz, D2O) 
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1H NMR spectrum (400 Mhz, CDCl3) of compound 57 
 
13C NMR spectrum (100.6 MHz, CDCl3) 
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1H NMR spectrum (400 Mhz, CDCl3) of compound 58 
 
13C NMR spectrum (100.6 MHz, CDCl3) 
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1H NMR spectrum (400 Mhz, CDCl3) of compound 59 
 
13C NMR spectrum (100.6 MHz, CDCl3) 
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1H NMR spectrum (400 Mhz, CDCl3) of compound 60 
 
13C NMR spectrum (100.6 MHz, CDCl3) 
 
  
  
231 
1H NMR spectrum (400 Mhz, CDCl3) of compound 61 
 
13C NMR spectrum (100.6 MHz, CDCl3) 
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1H NMR spectrum (400 Mhz, D2O) of compound 62 
 
13C NMR spectrum (100.6 MHz, D2O) 
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1H NMR spectrum (400 Mhz, CDCl3) of compound 63 
 
13C NMR spectrum (100.6 MHz, CDCl3) 
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1H NMR spectrum (400 Mhz, CDCl3) of compound 38a 
 
13C NMR spectrum (100.6 MHz, CDCl3) 
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1H NMR spectrum (400 Mhz, CDCl3) of compound 38b 
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1H NMR spectrum (400 Mhz, CDCl3, 50°C) of compound 67 
 
13C NMR spectrum (100.6 MHz, CDCl3, 50°C) 
 
  
  
237 
1H NMR spectrum (400 Mhz, CDCl3) of compound 68 
 
13C NMR spectrum (100.6 MHz, CDCl3) 
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1H NMR spectrum (400 Mhz, CDCl3) of compound 72a 
 
13C NMR spectrum (100.6 MHz, CDCl3) 
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1H NMR spectrum (400 Mhz, CDCl3) of compound 74 
 
13C NMR spectrum (100.6 MHz, CDCl3) 
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1H NMR spectrum (400 Mhz, CDCl3) of compound 75 
 
13C NMR spectrum (100.6 MHz, CDCl3) 
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1H NMR spectrum (300 Mhz, CDCl3) of compound 76 
 
  
  
242 
1H NMR spectrum (400 Mhz, CDCl3) of compound 73a 
 
13C NMR spectrum (100.6 MHz, CDCl3) 
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1H NMR spectrum (400 Mhz, CDCl3) of compound 73b 
 
  
  
244 
1H NMR spectrum (400 Mhz, CDCl3) of compound 74 
 
13C NMR spectrum (100.6 Mhz, CDCl3) 
 
  
  
245 
1H NMR spectrum (400 Mhz, CDCl3) of compound 75 
 
13C NMR spectrum (100.6 MHz, CDCl3) 
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1H NMR spectrum (400 Mhz, CDCl3) of compound 76 
 
  
  
247 
1H NMR spectrum (300 Mhz, CDCl3) of compound 80 
 
  
  
248 
1H NMR spectrum (400 Mhz, CDCl3) of compound 81 
 
13C NMR spectrum (100.6 MHz, CDCl3) 
 
  
  
249 
1H NMR spectrum (300 Mhz, CDCl3) of compound 82 
 
  
  
250 
1H NMR spectrum (400 Mhz, CDCl3) of compound 70 
 
13C NMR spectrum (100.6 MHz, CDCl3) 
 
  
  
251 
1H NMR spectrum (300 Mhz, CDCl3) of compound 83 
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